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ABSTRACT
Acinetobacter baumannii is an opportunistic pathogen that overtime has evolved into one
of the most problematic pathogens due to its ability to overcome antibiotic pressures and
harshly environments in the host and hospital environments. In this context, its genomic
evolution due to its capacity to acquire genes that contribute to its pathogenic and
antibiotic resistance nature has been the subject of research in the last decades providing
with the identification of several proteins aiding in the process of pathogenicity. Although
these findings have contributed to our understanding of A. baumannii pathogenic traits,
the regulatory network that control their expression are less understood. As such, our first
efforts to study gene regulation in this organism were focused on defining the complete
set of regulatory proteins in A. baumannii. As such, we examined the genome of a highly
pathogenic multidrug resistance (MDR) A. baumannii strain AB5075 and comparative
analyses to understand evolution of regulatory networks were performed using A.
baumannii strains with different MDR profiles. This work generated a complete set of
regulatory proteins identified in AB5075. This tool serves us as a foundation to investigate
the function of uncharacterized regulatory proteins in this organism. As a result of this,
we characterized the role of a two-component system in controlling metabolic pathways
and found that its disruption is detrimental for energy generation processes. In addition,
we defined the role of an extracytoplasmic sigma factor that is required for efficient growth
in the presence of hemin as a sole iron source. Overall, the work of this dissertation

vii

presents findings describing regulatory roles of a novel TCS and a sigma factor that will
extend the knowledge of gene regulation in A. baumannii.

viii

CHAPTER I: INTRODUCTION
The Genus Acinetobacter
Acinetobacter species were first isolated from soil samples in the earlier 1900’s by the
microbiologist Martinus Weillem Beijerinck 1. At the time, these species were known as
Micrococcus- calco-aceticus, a name that was given based on their cell morphology
(small coccobacilli) and ability to grow in minimal mineral media containing calcium
acetate as a sole carbon source 1. In the years following, bacteria were identified as
sharing common phenotypic characteristics with Micrococcus- calco-aceticus, including
a lack of pigmentation and motility, cocci-rod cell shape, and an inability to use glucose
as an lone carbon source, under different names, including Herrellea vaginicola, Mima
polyphorma, Moraxella lowffi, Moraxella glucidolytica, Acinetobacter spp., and Neisseria
spp. 2,3. As a result, it was difficult to classify these organisms into a single genus due to
the diversity of existing genus names, and epithets containing these species that were
phenotypically indistinguishable.

The first comprehensive taxonomic study published by Baumann, et. al. in 1967 tested
hundreds of bacterial species sharing phenotypes previously reported under different
names, for their oxidase activity and ability to use a myriad of carbon sources. This led to
the classification of all these species into three main groups Moraxella osloenesis,
Moraxella lacunata, and Nesseria catarrhalis 4. Following this publication, in 1968,

1

Baumann, et. al., based on an extensive biochemical examination of 106 bacteria strains
belonging to species from the Mima-Herrellea, Acinetobacter spp., and, Moraxella spp.,
were able to distinguish and classify a group of bacteria within the genus of Acinetobacter
5

. These studies for the first time provided a detail description of the characteristics

observed in species that were grouped within the Acinetobacter genus. Thus,
Acinetobacter species were described as Gram-negative bacteria cells that switch from
rods to cocci cell shape while transitioning from exponential to stationary growth, lack
motility, are strictly aerobic, catalase positive and oxidase negative, incapable of
fermenting glucose, and have a prodigious ability to use acetate, ammonia, nitrogen, and
a significant number of organic compounds as a sole carbon source

5,6

. These distinct

features reported in Acinetobacter species resulted in their recognition as single species
known as Acinetobacter calcoaceticus within the Acinetobacter genus in 1971 at the
International Committee Meeting on Nomenclature of Bacteria by the Sub-committee on
the Taxonomy of Moraxella and Allied Bacteria 7.

A. baumannii History and Identifying Features
Historically, bacteria belonging to the Acinetobacter genus are commonly found in water
and soil, yet pathogenic strains causing a variety of infections such as osteomyelitis,
pneumonia, urinary tract infections, vaginal infections in adults with weakened immune
systems and fatal meningitis in infants started to be reported as earlier as the 1950’s 8,9.
With the appearance of opportunistic pathogenic strains of Acinetobacter, the nutritional
requirements and distinct lack of oxidase activity could not further differentiate among
pathogenic and non-pathogenic species contained in the genus

10-12

. It wasn’t until the

2

emergence of new technologies such as DNA hybridization that made it possible to define
precisely Acinetobacter species at the genomic level. The first such study in 1986
examined 266 Acinetobacter strains using a combination of DNA hybridization and
phenotypic assays resulting in the identification of 12 Acinetobacter species that included
genomic species 1, 2, 4, 5, 7, and 8, named Acinetobacter calcoaceticus, Acinetobacter
baumannii, Acinetobacter haemolyticus, Acinetobacter junii, Acinetobacter johnsonii, and
Acinetobacter lwoffii, respectively13. Despite progress made in the identification of
Acinetobacter species, a major drawback of differentiation among Acinetobacter
baumannii and Acinetobacter calcoaceticus was highlighted by findings of their shared
DNA relatedness, which is as high as 97% according to Nishimura et. al 14.

Subsequent phenotypic and molecular studies on members of the Acinetobacter spp.
denoted 26 species and 9 genomic species

15,16

. Of note, the genomic species group

includes 4 closely related species associated with nosocomial infections known as the
Acinetobacter calcoaceticus-baumannii complex, which is comprised of: i) Acinetobacter
genomic species 3, ii) Acinetobacter genomic species 13TU, iii) A. calcoaceticus and iv)
A. baumannii

17

. Among members of this complex, A. calcoaceticus is the only

environmental bacterium that has not been recovered from clinical samples, however the
complex is still known as Acinetobacter calcoaceticus-baumannii due to the
indistinguishable phenotypes among these two organisms. However, further studies
exploiting the heterogeneity of genes such as 16SrRNA, recA, rpoB, and gyrB among the
A. calcoaceticus-baumannii complex have been used to single out these clinical
isolates15.

3

As discussed above, differentiation of Acinetobacter species at the genus and epithet
level has been the subject of research for over a century. Along this journey, the transition
from basic biochemical assays to genomic driven technologies have served to
differentiate among Acinetobacter species. Overall, this section summarizes findings
derived from more than 100 years of research in the Acinetobacter field that has led to a
more accurate identification and definition of the pathogenic bacterium A. baumannii,
which is the best characterized organism within the Acinetobacter genus over the last four
decades because of its multidrug resistance (MDR) nature and pathogenesis.

The Infections of A. baumannii
During the first quarter of the 20th century, A. baumannii, (previously reported under
different names), were infrequently associated with nosocomial infections compared to
other causative agents, including Streptococcus pyogenes and Staphylococcus aureus
18

. Nevertheless, during this period A. baumannii infections were documented in patients

with weakened immune system as a result of clinical conditions, including burns and
trauma or chronic disease, e.g. kidney and pulmonary diseases

8,9,11,19

. Soon after the

recognition of the Acinetobacter genus in 1971, epidemiological studies focusing on
Acinetobacter infections were the starting point for clinicians to recognize the role of this
bacterium as a causative agent for a wide spectrum of diseases, including pulmonary
infections, septicemia, urinary tract infections, wound infections, and cellulitis 20-22.
In this context, the high occurrence of A. baumannii infections in patients that require
devices such as respirators, catheters, or surgical implants, as well as the mortality rates,
which can be as high as 44% among patients that developed pulmonary infections, were

4

common findings of epidemiology studies during the period of 1970 -1977

10,12,20

. A

surveillance study in the United states during 1978 reported an increase of 14% in A.
baumannii infections compared to those documented within 1974-1977

23

. Perhaps this

increase in A. baumannii infections can be attributed to the extraordinary ability of this
bacterium to survive on surfaces for long periods of time in, for example, hospital settings.
Alongside this, there has been an uptick in invasive medical procedures and implants
during this time, providing favorable conditions for this pathogen to persist and cause
diseases in comprised hosts. Despite this fact, therapeutic options such as sulfonamides
and aminoglycosides remained effective for controlling these infections10.

A major complication that has emerged in the control of A. baumannii infections, however,
is the appearance of A. baumannii drug resistant strains, with the earliest reports dating
back to the 1990’s, initially in Asia and European countries

24-30

. Among these reports,

one of the first was published by Siau et. Al, and describes the strong association of
antibiotic resistance in A. baumannii strains isolated from patients treated for wounds and
urinary infections, and from ICU patients that required the use of mechanical ventilators
22

. In this regard, pneumonia has become one of the most prevalent diseases caused by

A. baumannii strains worldwide, and it has been proposed that the ability of this pathogen
to adhere and form biofilms on surfaces such as endotracheal tubes used for mechanical
ventilation provides a vehicle to establish ventilator associated pneumonia infections
(VAP) 31,32.

5

In 2001, cases of MDR A. baumannii strains isolated from critically ill wounded US
soldiers gave exposure to this pathogen in the mainstream as well as medical literature.
In this example, US hospitals and bases in Iraq and Afghanistan reported that 97% of A.
baumannii infections developed into bacteremia between 2002 and 2004 among soldiers
with trauma injuries 33. Consequently, military health care facilities encountered increased
mortality, longer periods of recovery, and the need for surgical removal of extremities due
to MDR A. baumannii infections

34-36

. Indeed, the ability of this organism to disseminate

from primary sites of infections to the bloodstream increases the risk of developing
bacteremia in patients, ultimately leading to untreatable infections due to the prevalence
of MDR A. baumannii strains 36.

Multiple retrospective studies in US hospitals have reported death rates of between
49.6% to 76% among patients with sepsis linked to A. baumannii infections

37

.

Furthermore, several US epidemiological studies have documented the increasing trend
of MDR in A. baumannii strains and the challenges this adds to the control of A. baumannii
infections among patients. A study focused on health care associated infections during
2011-2014 found that 64% of A. baumannii VAP infections were caused by MDR strains.
More alarming, this pathogen has already moved into communities causing pneumonia
in individuals with chronic diseases such as diabetes, kidney disease or alcoholism

38,39

.

Community associated A. baumannii infections are found increasingly in countries with
tropical climates, or during the summer season in places such as Alabama and Northern
cities in the USA that perhaps reflect conditions that favors survival of A. baumannii 40.

6

Regarding a timeline for A. baumannii infections, a notably recent trend is the evolution
of this bacterium that, although once considered avirulent, today is known for its ability to
cause a broad spectrum of diseases. These are largely a result of its presence in
nosocomial environments, and its ability to overcome host barriers by means of using
medical devices as shuttles to gain entry to the host. Ultimately, the whole situation is
complicated by the rapid and continued emergence of strains resistance to antibiotic
therapeutics treatments commonly used in the clinic.

The Drug Resistance of A. baumannii
The steadily rising rates of MDR A. baumannii strains in the last 30 years have
complicated the management of the Acinetobacter diseases as we mentioned in the
previous section. In this regard, the common therapeutic options to treat Acinetobacter
infections in the 1970s included single or combination administration of aminoglycosides
and carbenicillin

10

. However, the high prevalence of genes encoding aminoglycoside

modifying enzymes, b-lactamases, and the presence of porins reducing outer membrane
permeability renders many clinical strains resistant to these antibiotics41,42. These was
the first drug resistant phenotypes in this bacterium that led clinicians to move toward the
use of b-lactam antibiotics such as cephalosporin

43-45

. The effectiveness of

cephalosporins was short lived, however, and within a period of five years (1998-2001),
the ampC gene encoding a Cephalosporinase was found to be prevalent among clinical
strains, with carriage reportedly as high as 60% in hospitals around the world

39,46,47

. At

this point, other antibiotics including fluoroquinoles, tetracyclines, and the carbapenems,
imipenem and meropenem, were proven to be effective therapies to control MDR A.

7

baumannii infections

48

. Unfortunately, a rapid development of resistance displayed by

this pathogen to all these existing antibiotics has resulted in the rise of mortality rates
among patients infected with this organism 49.

Thus, what is next alternative to treat Acinetobacter infections unresponsive to standard
therapies? The usage of polymyxin, a drug that was discontinued due to toxicity in the
1960’s, has been the answer to control this problematic pathogen in recent years. Indeed,
polymyxin inhaling therapies are now used for the treatment of A. baumannii VAP
infections, whilst its toxic effects remain a complication 50,51. In addition to this, increasing
trends of A. baumannii polymyxin resistance in several countries, including the Unites
States, is now a concern, highlighting the critical need for research and the development
of new effective antibiotic agents 52-55.

The Mechanisms of Drug Resistance in A. baumannii

With the emergence of MDR A. baumannii strains, research has uncovered intrinsic and
acquired mechanisms that has provided us with a better understanding of the drug
resistance evolution in A. baumannii. Such mechanisms are illustrated by the constitutive
expression of multiple efflux pumps systems, including AdeABC and AdeIJK, and the
reduced expression of porins that together limit the passage of antibiotics such as
aminoglycosides, cephalosporin, carbapenems, and tetracycline

56

. Beyond this, the

natural ability of A. baumannii to acquire and transfer genes facilitates a rapid adaptation
to antibiotics pressures. Indeed, analysis of the genomes for MDR A. baumannii strains

8

has resulted in the identification of plasmids, transposons, and insertion elements such
as the 86kb pathogenicity island, AbaR, that harbors genes important for metal and
antibiotic resistance, the class integron 1 containing beta-lactamase genes, also found in
Klebsiella pneumoniae, and the insertion sequences ISAba1, ISAba125 required for the
expression of cephalosporinases, and carbapenemases 16,57.

In addition to genetic elements and intrinsic determinants, modification of cellular targets
e.g. DNA gyrase, topoisomerase IV and 16S rRNA present an additional strategy that
provides resistance to quinolones and aminoglycosides respectively

58,59

. Apart from

these mechanisms, the structural modification of lipopolysaccharides (LPS), resulting in
loss of LPS, or the addition of the amino-sugars phosphoethanolamine or galactosamine
to the lipid A, lead to reduction in the overall negative charge in the outermembrane that
hinders the entrance of polymyxin to the cell 60,61.

In this section a summary of findings that have identified drug resistance mechanisms in
A. baumannii have advance our knowledge of the strategies used by this pathogen to
rapidly adapt to and overcome antibiotic pressures. It does this via its ability to acquire
antibiotic resistant genes in combination with intrinsic mechanisms that exposes the
threat of this pathogen in times of scarce novel antibiotics, which places us in the position
today that is considered the beginning of the post-antibiotic era”.

9

Acinetobacter baumannii as a Public Health Threat
As early as the 1980s, surveillance reports documented cases of A. baumannii outbreaks
worldwide 62-64. In the USA, the National Healthcare Safety Network (NHSN) reported an
estimated range of (41,400 – 83,000) A. baumannii infections annually in the USA and
1,000,000 worldwide 65. Recently, the Centers for Disease Control and Prevention (CDC)
reported that approximately 60% of all A. baumannii infections are associated with
multidrug resistant strains

66

. In addition, the combined effects of $389 million in

healthcare cost and 4,590 deaths associated with A. baumannii multidrug resistant
infections presents a worrisome problem for the US health system

65

. In light of this, in

2017 the World Health Organization (WHO) published a list of top priority pathogens,
which includes A. baumannii, largely as a result of its prevalent multidrug resistant nature
and negative impacts on the outcomes of patients treated with standard antibiotic
therapies. A major reason for the WHO list was to advocate for substantially more
research to develop effective therapeutic alternatives to treat MDR infections, such as
those caused by A. baumannii 15.

A major distinction for pathogens within the Acinetobacter calcoaceticus - Acientobacter
baumannii complex is its natural reservoir. Unlike other Acinetobacter species, which
have been recovered from diverse sources, including: soil, water, food and poultry, A.
baumannii has been exclusively isolated from clinical samples 67. Strikingly, as a result of
its ability to use a myriad of carbon sources, adapt to temperature shifts, and survive
harsh conditions, this bacterium has turned hospitals and health care assisting facilities
into its reservoirs68. Indeed, its persistence in countless hospital environments has been

10

described in numerous reports, demonstrating the resilient nature of A. baumannii

69-71

.

Perhaps one of the most striking cases described an MDR A. baumannii isolate that
caused a two year long outbreak in a Netherlands hospital. In this situation it was
demonstrated that, despite being on an empty bottle devoid of nutrients for nearly a year,
the bacterium remained viable; a pattern of survival that mimics methicillin-resistant S.
aureus (MRSA) strains in hospitals

72

. Similarly, positive A. baumannii air cultures from

Intensive Care Units (ICU) rooms in US hospitals have also been reported73.

The ubiquity of A. baumannii strains in health care facilities, alongside its ability to remain
viable on dry surfaces and its extreme resistance to desiccation and chemical
disinfectants, further complicate its eradication from hospitals15. From the infection control
perspective, failure to eliminate this pathogen from hospital environments is of great
concern, as mechanical ventilators, urinary catheters, and surgical instruments are just a
few examples of devices that provide a shuttle for A. baumannii to enter the host and
establish infection. As a result, disinfection and the development of sterilization
techniques to eradicate and minimize the risk of Acinetobacter infections in clinical
settings, has been an area of active research in recent years.

The Virulence Factors of A. baumannii

Another aspect that is equally important as the evolution of MDR phenotypes is the
emergence of contemporary clinical isolates that display more virulent phenotypes when
compared to their historic counterparts, such as the drug susceptible A. baumannii strains

11

ATCC 19606 and ATCC 17978 isolated in the 1950s. The increase in virulence observed
in this pathogen stems from the variable size of its genome, defined by the presence of
plasmids, transposons, and insertion elements; highlighting the role of gain and loss of
genes during the process of adaptation in the host and to the hospital setting

74

. Despite

considering this organism an “opportunistic pathogen” that can colonize healthy
individuals without causing diseases, A. baumannii is without debate a major threat for
unhealthy individuals.

In the course of infection, biofilm formation facilitates cell adherence, providing a
protective shield that is able to thwart external stressors, including host cationic peptides
and antibiotic treatments. In this regard, A. baumannii is well known for its ability to form
biofilms on medical devices used for invasive procedures

75

. Research has identified

several genes involved in adherence and biofilm formation, including the csu/A/BABCDE
operon, the biofilm-associated protein (BaP) and capsule formation 76,77. First discovered
as a virulence factor required for cell adhesion and biofilms is the outer-membrane protein
A (OmpA). Studies have revealed its interaction with host factors such as fibronectin and
host-immune cells, highlighting its role in establishing infection. Sugawara et al. identified
this protein as a porin protein and Ramkumar et. al in a more recent paper shed light onto
the permeability properties of this porin, explaining its direct role in antibiotic
resistance78,79. Other factors recently associated with adherence includes a partner
secretion system AbFhaB/AbFhaC that is required for attachment to epithelial cells,
fibronectin, and virulence in murine and worm models of infection; and the Type 1

12

secretion system (T1SS) that is proposed to secrete the biofilm-associated proteins (BAP)
80,81

.

Evasion or modulation of the innate immune system is also required for infection. In line
with this notion, the presence of the K1 locus is required for capsule synthesis, a virulence
factor that is important for survival in serum, human ascites fluids, and, murine models 82.
In addition, several groups have studied the role of LPS for A. baumannii serum survival,
demonstrating that LPS-deficient strains exhibit decreased survival in serum and are less
virulent in animal models 61,83.

The characteristic role of lipid A as a potent immune toxic molecule in other Gramnegative pathogens, such as Escherichia coli or Pseudomonas aeruginosa, has also
been observed in A. baumannii. Studies has found that lipid A from A. baumannii induces
the signaling of TLR2/TLR4 receptors found in host immune cells

84

. This pathogen-host

interaction initiates a storm of cytokine production and pro inflammatory molecules
leading to clinical symptoms such as fever, increased heart rate, and damage to blood
vessels during A. baumannii bacteremia. It has also been shown that A. baumannii add
galactosamine or phosphoethanolamine groups to its lipid A, conferring resistance to the
cationic host peptides LL-37 and the antibiotic colistin 60. Other virulence factors important
for serum resistance and colonization are the phospholipases C and D; as disruption of
genes encoding these proteins decreases the ability of A. baumannii to invade epithelial
cells and survive in blood compared to other tissues 24 hours after initial inoculation

85

.
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Perhaps these results could reflect their important role for survival in blood, allowing the
development of septicemia, which is one of the most prevalent A. baumannii infections.

As nutrients are depleted, bacteria disseminate to proximal sites of infections. To achieve
this, bacteria rely on several mechanisms, including interaction with host cells,
proteolysis, and, motility. Although first characterized as a non-motile bacterium, the
motility patterns among A. baumannii clinical isolates are diverse. It has been shown that
A. baumannii displays surface associated and twitching motility 86. A connection between
motility and several factors, including iron chelated media, blue light, and autoinducer
molecules has been established 87,88. In addition, the capsule genes epsA, ptK, the lpsB
gene involved in LPS synthesis, as well as type IV pili and the fimbriae protein A (PilA),
have been shown to affect motility in A. baumannii 88.

Finally, the role of proteases in other pathogenic bacteria, including deregulation of
complement and coagulation cascades, and dispersal of biofilms to facilitate detachment
of cells and proliferation, has been demonstrated. The A. baumannii genome has several
hypothetical proteases, although thus far only the serine protease PFK and the
coagulation targeting metallo-endopeptidase of A. baumannii (CpaA) have been
characterized

89,90

. The PFK protease has been implicated in biofilm dispersion and

protection from complement killing, whilst the CpaA protease allows A. baumannii to
survive in blood and serum as a result of its ability to cleave the purified factor (FV), and
fibrinogen, resulting in conditions that promotes dissemination and survival 90.
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Genome Plasticity of A. baumannii

Amplified fragment length polymorphism (AFLP) analysis of hypervirulent MDR A.
baumannii outbreak strains recovered from different geographic sites worldwide has led
to the classification of three primary international clonal lineages: CC1, CC2 and CC3 57.
Although other methods such as MLST (multi-locus sequenced typing) are used to
classify strains based on mutations present in elements such as housekeeping genes,
this section will focus on the use of whole genome sequencing (WGS) as a tool that has
revealed unique findings that suggest the concept of genome plasticity in A. baumannii.

With the development of sequencing technologies and the availability of more than 2000
genomes of A. baumannii strains, unique signatures within isolates belonging to lineages
CC1, CC2, and CC3 have been reported

91-93

. These findings have added an additional

criterion to define these lineages based on the presence of genetic elements responsible
for their multidrug resistance phenotypes that are otherwise absent in the genome of the
drug susceptible ATCC 17978, and the environmental microbe A. baylyi. 57,94. Specifically,
strains belonging to CC1 possess a signature pathogenic island known as AbaR1

57,93

.

This pathogenic island has been suggested to originate from insertions and transposition
events that led to the incorporation of antibiotic genes present in Pseudomonas,
Salmonella and Escherichia species into the AbaR1 cluster of A. baumannii. Similarly,
strains belonging to CC2 lineages are characterized by the presence of eight unique
islands that bear several genes required for antibiotic resistance and virulence, including
phage proteins, antitoxins, and hemolysins 95. Of particular note, CC2 strains also contain
a pathogenic island named AbaR2 that lacks an extensive region from an integration site
15

in AbaR1 to 116 nucleotides upstream of the aphA1 gene, suggesting a deletion event
and perhaps divergence from a common ancestor 95. Strains grouped in the CC3 lineage
have the signature genes aphA6 and aadB, which are associated with a class 1 integron
conferring resistance to aminoglycosides

96

. In addition, the presence of efflux genes of

type tetA and ribosomal protection genes of type tet (M) are found in this lineage, which
allows for resistance to tetracycline and minocycline antibiotics, respectively 97.

In one study, two A. baumannii clinical isolates recovered from the same patient named
AB210 and AB211 were collected before and after tigecycline treatment respectively.
Sequencing analysis revealed a disruption of the mutS (DNA repair gene) in AB211 that
perhaps could explain the presence of single nucleotide polymorphisms (SNP) in this
strain, including one in the adeS sensor histidine kinase, which has been linked to
increased activity of the AdeABC efflux system in response to tigecycline exposure

98

.

Similarly, other studies have found genetic variation as a result of deletions and SNPs in
strains from the same clonal lineages collected from the same patients. These findings
have provided evidence of the plasticity of the A. baumannii genome that enable this
bacterium to quickly adapt to antibiotic pressures and stress conditions encountered
within the host.

Regulation in A. baumannii

The adaptability of A. baumannii to unique niches within a host requires a regulatory
network able to respond to intrinsic signals, facilitating survival. Given the attention that
16

this bacterium has gained due to the recurrent recovery of MDR strains from patients, the
increase in research within the Acinetobacter field has led to the identification of genes
with roles in drug and disinfectants resistance, biofilm formation, metal acquisition,
motility, and the secretion of virulence factors. However, more recently, this research has
extended towards the characterization of regulatory proteins, including two component
systems (TCS) and transcription factors (TF).

In this context, genes with putative regulatory functions associated with antibiotic
resistance guided much of the initial research in this field, resulting in the identification of
the two component systems (TCSs) AdeRS and BaeSR, which have overlapping
regulatory roles in controlling expression of the AdeABC efflux pump system

56,99

. The

AdeRS regulon is comprised of 579 genes, and deletion of AdeRS leads to a decrease in
virulence and biofilm formation 100. The TCS BaeSR is found to controls expression of the
AdeIJK and MacAB TolC efflux pumps systems and is required to resist osmotic stress
conditions 99,101.

Further research has characterized three other TCSs: BfmRS, GacSA, and PmrAB 74,102.
BfmRS has been shown to control expression of the cusA/BABCDE genes required for
biofilm formation103. A more recent study identified 1827 genes differentially expressed
upon disruption of bfmRS, and defined a direct role for BmfRS in regulating cell
morphology associated with different growth phases 104. Work by Peleg et. al., screening
of an A. baumannii mutant library in a C. elegans model of infection identified a gene
encoding the GacS sensor as being essential for survival in this model 105. A subsequent
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study identified GacA as the response regulator of GacS, which directly regulates
metabolic genes, including the phenylacetate operon which has been found to be
important in evasion of the immune system 102,106. Finally, the PmrAB system have been
implicated in controlling genes required for LPS modification resulting in the development
of colistin resistance 74,94.

In addition to TCSs, the role of transcriptional regulators in the adaptation and
pathogenesis of A. baumannii has become the topic of much investigation. The
examination of changes in levels of siderophore production, for example, led to the
identification of the iron uptake regulator Fur

107

. Work by Hood et.al focused on the

effects of zinc host sequestration and identified the zinc uptake regulator Zur. Further
studies have established the requirement for this latter factor in survival during the course
of infection in a murine model of pneumonia

108,109

. Recently, screening of an AB5075

transposon mutant library in a worm model uncovered the requirement of 31 putative
transcriptional regulators for survival110. From this work, two independent studies
following these findings characterized two important regulators: The first, ABUW_1645,
was found to induce a phenotypic switch correlated with capsule production and
increased virulence

111

. The second, named GigA, was characterized as an orphan

response regulator linked to the anti-sigma -sigma factor GigB

112

. In this study, it was

proposed that GigA dephosphorylates GigB, resulting in sequestration of the anti-sigma
factor NPr, allowing RpoE (sE) to function during stressful conditions

112

. Finally, the TF

BlsA was found to regulate motility and biofilm formation in response to light, highlighting
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the potential role of this regulator to use light as a clue to adapt to external environments;
although the significance of this regulator in the context of infection is still unknown 87.

Although these studies have provided some understanding of the regulatory framework
within this bacterium, it is important to consider that there are a vast number of
uncharacterized regulatory proteins in A. baumannii; which forms the focus of the next
chapter of this dissertation. Collectively, research is required to elucidate the role of these
regulatory proteins, which could aid in explaining the extraordinary capacity of A.
baumannii to adapt and evolve so rapidly, bestowing it with a great ability to cause
disease and persist in the most harsh of environments.

A baumannii Metabolism

A combination of nutrient uptake and nutrient utilization pathways to meet energy
requirements for growth and cellular maintenance is of great importance for bacteria to
survive and adapt to ever changing environments. In this vein, A. baumannii is considered
to have a metabolic adaptability that allows for growth when supplemented with nutrients
including amino acids ( L-phenylalanine, L-histidine, L-leucine, L-arginine, D- malate and
L-ornithine), saccharides (glucarate, glucose, xylose, and arabinose) mucin, acetate and
ethanol as a carbon sources. 13. In support of this, a global proteomic analysis examined
the cytoplasmic and membrane proteinaceous composition of A. baumannii strain
ATCC17978, revealing the presence of 37 membrane and 155 cytoplasmic proteins as
having putative metabolic functions. These included a glucose sensitive porin that is
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homologous to OprB in P. aeruginosa, which enables the diffusion of glucose, mannitol,
glycerol, and fructose into the cell 113. In the cytoplasmic fraction, around 36% of proteins
were associated with metabolism of amino acids including glutamine, serine, aspartate,
methionine, cysteine, tryptophan, lysine, glutamine, proline, histidine, leucine, isoleucine,
and valine, suggesting that A. baumannii has sturdy amino acid metabolism. Further
worked by Farrugia et.al. examined the ability of 4 representative clinical isolates to use
a panel of 190 individual carbon and nitrogen substrates to support growth. Of this set,
80 carbon and nitrogen sources tested positive for utilization, including amino acids,
nitrate, nitrite, ammonia, carboxylic acids, and sugars. These phenotypes were correlated
to genes present in the genomes of these strains, supporting the existence of systems
dedicated for catabolism and energy generation from these substrates 114,115.

Despite the identification of genes with putative functions in metabolism via proteomic
and genomic technologies, a functional characterization of factors, and their involvement
in metabolic pathways used for assimilation and utilization of different carbon sources in
A. baumannii has only just begun. One such example comes from the characterization of
genes encoding the Histidine (His) utilization system and a Zinc metalloprotease
chaperon (zigA), which showed that both are required to allow for histidine degradation
to ammonia and glutamate as a nitrogen source and carbon source respectively. 116. The
genes contained in the paa operon encode the phenylacetate pathway in A. baumannii,
which allows for growth on L-phenylalanine as a sole carbon. This operon is required for
degradation of this amino acid, and results in the generation of intermediates acetyl-coA
and succinyl-coA that are incorporated into the tricarboxylic acid (TCA) cycle. Further to
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this, the presence of the porin CarO has been found to be required for L-ornithine uptake
and its disruption affects the ability of A. baumannii to grow in minimal media
supplemented with this amino acid 117. Additionally, screening of a Tn mutant library of A.
baumannii uncovered genes required for cysteine/sulfur assimilation, which were also
shown to be essential for survival in a worm model of infection 110. All these studies have
collectively provided a further understanding of the function of genes in A. baumannii that
support amino acid metabolism. Given the presence of putative genes and the ability of
A. baumannii to grow on the presence of a vast number of amino acids, however,
characterization of other pathways required for their assimilation has still yet to be
performed 118.

A. baumannii has notably been found to grow in the presence of ethanol as a sole carbon
source

119

. Ethanol can be degraded to acetate via acetaldehyde, which is further used

to generate acety-coA feeding the TCA cycle 120. A transcriptional study examined genes
differentially expressed in the presence of ethanol and found that several encoding
alcohol dehydrogenases, phosphotransacetylase, and acetate kinase were upregulated;
supporting the ability of this organism to convert ethanol to acetate that can be further
assimilated via the TCA cycle. 121. In addition, A. baumannii can grow on glucose despite
the absence of genes encoding hexokinase or glucosekinase, which are required for
glucose phosphorylation in the first step of glycolysis. However, the presence glucose
dehydrogenases and the pyrroquinoline (PQQ), used to convert glucose to gluconate that
then enters Entner-Doudoroff pathway, provides a route in this organism to use glucose
as a substrate for growth. Overall these studies have suggested the presence of genes
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in A. baumannii that allow the use of different metabolic pathways, favoring those for
utilization of amino acids that provide a metabolic plasticity for rapid adaptation in
response to nutrient availability.

Metal Acquisition in A. baumannii

Another important factor in bacterial metabolism is the ability to acquire and utilize metals
that are essential for growth and cellular process 122. The most extensively studied metal
acquisition systems in A. baumannii is that of iron. In humans, extracellular iron
concentrations are maintained between 10-30µM in which ferric iron (Fe+3) is
predominantly found to be associated with the host proteins lactoferrin and transferrin. In
such conditions, A. baumannii is known to express iron sequestering molecules known
as siderophores to obtain iron from these host iron proteins

122,123

. The first such

siderophore system identified was in strain A. baumannii 8399. This system secretes the
iron chelator 2,3 -dihydroxybenzoic acid (DHBA), which allows for binding of Fe+3 bound
to transferrin 124. Following this, Antunes et. al. analyzed the genome of 50 clinical isolates
(and identified conservation among 49 of them) of an operon having genes for the
production of the siderophore hydroxamate, which was found to be upregulated in iron
limited conditions

86,125

. Among the siderophore systems present in this bacterium, the

most studied iron acquisition system is the catechol-hydroxymate siderophore
acinetobactin that was first identified in work published by Mihara et. al who reported a
cluster of 18 genes with putative iron acquisition functions 126. Further phenotypic assays
performed in strains with disruption of each gene in this cluster revealed the role of genes
basABCDEFGHIJ in production of acinetobactin and barAB for iron transport

126

. In
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addition to the acinetobactin system, a parallel ferric acinetobactin system in A. baumannii
exists which is comprised of an ABC tripartite system (BauD and BauC putative inner
membrane proteins and the putative ferric-siderophore transport ATPase BauE), a
putative lipoprotein BauB, and the outer-membrane receptor BauA Disruption of genes
encoding these proteins have resulted in reduced growth during limited iron limited
conditions supporting their role in iron acquisition in A. baumannii 124.

The essential role of genes involved in iron acquisition within the infection process has
been demonstrated in ex vivo and in vivo models. For example, the disruption of genes
with functions in production or secretion of acinetobactin siderophores have led to
decreased survival in A549 epithelial cells and in the Galleria mellonella and mouse
sepsis models

127

. Another source of iron is the reduced form of iron Ferrous iron (Fe+2).

Several gram-negative bacteria possess genes dedicated to transport ferrous iron into
the cell 122. One transporter conserved among some Gram- negative pathogenic bacteria
is the FeoAB system. In A. baumannii the FeoAB system has been identified and its
disruption resulted in decreased survival in blood, growth defects in limited iron media
and increased susceptibility to polymyxin

128

.

In addition to iron, zinc is an essential cofactor for numerous enzymes, including
metalloproteases. A zinc acquisition system homologous to those in other pathogenic
bacteria, including Pseudomonas aeruginosa, Streptococcus pneumoniae and Listeria
monocytogenes, was discovered in A. baumannii

129

. The study published by the Skaar

group identified the genes encoding key zinc transporters in A. baumannii. This system
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was found to be important for competition in zinc acquisition against the host zinc chelator
Calprotectin, a protein found in neutrophils, in a mouse pneumonia model 116,129. Finally,
manganese has been shown to be important for bacterial infection as it is used as a
cofactor for bacterial proteins with diverse biological functions. In vitro studies have shown
that calprotectin also acts as a manganese chelator, with antimicrobial activity against
many different pathogenic bacteria, including A. baumannii

116

. In a recent studied L.

Juttukonda et. al. identified a manganese transport system required for growth and
virulence in the presence of calprotectin 130.

All this work together shows the importance of A. baumannii metal acquisition systems in
the course of infection, which allow it to overcome host nutritional limitation strategies.
Although these studies have started to reveal these mechanisms in the context of A.
baumannii infections, more studies are required to provide a better understanding of their
role in metal homeostasis and infection, which could aid in the development of new
antimicrobials.

Project Aim.

The emergence of virulent and MDR A. baumannii strains have directed most of the
Acinetobacter field towards the identification of virulence determinants and understanding
their contribution to pathogenicity and drug resistance. However, the regulatory
framework and controlling mechanisms that account for the successful adaptability of this
organism are poorly defined. With this in mind, this dissertation sought to further
investigate the regulatory framework of this organism. As such, the first part of this work
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will present the repertoire of regulatory proteins in A. baumannii with an emphasis on their
conservation among strains with different virulence and MDR profiles. The primary
rationale for this was to use this information to perhaps explain their role in pathogenicity
and the evolution of this bacterium. The second aim seeks to explore the function of A.
baumannii two-components systems, focusing on a homolog of ArcAB and its role in
controlling metabolic process for energy generation. Ultimately, the third aim will identify
and discuss the role of an uncharacterized operon containing homologs genes to the fecI
operon found in other Gram-negative bacteria, and its function in the context of iron
acquisition. Collectively, the work presented in this dissertation will provide further insights
and a deeper understanding of the regulatory framework that exists within A. baumannii,
and how this contributes to growth survival, adaptation and virulence.
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CHAPTER II
TOWARD THE COMPLETE PROTEINACEOUS REGULOME OF ACINETOBACTER
BAUMANNII

Note to the reader. This chapter was previously published as a manuscript, and has
been included with permission form the publisher. (Appendix 1).
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CHAPTER III
IDENTIFICATION OF A NOVEL TWO COMPONENT SYSTEM GOVERNING
MEMBRANE ENERGETICS IN ACINETOBACTER BAUMANNII

ABSTRACT. The emergence of hypervirulet multidrug resistant Acinetobacter baumannii
strains has increased public health awareness worldwide. Whilst genes have been linked
to virulence and antimicrobial resistance, the characterization of genes with potential
regulatory roles towards these behaviors are still ill-defined. Previously, we reported the
identification of regulatory elements in A. baumannii, which includes 14 two-component
systems (TCSs). Of these, only six have been well characterized to date. A bioinformatic
analysis performed on the remaining 8 systems identified the (RR) ABUW_2426, and its
corresponding sensor kinase (ABUW_2427) as a homolog of the ArcAB from E. coli.
Transcriptional

analysis

using

a

reporter

gene

fusion

showed

that

the

ABUW_2426/ABUW_2427 operon was induced by the protonophore carbonyl cyanide
m-chlorophenylhydrazone (CCCP). Additionally, decreases in intracellular pH and
reduced response to dissipation of the electrochemical gradient and increased
depolarization of the cytoplasmic membrane were observed in both mutant strains. RNA
seq analysis revealed an altered expression of genes involved in energy generation and
measurement of metabolites generated via aerobic energy generation pathways further
support an altered energy state in our mutants. In summary, we demonstrate that
disruption of ABUW_2426/ABUW_2427 alters the metabolic state of A. baumannii,
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concomitantly affecting energy generating pathways dependent processes resulting in an
increased susceptibility to aminoglycosides.

INTRODUCTION

Acinetobacter baumannii is a Gram-negative bacterial pathogen commonly associated
with life threating and deadly diseases, including skin and soft-tissue infections, urinarytract infections, ventilator associated pneumonia, meningitis, endocarditis and
septicemia. Such infections are commonly in patients from healthcare facilities, and
primarily those in intensive care units 34,131-133. The first line therapeutics used to treat A.
baumannii infections are broad spectrum antibiotics, including cephalosporins,
fluoroquinolones and carbapenems17,48,134. Resistance among clinical isolates to these
agents is, however, becoming increasingly common, leading physicians to explore
alternatives, such as aminoglycosides, to treat multidrug-resistant (MDR) infections
135,136

. Unfortunately, the recurrent isolation of pan-resistant A. baumannii strains on a

global scale has complicated such therapeutic intervention47,137-140. As a result, the
Worldwide Health Organization (WHO) has categorized A. baumannii in the highest
priority group of pathogens, who are defined as being the most critical organisms for new
antimicrobial drug development141.

During infection, bacterial pathogens encounter myriad of unfavorable environmental
conditions, including osmotic stress, heat stress, acid stress, oxidative stress, nutrient
limitation and host cationic antimicrobial peptides142,143. Under these harsh conditions,
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survival is dependent on an adaptive response controlled by regulatory elements, such
as transcriptional regulators (TF), σ factors and two-component systems (TCSs)144-146. Of
these regulatory elements, TCSs are widely employed by bacteria to sense and response
to environmental stimuli147. TCSs normally consist of a membrane sensor histidine kinase
(HK) that, upon perceiving external insult, autophosphorylates at a conserved histidine
residue148,149. This phosphate group is then transferred to a conserved aspartate residue
on its cytoplasmic response regulator (RR) partner that is typically a DNA binding
protein150,151. This signal transduction cascade leads to the coordinated activation or
repression of genes required for a wealth of responses, including biofilm formation,
motility, and the expression of adherence proteins, exotoxins, efflux pumps and outer
membrane porins 152.

Recently, we performed a study to identify the entire proteinaceous regulome of A.
baumannii strains. As part of this work we identified 14 TCSs conserved within the
genome of a variety of representative clinical isolates,153 with only six having been
characterized to date, including BfmSR, PmrAB, AdeRS, BaeRS, Ompr-EnvZ and GacSA
56,99,112,154-156

. These systems have been shown to influence the expression of genes

required for various functions, including motility, biofilm formation, metabolism and the
expulsion of antimicrobials via efflux pumps. 100,101,157

Herein, we present the characterization of one of the uncharacterized TCS,
demonstrating that it is an A. baumannii homolog of the ArcAB system (Aerobic
Respiratory Control) found in E. coli and other organisms

158,159

. Early work on this
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system, using an arcA mutant of E. coli, revealed alterations in the enzymatic activity of
proteins belonging to the TCA (tricarboxylic acid cycle), glyoxylate shunt, and other
energy generation pathways, alongside the repression of genes involved in anaerobic
respiration in the presence of oxygen.158. Later work identified ArcB as the sensor partner
of the ArcA response regulator159,160, demonstrating that, in the absence of oxygen,
autophosphorylation

of

ArcB

leads

activation/repression

of

genes

to

associated

the
with

phosphotransfer
energy

to

generation,

ArcA

and

glycolysis,

fermentation, and cellular respiration161-163. Although oxygen levels were initially
proposed as the activation signal for ArcAB, the kinase activity of ArcB is in fact
dependent on changes in the redox state of the cell as a result of variation in ubiquinone
and menaquinone concentrations

164-166

. In the presence of oxygen the transfer of

electrons from quinones to cysteine residues located in the N-terminal domain of ArcB
has the effect of silencing ArcB kinase activity and suppressing the activation of ArcA 167.

ArcAB homologs with similar functions have also been reported in other organisms,
including Salmonella enterica, Shewanella oneidensis, and Haemophilus influenzae168172

. Independent studies on ArcAB in these organisms has identified genes functioning in

motility, metabolism, and cell division as belonging to the ArcA regulome173-175. Other
studies in H. influenzae and S. enterica have also shown the important regulatory role of
ArcAB in responding to oxidative stress induced by H2O2

174 173

. Similar results to this

latter point have also been reported in E. coli 176. Further work has demonstrated a role
for ArcA in facilitating E. coli colonization of the intestinal epithelium in a mouse model, a
niche that is devoid of oxygen

177

. In S. enterica, arcA and arcB have been shown to be
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required for dissemination in a murine model of infection, and for survival in
macrophages178.

Using a bioinformatic approach, we identified the ABUW_2426 RR and its cognate HK
ABUW_2427 as homolog of ArcAB from E. coli. Transcriptional analysis revealed that
the proton ionophore carbonyl cyanide m-chlorophenylhydrazone (CCCP), which
collapses the PMF, induces the arcAB promoter. Further to this, we determined that
disruption of arcA and arcB in A. baumannii leads to decreased membrane polarity and
acidification of the cytoplasm. Transcriptomic profiling of an arcA mutant revealed altered
expression of genes involved in metabolism and energy generation, leading to an
abundance of metabolites produced from an overactive glyoxylate shunt, and increased
activity of energy generation pathways typically used by bacteria growing in the absence
of oxygen. Collectively, our data identifies the ABUW_2426/2427 TCS as an ArcAB
homolog that controls the expression of a variety of genes necessary for modulating
membrane energetics and metabolic pathways in A. baumannii.

MATERIAL AND METHODS

Bioinformatic analyses. A search for homologues of ABUW_2426 and ABUW_2427 in
the genome of Escherichia coli K-12 MG1655 (GenBank accession no. NC_000913), was
performed using blastp searches (with an E value ≤10−20 and coverage of ≥60 %). Protein
sequences of ArcA and ArcB from Eschericha coli, Salmonella enterica, Vibrio cholerae,
Haemophilus influenzae, and Shewanella oneidensis were downloaded from the NCBI
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ftp server (www.ncbi.nlm.nih.gov/genome) and alignments were generated using CLC
Genomics Workbench (version 7.6.1; CLC bio). Topology maps of ArcA and ArcB
proteins were generated using the protter tool (http://wlab.ethz.ch/protter/start/).
Strains and growth conditions. The strains and cloning primers used in this study are
listed in Table 1. All strains were cultured in lysogenic broth (LB), unless otherwise
indicated, with shaking at 37°C. When appropriate, antibiotics were added for selection:
tetracycline at a final concentration of 5 µg/mL and hygromycin at a final concentration of
140 µg/mL. Mutants of ABUW_2426 (arcA) and ABUW_2427 (arcB) were acquired from
the AB5075 transposon mutant library179. Strains were confirmed using primers
OL4155/OL4156

(arcA)

or

OL4157/OL4158

(arcB).

Unless

stated

otherwise,

synchronous cultures were prepared as follows: A. baumannii strains were grown in LB
overnight at 37°C with shaking. These cultures were then diluted 1:100 into 100mL of
fresh LB, grown to exponential phase, before being used to seed new 100mL cultures at
an OD600 of 0.05.
Table 1. Bacteria strains, plasmids and cloning primers
Strain
E. coli

Description

Source

DH5α
A. baumannii
AB5075
AB5075 178::T26
AB5075 156::T26
LGC2591
LGC2592
LGC2463
Plasmids
pMQ557

Cloning strain

1

Wild-type strain
AB5075 with transposon insertion in ABUW_2426
AB5075 with transposon insertion in ABUW_2427
AB5075 178::T26 complemented with pMQ557::arcA
AB5075 156::T26 complemented with pMQ557::arcB
AB5075 containing pSLG2 (ParcB–lacZ fusion)

2

Cloning vector for complementation

Gift,
Dr.
R.
Shanks, University
of Pittsburgh

pAZ106

Promotorless lacZ insertion vector

3

2
2

This study
This study
This study
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Table 1 (Continued)
pSLG1
pSLG2
pSLG3
pSLG4
Primers
OL4155

pAZ106::ParcB–lacZ
pMQ557::ParcB–lacZ
pMQ557::arcA
pMQ557::arcB

This study
This study
This study
This study

ATGCCCGGGGGTAATCAAGTCAAGGTCGA

This study

OL4156

ATGCCCGGGTTAGTGGTGGTGGTGGTGGTGTTGCTT
ATCCTGAATCAATC

This study

OL4158

ATGCCCGGGTTAGTGGTGGTGGTGGTGGTGGTGAA
ACTCTTGCACCAAGC

This study

OL4169

ATGGGATCCATAACCGCTGCCCACCATGCT

This study

OL4170

ATGGAATTCTACGACAATTGCTGCCCATA

This study

OL4230
OL4232

ATGCTCGAGATAACCGCTGCCCACCATGCT
ATGGCGGCCGCGACCCAACGCTGCCCGAGAAA

This study
This study

*Underscore indicates restriction enzyme site
Construction of an arcAB-lacZ transcriptional fusion strain. A PCR fragment was
generated that begins 500 nt 5’ of arcB and ends 1309 nt 3’ of it, using primers
OL4169/OL4170. This fragment was cloned into the vector pAZ106, which contains a
promoter-less lacZ cassette, creating plasmid pSLG1. This plasmid was then used to
amplify the ParcB-lacZ fusion fragment using primers OL4230/OL4232, which was
subsequently cloned into the A. baumannii shuttle vector pMQ557, resulting in plasmid
pSLG2. AB5075 was then transformed with pSLG2, and colonies were selected using LB
plates supplemented with hygromycin (plasmid encoded). All strains were confirmed by
PCR.
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Construction of arcA and arcB complementation strains. A 3,979 bp fragment
including 500 bp upstream and downstream of the arcB gene, and a 4,945 bp fragment
that is identical to the first, but also includes the complete arcA gene as well, were
amplified using primers OL4155/OL4158 and OL4155/OL4156, respectively. These PCR
products were cloned into pMQ557, creating plasmids pSLG4 and pSLG3, respectively.
Clones were confirmed by PCR and Sanger sequencing (MWG Operon), before being
transformed into the relevant A. baumannii arcA and arcB mutants. A. baumannii strains
were again confirmed by PCR and Sanger sequencing (MWG Operon).

Transcriptional profiling assays using b-galactosidase. A plate-based screening
assay was performed as previously described
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. Briefly, LB plates were overlaid with

5mL of LB top agar (0.7% w/v) supplemented with X-Gal at a final concentration of
40µg/mL and the A. baumannii ParcA-lacZ fusion strain. Sterile disks were placed on plates
and each disk was inoculated with 10µL of a given chemical stressor. Plates were
incubated overnight at 37°C and induction of expression was recorded as a blue halo
around the filter discs. For expression over time, synchronize cultures at an OD600 of 0.05
were prepared in LB as detailed above, before the following compounds were added at
subinhibitory concentrations: Chloramphenicol = 12.5 µg/mL, Ampicillin = 100 µg/mL,
Gentamicin = 100 µg/mL, Sulfanilamide = 100 µg/mL, CCCP = 6.25 µg/mL N’N’
dicyclohexylcarbodiimide (DCCD) 100 µg/mL, Valinomycin 25 µg/mL, and 2-4
dinitrophenol 75 µg/mL. Cultures were incubated with shaking at 37°C, with 0.1mL
samples collected every hour. Levels of b-galactosidase were measured as described
previously181. Results are presented from three independent experiments.
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Intracellular pH measurement. Synchronous cultures were prepared in Mueller Hinton
Broth (MHB) before being centrifuged and washed with a potassium phosphate buffer,
pH 7.0, supplemented with 5mM EDTA. Cell were then pelleted again and resuspended
in the same buffer, followed by the addition of the BCECF-AM dye at a final concentration
of 20µM. Samples were then incubated for 30 minutes at room temperature. After this
time, cells were pelleted, washed and resuspended in the same buffer, followed by the
addition of glucose to a final concentration of 10mM. Samples were incubated for 5
minutes at 37 °C, before 200µL aliquots were withdrawn and added to the wells of a 96well plate. Fluorescence signals were read for 5 minutes at an excitation of 490nm and
emission of 530nm using a BioTek Synergy II plate reader. As a control, CCCP at a subinhibitory concentration of 6.25 µg/mL was added to decrease the intracellular pH. To
create a calibration curve, cells were resuspended in high potassium buffers with a pH
range from 6.5 to 8.0. Results are presented from three independent experiments.

Membrane Depolarization Assay. Membrane depolarization was measured using the
membrane potential sensitive fluorescent DISC3 dye (3,3'-Dipropylthiadicarbocyanine
Iodide). Synchronous cultures of the wild-type and its arcA and arcB mutants were
prepared as detailed above before being harvested by centrifugation and washed 3 times
with 5 mM HEPES buffer, pH 7.2, containing 5mM glucose. Samples were then
resuspended to an OD600 of 0.05 in the same buffer. Cell suspensions were incubated
with 100mM KCl and 2 µM of DISC3 for 15 min at room temperature. Mixtures were added
to the wells of 96 well plates, and lysozyme was added at decreasing concentrations.
Fluorescence was monitored at an excitation wavelength of 662nm and an emission
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wavelength of 670nm. Reads were taken for a period of 30 minutes at 2 minutes intervals.
Results are presented from three independent experiments.

RNA Sequencing and Bioinformatic Analysis. RNAseq experiments were performed
as described previously
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. Briefly, synchronous cultures of the A. baumannii wild-type

and arcA mutant strain were prepared in biological triplicate. After growth for 1 hours,
CCCP was added to a final sub-inhibitory concentration of 6.25 µg /mL. Cultures were
allowed to grow for 2 additional hours, before 5 mL was harvested from each flask. This
was added to 5 mL of ice-cold PBS, pelleted by centrifugation at 4°C, and the supernatant
removed. Total RNA was isolated using a RNeasy Kit (Qiagen) and DNA was removed
using a TURBO DNA-free kit (Ambion). Sample quality was assessed using an Agilent
2100 Bioanalyzer system with an RNA 6000 Nano kit (Agilent). AN RNA integrity value of
>9.7 was used as a cutoff. Prior to mRNA enrichment, biological triplicate RNA samples
were pooled at equal concentrations followed by rRNA removal using a Ribo-Zero Kit for
Gram Negative Bacteria (Illumina) and a MICROBExpress Bacterial mRNA enrichment
kit (Agilent). Removal efficiency of rRNA was confirmed using an Agilent 2100
Bioanalyzer system and an RNA 6000 Nano kit (Agilent). Library preparation was
performed using the TruSeq Stranded mRNA Kit (Illumina) omitting mRNA enrichment
steps. Quality, concentration, and the average fragment size of each sample was
assessed with an Agilent TapeStation and High Sensitivity DNA ScreenTape kit. Library
concentration for the pooling of barcoded samples was assessed by qPCR using a KAPA
Library Quantification kit (KAPA Biosystems). Samples were run on an Illumina MiSeq
with a corresponding 150-cycle MiSeq Reagent kit. Upon completion, data was exported
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from BaseSpace (Illumina) in fastq format and uploaded to Qiagen Bioinformatics for
analysis. Data was aligned to the AB5075 reference genome (NZ_CP008706.1), and
experimental comparisons were carried out after quantile normalization using the Qiagen
Bioinformatics experimental fold change feature. https://www.ncbi.nlm.nih.gov/geo/. Raw
data from this study can be found at GEO Accession number GSE123635, Token
oxczecoehvyxfah.

Quantitative real time PCR. Quantitative real time PCR (qPCR) analyses were
conducted as described previously using primers detailed in Table 2. 181 Bacteria cultures
were grown and RNA extracted as described for the RNA-seq experiment in this study.
Data is derived from three independent replicates.
Table 2. List of qPCR primers used in this study.
Strain

qPCRGene
CCTAGAGATAGTGGACGTTACTCG

16S F

CCAGTATCGAATGCAATTCCCAAG

16S R

OL4694

TTCACGAGATTAATACTGACTGGAG

pqqA F

OL4695

ACCAATACGTAAATCAGTGAAAGC

pqqA R

OL4696

AGGCAATGTCGGTGATATTC

gcdH F

OL4697

TGTAATCGAGGCACGTAAAC

gcdH R

OL4698

CTTGCGCCTGGTTCTAAA

acnA F

OL4699

AAAGGACCTGAGTTACCAATAC

acnA R

OL4498
OL4499
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Table 2. (Continued)
OL4700

AGTTCATACAACCGCCAATAC

Pta F

OL4701

CACAGTCACCGTAGACATAGA

Pta R

OL4702

CTATGGTTTCCACGGTACAAG

ackA F

OL4703

CACAAGTCGAGCTACCATTAC

ackA R

OL4704

CTTCATTCGCTGAAGCATTAC

eno F

OL4705

AAACCACCTTCATCACCTAC

eno R

OL4706

GTCAGGTGTTAGCGGTAAAT

sdhC F

OL4707

CAAATCCTTCTGGTGAAGATAATG

sdhC R

OL4708

GCAAACATTCGTGGAAGATTAC

Pil F

OL4709

GATGGCTAATACACAGCACTT

Pil R

OL4710

CACGTTTAATCGCTCCTCTT

atpB F

OL4711

GTGAGGGTCCATACCAAATAC

atpB R

OL4712

GGTTCTTGGAATATCCGTTGTA

csuB F

OL4713

AACCATTCTTCATACGTCTTGT

csuB R

Letters in bold indicate F= Forward ; R= Reverse

Intracellular metabolite quantification assays. To measure intracellular metabolite
concentrations, the wild-type and its arcA and arcB mutants, alongside complemented
strains, were synchronized and grown for 3 hours in LB media. For glucose quantification,
cultures were supplemented with glucose to a final concentration of 0.2% w/v. After 3
hours, cells were collected by centrifugation and lysed using a Mini BeadBeater -16
(Biospec). For acetate, pyruvate and succinate quantification, cells were resuspended in
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100µL of their dedicated assay buffer (Biovision) before lysis. For pyruvate quantification,
cells were not lysed, but instead were pelleted by centrifugation and pyruvate was
extracted with 4 volumes of pyruvate assay buffer (Biovision). For NADH, cells were also
not lysed, but instead were pelleted by centrifugation and total NADH (NADH and NAD)
extracted with 400 µL extraction buffer (Biovision). NAD was decomposed by incubating
samples for 30min at 60 °C. Intracellular metabolite quantification was then performed
using a: glucose colorimetric assay kit (Biovision), acetate colorimetric assay kit
(Biovision), pyruvate colorimetric assay kit (Biovision) oxaloacetate colorimetric assay kit
(Biovision), succinate colorimetric assay kit (Biovision), or NADH colorimetric assay kit
(Biovision), all as per the manufacturer’s protocol. All data is derived from three
independent replicates

Antimicrobial susceptibility assays. Overnight cultures from the wild-type and its arcA
and arcB mutants were diluted 1:1000 in fresh MHB and 180µL was transferred to the
wells of a 96-well plate. Antibiotics were added to wells in decreasing concentrations to a
final volume of 200µL. Plates were incubated at 37°C and the OD600 was determined
following overnight incubation to quantify growth or lack thereof. All assays were
performed in biological triplicate.

Assaying ATP levels within cells. The wild-type and its arcA and arcB mutants,
alongside complemented strains, were synchronized and grown for 3 hours in LB media.
Following 1 hour of growth, CCCP was added to a final sub-inhibitory concentration of
6.25 µg /mL and cultures were allowed to grow for 2 additional hours. Cells were then
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washed and pelleted by centrifugation, resuspended in HEPES buffer and allowed to
incubate on ice for 30 minutes. These samples were then incubated in the presence of
pyruvate (10mM) at 30 °C for 30 minutes. After incubation cells were collected and
resuspended in ATP buffer (Biovision), before being lysed using a Mini BeadBeater -16
(Biospec). ATP quantification was performed using an ATP colorimetric assay kit
(Biovision) following the manufacturer’s protocol. Data is derived from three independent
replicates.

Determination of cytochrome oxidase activity. The wild-type and its arcA and arcB
mutants, alongside complemented strains, were synchronized and grown for 3 hours in
LB media. Cells were collected and resuspended in 1X assay buffer (10mM Tris-HCl,
120mM KCl pH 7.0) before being lysed using a Mini BeadBeater -16 (Biospec).
Cytochrome activity was quantified using a cytochrome c oxidase assay kit (SigmaAldrich) following the manufacturer’s protocol. Data is derived from three independent
replicates.

RESULTS

Identification of ArcAB homologs in the genome of Acinetobacter baumannii.
Previously, our group performed a global analysis of the A. baumannii genome, identifying
its complete set of regulatory factors.153 To extend this work herein, we focused our
attention on the 14 two component systems identified in strain AB5075. While six of these
have been studied, the remaining TCSs have yet to be characterized. As such, we

40

performed a smart BLASTP analysis to identify homologs that could provide insight into
possible functions of the uncharacterized TCSs. In so doing, we identified a response
regulator and histidine kinase (ABUW_2426 and ABUW_2427, hereafter referred to as
Anoxic Respiration Control (ArcAB)), with strong similarities to other previously
characterized ArcAB modules found in Escherichia coli, Salmonella enterica, Vibrio
cholerae, Haemophilus influenzae, and Shewanella oneidensis. (Supplemental Figures
S1 and S2, Table 3).
Table 3. Blast analysis of ABUW_2427 and ABUW_2426 from A. baumannii identifies
them as ArcAB homologs.

Organism
Escherichia coli
Salmonella enterica
Haemophilus influenzae
Shewanella oneidensis

1

Vibrio cholera

Protein
ArcB
ArcA
ArcB
ArcA
ArcB
ArcA
ArcB
ArcA
ArcB
ArcA

Identity1
Similarity2 Reference
31%
54% 4
24%
46%
31%
54% 5
24%
46%
29%
49%
27%
48% 6
30%
50% 7
27%
44%
30%
52% 8
26%
47%

Shown is the percent identity from a BLASTP analysis using ABUW_2426 (ArcA) and
ABUW_2427 (ArcB).
2
Shown is the percent similarity from a BLASTP analysis using ABUW_2426 (ArcA) and
ABUW_2427 (ArcB).

Looking at the topology of the A. baumannii sensor ArcB revealed a membrane bound
HK with 14 transmembrane (TM) domains and very limited exposure to the periplasm;
with both the N- and C-terminus orienting to the cytoplasm (Figure 1). The A. baumannii
HK seemingly lacks an obvious input sensory domain, which is perhaps explained by the
observation that HKs with large numbers of TM domains typically sense membrane
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associated stress150,151. Interestingly the ArcB of H. influenzae also lacks a sensory
domain, but is able to complement an arcB mutant of E. coli, suggesting that this domain
maybe not be required for ArcB function171. Beyond this, the A. baumannii HK has a
classic transmitter domain (aa683-749) that harbors a conserved histidine residue
(H693), a HTApase domain (aa796-909) and a receiver domain (aa930-1042) with a
conserved aspartic residue (D980). The presence of both, transmitter and receiver
domains in the same HK (including other ArcB homologs) has previously been described
(known as HK hybrids) and is believed to enhance the signal transmission via a
phosphorelay mechanism.

Figure 1. Predicted topology of ArcB from A. baumannii. Shown is the predicted topology of ArcB from A. baumannii
generated using the Protter bioinformatic website. Depicted are 14 predicted transmembrane domains. Blue shading
indicates amino acids located in the transmitter domain. Red shading indicates the conserved histidine reside (H693).
Pink shading indicates amino acids located in the HTApase domain. Green shading indicates residues located in the
receiver domain. Yellow shading indicates the conserved aspartic acid residue (D980).

Of note, although present in other ArcB proteins, the A. baumannii homolog seemingly
lacks a phosphotransferase (Hpt) domain, which participates in the phosphorelay
mechanism of hybrid HKs. In this scenario, activation of ArcA is achieved by the transfer
of a phosphate within ArcB from a histidine residue in the transmitter domain, to an
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aspartic acid residue in its receiver domain, and finally to a second histidine residue in
the phosphotransferase (Hpt) domain. From here, ArcB transfers the phosphate to an
aspartic residue of ArcA located in its receiver domain.183-185. The lack of a Hpt domain in
the ArcB of A. baumannii could suggest the participation of an additional protein harboring
a Hpt domain. In such a situation, the Hpt containing protein could accept the phosphate
group from the aspartic acid residue located in the receiver domain of ArcB and transfer
it to ArcA. Indeed, this type of signaling pathway has been described for the RcsCB TCS
of E. coli 186.

We also found differences in sequence homology in areas that facilitate regulation of
phosphotransfer in ArcB. Specifically, the E. coli ArcB has two cysteine residues (aa180,
aa241) within its sensor domain that are oxidized by quinones during aerobic growth to
facilitate dephosphorylation of ArcA. Conversely, during anaerobic growth reduction of
these cysteine residues occurs as a result of decreased ubiquinone pools, which induces
ArcB kinase activity, leading to phosphorylation of ArcA. This dual-cysteine arrangement
is only conserved in S. enterica, whilst V. cholera and A. baumannii only have Cys 180,
whilst H. influenzae and S. oneidensis appear to lack both residues. The lack of
conservation of both cysteine residues does not appear to affect the function of ArcB in
these organisms, suggesting that regulation of ArcB kinase is potentially quite variable
across different organisms171,187.

We also generated alignments for ArcA proteins, and found that all organisms have a
conserved aspartic acid within the N-terminus that is known to be phosphorylated by ArcB
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to activate ArcA in E. coli. Beyond this, we found a strong conservation of amino acid
residues in the regulatory domain located at the interface a4-b-5-a5 from ArcA in E. coli,
including those residues present at the interface of this region that facilitate dimer
formation188. Lastly, the ArcA proteins from each of the organisms used in our comparison
analysis have been classified as OmpR family members based on conservation of the Cterminal winged- helix turn helix (HTH) binding motif that distinguishes RR regulators
grouped in this family189. Interestingly, we observed low conservation of this region in the
ArcA protein of A. baumannii. Indeed, in a previous bioinformatic study by our group on
the proteinaceous regulome of A. baumannii, we classified ABUW_2426 as a LuxR-type
response regulator based on homology of its tetrahelical HTH motif

153,189

. As such, this

would perhaps suggest a divergent origin and/or function of the ArcA protein within A.
baumannii.

We next compared the arcAB genomic organization in A. baumannii with previously
characterized arcAB clusters from the same five different bacteria (Figure 2). In E. coli
and S. enterica the genetic organization is very similar, with arcB located 4 genes
upstream of its RR arcA. Conversely, in S. oneidensis arcA is located 7 genes upstream
of arcB. V. cholera has a more traditional arrangement, with the RR located adjacent to
the sensor but in the opposite transcriptional direction. Finally, A. baumannii is the only
organism from this collection that bears a classic TCS arrangement, with arcB and arcA
clustering immediately adjacent to each other, in the same transcriptional direction.
Interestingly, with the exception of E. coli and S. enterica, none of the organisms maintain
any type of similarity for surrounding genes, with each encoded in entirely unrelated areas
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of the genome. This unique arrangement could perhaps reflect horizontal acquisition of
these genes across different species.

Expression of the ArcAB TCS is induced upon disruption of the proton gradient
in A. baumannii. To explore a potential function for the putative ArcAB cluster in A.

Figure 2. Syntenic comparison of the arcAB module from A. baumannii. Genes are shown as arrows indicating
the direction of transcription. Green arrows indicate arcA genes, whilst blue arrows indicate arcB genes. White arrows
correspond to genes with no similarity to any surrounding gene across the various organisms. Purple arrows indicate
genes of shared homology between E. coli and S. enterica, encoding proteins with the same known or predicted
function.

baumannii we first set out to examine how its transcription is induced in the cell by external
stress. As such, a lacZ-reporter gene fusion was created for the arcAB promoter in the
wild-type strain and used in a plate-based disk diffusion-based assay detailed by us
previously 190. Of the 23 different compounds used, which elicited myriad cellular stresses
(including, DNA stress, oxidative stress, osmotic stress, detergent stress, alkali stress,
acid stress, nitric oxide stress, alcohol stress, and membrane stress), we observed that
only the protonophore CCCP resulted in enhanced expression of the arcAB promoter
(Supplemental Figure S3).

45

Figure 3. arcAB transcription is induced upon exposure to the protonophore CCCP. ß-galactosidase activity of
an arcAB-lacZ fusion strain was measured hourly during exposure to sub-inhibitory concentrations of the agents shown.
Transcriptional activity is expressed as Miller Units. Data is derived from three independent experiments, with error
bars shown as +/- SEM.

To validate this observation, β-Galactosidase activity in the fusion strain was measured
over time in the presence or absence of sub-inhibitory levels of several compounds used
in the plate-based screen. Again, we observed that transcription from this promoter was
very low in all conditions other than those containing CCCP (Figure 3A). This finding is
of interest because CCCP has the effect of collapsing the PMF by shuttling protons
against the electrochemical gradient across the cell membrane, into the cytoplasm. This
results in a decline in proton-coupled ATP production, and thus changes in the energy
state of the cell; resulting from decreased movement of electrons along the respiratory
chain, and a concomitant reduction in ubiquinone pools 191,192. To explore this phenotype
more broadly, we next measured the activity of this promoter in the presence of
uncouplers

with

different

mechanism

of

actions.

These

included

N’N’

dicyclohexylcarbodiimide (DCCD), an inhibitor of the ATPase subunit Fo/F1 that impedes
translocation of H+ resulting in the arrest of ATP production; valinomycin, an uncoupler
that increases the efflux of potassium (K+) ions and disrupts membrane potential; and 24 dinitrophenol, a protonophore that translocate H+ ions against the electrochemical
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gradient. Interestingly, we again observed that arcAB promoter activity was only higher in
the presence of CCCP as compared to the other uncouplers, supporting a specific
response of the arcAB promoter to this agent (Figure 3B). This corroborates that seen
for other ArcAB systems, which sense a reduction in the concentration of quinones during
electron flow, and the subsequent decline in ATP production, as the respiratory chain
ceases; which effectively mirrors a diminished PMF caused by CCCP. 168,172,187,193,194

Disruption of ArcAB impairs the PMF in A. baumannii. Given that our transcriptional
studies demonstrate that A. baumannii induces expression of arcAB in response to a
decreased PMF and limited cellular ATP (induced by CCCP), we next wanted to
determine if deletion of arcA or arcB resulted in an altered PMF within the cell.
Collectively, the PMF consists of a transmembrane proton gradient (△pH) and a
transmembrane potential (ΔΨ), both of which are important for maintenance of an
electrochemical gradient across the cell membrane 195,196

Accordingly, we first used the pH sensitive dye BCECF-AM to measure the
transmembrane proton gradient. This dye crosses the bacterial membrane and is
hydrolyzed by bacterial esterases to give a fluorescence signal used as a measure of
intracellular pH. Upon treatment of the wild-type, arcA and arcB mutants and
complemented strains with this dye, alongside an addition of glucose to energize the cells,
a steady increase in the intracellular pH was observed for the parent and complemented
strains. This indicates active pumping of (H+) protons across the membrane as a result of
active glycolysis. (Figure 4A). In contrast, the arcA and arcB mutants showed no
significant changes in intracellular pH during this same analysis, indicating a lack of
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proton exchange across their membranes. In addition, we also observed an overall lower
intracellular pH for both mutant strains, indicating a higher proton (H+) concentration
within the cell. This would again suggest the mutants lack the ability to pump H+ ions out
of the cell, confirming an ablated transmembrane proton gradient in these strains.

As an additional step in these analyses, we also added the protonophore CCCP midway
through incubation as a control. This would have the effect of bringing protons (H+) across
the membrane to decrease the intracellular pH. As expected, a rapid decrease in the
intracellular pH of the wild-type and complemented strains was observed, followed by
recovery from cytoplasmic acidification, indicating the ability of these strains to respond
to intracellular pH shifts. In contrast, we did not observe any changes in the intracellular
pH for either mutant upon addition of CCCP. The lack of response to CCCP from our
mutant strains is logical given that this molecule requires an energized membrane to
produce its H+ transport effect; whilst our mutant strains appear to have defects in their
membrane energetics.

We next sought to measure transmembrane potential using the voltage sensitive dye
DiSC3 (5), which accumulates and quenches itself in negatively charged cytoplasmic
membranes. Thus, when membranes are depolarized the DiSC3 (5) dye is released
because the cytoplasmic membrane is less negatively charged, resulting in increased
fluorescence. As shown in figure 4B, DiSC3 (5) fluorescence increased 2-fold in intensity
in the arcA and arcB mutants, compared to the parental and complemented strains. Thus,
it would appear that our mutant strains have a destabilized cellular membrane, indicating
that the second component of the PMF, transmembrane potential, is also disrupted.
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Taken together, these results suggest that disruption of arcAB hinders energy generation
pathways (a hallmark of arcAB mutants in other organisms [164,197]), resulting in
imbalances of PMF components.

Figure 4. A. baumannii arcAB mutants have a reduced intracellular pH and depolarized membrane. (A)
Intracellular pH was measured using the pH sensitive dye BCECF_AM. Exponentially growing cells were treated with
the dye alongside the addition of glucose to a final concentration of 10mM. A black arrow indicates the time at which
CCCP was added to cultures to a final concentration of 6.25 µg/mL, which is sub-inhibitory. Data is derived from 3
independent experiments, with error bars shown as +/- SEM. (B) Depolarization of the cytoplasmic membrane was
monitored by measuring release of the fluorescence dye DiSC3 (5). Data is derived from three independent
experiments, with error bars shown as +/- SEM. Student’s t-test was used to assess statistical significance, **** =
p<0.0001. ns = not significant relative to the wild-type.

Transcriptomic profiling reveals a shift in expression of genes required for glucose
utilization upon arcA disruption. To determine if the ArcAB system in A. baumannii has
functional similarity to that of other organisms, and to specifically hone in on its
mechanistic role, we next set out to explore its regulon using RNA-seq technologies.
Given that transcription from the arcAB promoter is minimal under standard conditions
(above and in [198]), and that CCCP dramatically induces the expression of this system,
we performed these experiments using the wild-type and arcA mutant grown in the
presence of a sub inhibitory concentration of this compound for 2h. Upon analysis, we
identified 725 genes that were significantly differentially expressed between the two
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strains at a level ³ 2-fold. (Figure 5A, Supplemental Table S1). This included 379 that
were upregulated in the mutant strain, and 346 that were downregulated. These findings
were confirmed via qRT-PCR for a collection of unrelated genes, demonstrating similar
fold changes in all cases (Supplemental Figure S4). When these alterations were parsed
into their ontological groups (Figure 5B) we found that the majority of transcriptional
changes were for genes associated with regulatory-, transport-, energy- or metabolicfunctions.

Figure 5. Transcriptomic profiling of the arcA mutant. (A) Genomic map showing major transcriptional changes in

△arcA compared to the parental strain after 2h of exposure to a sub-inhibitory concentration (6.25 µg /mL) of the
protonophore CCCP. The outermost circle represents a heat map of changes in △arcA compared to AB5075. The
middle circle (black) depicts RPKM values for AB5075. The inner circle (turquoise) depicts RPKM values for △arcA.
Black arrows at specific locations within the map highlight genes that function in energy conversion and production.
Genes in blue are upregulated and in red are downregulated in △arcA. (B) Categorization of genes differentially
expressed in △arcA compared to AB5075 based on predicted functions.

One of the most striking findings from this collection was a 30-fold decrease in expression
of the Coenzyme PQQ synthesis protein A (pqqA). This enzyme is involved in
Pyrroquinolone quinone (PQQ) synthesis, which is a required cofactor for the conversion
of glucose to gluconate in Acinetobacter calcoaceticus

199,200

. This is important because

A. baumannii is unable to undergo the initial steps of the glycolytic pathway as it lacks the
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early components of the Embden-Meyerhof-Parnas (EMP)114. Instead it metabolizes
gluconate to gluconate-6-P initially via the Entner Doudoroff pathway (ED), before
processing this further via the remaining ED pathway, or the Pentose Phosphate pathway
(PP) (Figure 6). From here, this can be fed into the later stages of glycolysis via those
EMP pathway genes that are present in A. baumannii. Given the magnitude of this change
in pqqA expression, one might reasonably expect that glucose would potentially
accumulate in our mutant strain, given its potentially impaired ability to process this
carbon source metabolically. As such, we determined the intracellular concentration of
glucose within our various strains (Figure 7). In so doing we noted that our mutants have
an increased concentration of intracellular glucose compared to the wild-type and
complemented strains. This suggests an accumulation of glucose in the mutants, which
may serve as a response to its slower processing within their cells.

Interestingly, genes encoding enzymes from the EMP and PP pathways that would
process the generated gluconate-6-P are also downregulated in our mutant strain. These
include glyceraldehyde-3-phosphate dehydrogenase (gap = -2.34) and phosphopyruvate
hydratase enolase (eno = -2.55) from the EMP pathway, and ribulose-phosphate 3epimerase (rpe =-2.06) from the PP pathways. This would tend to suggest that our mutant
strain might bypass these metabolic avenues, and instead choose to create pyruvate,
which could be fed in the TCA cycle (Figure 6). To test this, we measured the intracellular
concentration of pyruvate for our wildtype, mutants and complemented strains (Figure
8A). In so doing, we noted that our arcA and arcB mutants had much higher levels of
pyruvate (arcA = 1.92mM and arcB = 3.21 mM) compared to the wildtype (0.5mM) and
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Figure 6. Metabolic map for A. baumannii indicating nodes of change in the arcA mutant. Shown is a metabolic
map for A. baumannii depicting genes with altered expression from the transcriptomic analysis of △arcA. Blue font
indicates genes upregulated in the mutant, whilst red indicates genes that are downregulated. Green boxes indicate
metabolites of the glyoxylate pathway. Dashed arrows indicate the two products formed (glyoxylate and succinate) from
isocitrate conversion through the glyoxylate shunt. Yellow boxes indicate accumulated metabolites in the △arcA strain.

complemented strains (arcA+ = 1.2 mM and arcB+ = 0.67 mM). Interestingly, elevated
levels of pyruvate have been previously reported in arcA mutants of E. coli as a result of
a higher influx of glucose via the ED pathway197.
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Figure 7. Disruption of ArcAB leads to increased glucose concentrations within the cell . Cultures from
exponentially growing strains were lysed and glucose concentrations measured using a glucose colorimetric assay kit
(Biovision). Data is derived from three independent experiments. Error bars are shown in +/- SEM. Significance was
determined using a Student’s t-test, * = p<0.05, *** =p<0.0001, ns = not significant relative to the wild-type.

Increased glycolytic influx in the arcA mutant favors activation of the Pta-AckA
pathway generating acetate from pyruvate. Interestingly, our RNA-seq dataset reveals
increased expression of the pyruvate dehydrogenase dihydrolipoamide acetyltransferase
(aceF) and dihydrolipoamide dehydrogenase (lpdA1), which form the pyruvate
dehydrogenase complex that converts pyruvate to acetyl CoA (Figure 6). This would
make sense given that our mutant accumulates pyruvate, and that the generated acetylcoA could then be fed into the TCA cycle to generate energy. Additionally, when bacterial
cells grow rapidly in the presence of excessive amounts of glucose, the
phosphotransacetylase-acetate kinase (Pta-AckA) pathway is known to be induced,
favoring the conversion of acetyl-coA to acetate 120,201 to prevent what is known as carbon
overflow, which can have toxic effects. Interestingly, we found the ackA-pta operon was
upregulated in the arcA mutant (ackA = 3.37 and pta = 3.54 fold), thus it seems
reasonable to hypothesize that our arcA mutant might be preventing carbon overflow,
caused by excessive glucose accumulation and consumption, by generating higher
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amounts of acetate. To explore this, the wild-type, mutants, and complemented strains
were cultured in LB media, and cells were collected to measure intracellular acetate
levels. As shown in figure 8B, we observed that the arcA and arcB mutants had
significantly higher concentrations of intracellular acetate (arcA = 25.4 nmol/mL and arcB
= 32.60 nmol/mL) than the wild-type (10.27 nmol/mL) and complemented strains (arcA+
= 9.57nmol/mL and arcB+ = 14.64 nmol/mL). Accordingly, it appears that upon disruption
of arcA cells do indeed produce significantly more pyruvate, which is redirected towards
acetate production so as to prevent the potentially negative effects of excessive carbon
flow through the TCA cycle.

Figure 8. Increased pyruvate levels in arcA and arcB mutant strains leads to a glyoxalate shunt that favors
acetate production. The levels of pyruvate (A) or acetate (B) was measured in exponentially growing cells using either
a pyruvate colorimetric assay kit (Biovision) or an acetate colorimetric assay kit (Biovision). Data is derived from three
independent experiments, with error bars shown as +/- SEM. Student’s t-test was used to assess statistical significance
* = p<0.05, ** =p<0.001, ns = not significant relative to the wild-type

arcA mutants of A. baumannii use an incomplete TCA Cycle, instead favoring the
glyoxylate shunt: When examining the expression of genes for the TCA cycle in A.
baumannii, we noted that aconitate hydratase-1 (acnA) and isocitrate lyase (aceA) were
both upregulated in our mutant strain. This latter gene is of particular interest as it is used
to circumvent the complete TCA cycle, instead facilitating the glyoxylate shunt (Figure
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6). This finding would appear to make sense as we also observed diminished expression
of succinate dehydrogenase, which allows for the conversion of succinate within the TCA
cycle into fumarate. As such, one would predict that our arcA mutant is unable to complete
the full TCA cycle, and is thus forced into using the glyoxylate shunt to generate energy.
As a consequence, the malate produced would be converted to oxaloacetate, which in
turn would then have two fates: Firstly, oxaloacetate can be converted into
phosphoenolpyruvate that can be funneled into gluconeogenesis. Importantly, in our
mutant, the enzyme phosphoenolpyruvate carboxykinase, which catalyzes the
conversion of oxaloacetate to phosphoenolpyruvate is downregulated. Secondly, citrate
synthetase catalyzes the 1:1 condensation of oxaloacetate and Acetyl-coA to generate
citrate, thus continuing the glyoxylate shunt. Because the glyoxylate cycle produces
increased oxaloacetate that is used for gluconeogenesis, and that the enzyme required
for this step is downregulated in our mutant, it could be possible that oxaloacetate
accumulates in mutant cells. To test this, we grew our wild-type, mutants and
complemented strains in LB media, and measured oxaloacetate concentrations within
cells. Upon analysis, we observed that both arcA and arcB mutants had higher amounts
of oxaloacetate (arcA = 27.87µmol/µL and arcB = 22. 65 µmol/µL) than the wildtype (8.51
µmol/µL) and complemented strains (arcA+ = 9.69 µmol/µL and arcB+ = 5.46 µmol/µL)
(Figure 9A). These results confirm that our mutants accumulate oxaloacetate as a result
of an impaired conversion of oxaloacetate to phosphoenolpyruvate.

Of note, the glyoxylate pathway has the interesting side effect of generating succinate as
a byproduct. As suggested earlier, the arcA mutant has diminished expression of the
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enzyme that converts succinate into fumurate, succinate dehydrogenase. As such, one
might reasonably predict that the limited activity of this enzyme would lead to
accumulation of succinate within our arcA mutant cells as a result of a stalled TCA cycle.
Accordingly, the wild-type, mutant and complemented strains were grown in LB media,
before extracts were generated and the level of succinate within cells determined (Figure
9B). In so doing, we noted that the arcA and arcB mutants had much higher levels of
succinate within their cells (arcA = 41.47 and arcB = 43.20 ng/mL). Conversely, succinate
levels were lower in the parental (11.71ng/ml) and complemented strains (arcA+ =
15.87ng/mL and arcB+ 13.24ng/mL). As such, this confirms our hypothesis and RNAseq
data, that a stalled TCA cycle created by decreased succinate dehydrogenase expression
has the result of succinate accumulation in mutant cells.

Figure 9. Disruption of ArcAB leads to the accumulation of oxaloacetate and succinate as a result of an
impaired TCA cycle. The concentration of oxaloacetate (A) or succinate (B) was measured in exponentially growing
cells using either an oxaloacetate colorimetric assay kit (Biovision) a succinate colorimetric assay kit (Biovision). Data
is derived from three independent experiments, with error bars shown as +/- SEM. Student’s t-test was used to assess
statistical significance * = p<0.05, **** = p<0.0001, ns = not significant relative to the wild-type.
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NADH levels are increased in the arcA mutant as a result of its hyperactive
glyoxylate shunt: During the glyoxylate shunt, malate is converted to oxaloacetate by
the enzyme malate dehydrogenase. This has the side effect of generating NADH as a
byproduct (Figure 6). As such, one might reasonably hypothesize that our arcA mutant,
engaging in a hyperactive glyoxylate shunt, would have increased cellular levels of NADH
as a consequence. Accordingly, we next set out to measure the NADH levels in our
collection of strains (Figure 10). In so doing, we observed that the arcA and arcB mutants
had significantly higher levels of NADH (arcA = 4.9pmol/mg and arcB = 5.2 pmol/mg,
respectively) compared to the wildtype and complemented strains (WT = 3.1pmol/mg,
△arcA+ = 3.3 pmol/mg and △arcB+ = 3.2 pmol/mg). This implies that the increased levels
of NADH in our mutants may be the result of a hyperactive activity of TCA enzymes
generating NADH. Additionally, the excess NADH produced is perhaps unable to be
oxidized via the ETC due to a reduction in its activity202. This is supported by our
transcriptome analysis, which showed decreased expression of genes encoding the
succinate dehydrogenase complex (sdhC -3.72, sdhD -2.4tyrt3 and sdhB -2.05), also
known as complex II, which has distinct roles in both the TCA cycle and ETC; a gene
encoding part of the cytochromes bc1 complex III, (cyoE -2.64 fold ) which has a high
affinity for oxygen; a putative complex IV terminal oxidase cytochrome B561
(ABUW_2753, -4.14 fold); and genes within the ATP generation machinery: atpH, atpB
and atpE (-2.65, -2.28 and -2.02 fold)203 204. All this together supports a disruption of the
respiratory chain that likely result in a decreased electron flow and explains the lack of
proton gradient in our mutants in the presence of glucose.
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Figure 10. Disruption of ArcAB results in elevated intracellular NADH levels. Intracellular levels of NADH were
measured in exponentially growing cells for the wild-type, △arcA, △arcA+, △arcB and △arcB+ strains using a colorimetric
assay kit (Biovision). Data is derived from three independent experiments, with error bars shown as +/- SEM. Student’s
t-test was used to assess statistical significance, * = p<0.05.

The altered metabolic state of arcAB mutants favors ATP production via substrate
phosphorylation: The generation of ATP in bacteria occurs via two major processes:
oxidative phosphorylation, which is dependent on a functional PMF; and substrate
phosphorylation, which is dependent on the partial oxidation of metabolites 205-207 .Given
that we observed an imbalance in the PMF of our mutant strains, as well as a seemingly
impaired ETC, one might hypothesize that the first of these two processes would be
diminished upon arcAB disruption. As such, to test our hypothesis the wild-type, and its
arcA and arcB mutants, alongside their complemented strains, were grown for 3 hours
before being processed to determine their ATP levels (Figure 11A). These assays were
performed in the presence of pyruvate, which, during aerobic growth, is converted to
acetyl-CoA before being oxidized via the TCA cycle, resulting in the donation of electrons
to the ETC; thus feeding both pathways for bacterial ATP generation. Upon comparing
this data to that generated in the absence of pyruvate, we observed a slight increase in
ATP levels in our mutants (arcA= 28.7 pmol/ µL, arcB = 47.9 pmol/µL) as compared to
the wildtype and complemented strains (wild-type = 17.2 pmol/µL, △arcA+= 16.0 pmol/µL
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and △ arcB+ =14.6.pmol/µL) (Figure 11A). These findings may be the result of the
hyperactive glyoxylate shunt observed in our mutants strains, which would result in the
enhanced generation of ATP via substrate phosphorylation. Conversely, when ATP levels
were measured after incubation with pyruvate, we observed reduced ATP levels (arcA=
85.0 pmol/ µL, arcB = 30.7.pmol/µL) in both mutants when compared to the WT and
complemented strains (wild-type 106.6 pmol/µL, △arcA+= 121.1 pmol/µL and △arcB+
=83.6.pmol/µL) (Figure 11B). These results are perhaps explained by a stimulation of the
TCA cycle in our wild-type and complemented strains, resulting in excess ATP
generation. The fact that our mutants demonstrate diminished ATP production in these
assays compared to the parent are perhaps a result of an impaired ability to generate
ATP via oxidative phosphorylation.

We next hypothesized that ATP levels amongst the various strains might be equalized by
inhibition of the ETC in the wild-type and complemented strains, impairing their capacity
to engage in oxidative phosphorylation. As such, we repeated these studies in the
presence of sub-inhibitory concentrations of CCCP, which disrupts the electrochemical
gradient. When these assays were performed (Figure 11C), the basal ATP levels across
all strains was found to be essentially the same. After treatment with CCCP and pyruvate,
however, we found that the DarcA andDarcB mutants (220.4 pmol/µL and 151.7 pmol/µL,
respectively) demonstrated significantly higher levels of ATP when compared to the
wildtype and complemented strains (wild-type = 108.3 pmol/µL, △arcA+= 95.5 pmol/µL
and △arcB+ = 105.1 pmol/µL) (Figure 11D). As such, it would appear that when ATP
generation via oxidative phosphorylation is abolished by the addition CCCP our mutants
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actually generate higher levels of ATP than the wild-type and complemented strains.
Collectively, these data suggest that our mutant strains are impaired in their capacity to
produce ATP via oxidative phosphorylation, but compensate for this defect by their
capacity for ATP generation via substrate phosphorylation.

Figure 11. arcAB mutants produce ATP via substrate phosphorylation more efficiently than through oxidative
phosphorylation. Intracellular ATP levels were measured using a colorimetric assay kit (Biovision) in exponentially
growing cells from the wild-type, △arcA, △arcA+, △arcB and △arcB+ strains. Strains were grown in LB alone (A), or LB
containing: pyruvate (10mM), a sub-inhibitory concentration of CCCP (6.25 µg mL-1) (C), both CCCP (6.25 µg mL-1)
and pyruvate (10mM). Data is derived from three independent experiments, with error bars shown +/- SEM. Student’s
t-test was used to assess statistical significance, * = p<0.05, ** =p<0.01, *** =p<0.001, **** = p<0.0001 , ns = not
significant relative to the wild-type.

Cytochrome oxidase activity is reduced as a result of arcAB disruption: Our findings
above suggest that our mutants have increased production of ATP via substrate
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phosphorylation, whilst generating lower ATP levels via oxidative phosphorylation. This
effect seems to be mediated via an altered ETC in our mutants, which hinders ATP
production as a result of an impaired PMF. To test this hypothesis, we used an assay that
measures activity of the cytochrome oxidase C to gauge activity of the ETC (Figure 12).
In so doing, we observed lower activity of cytochrome oxidase in our mutants (△arcA =
0.02 U/mL and △ arcB = 0.04 U/mL) compared to our wildtype (0.11 U/mL) and
complemented strains (△arcA+= 0.08 and △arcB+ = 0.07). Collectively, these findings
suggest that disruption of arcAB affects the function of the aerobic respiratory chain,
impacting the energy status of the cell, which in turns upregulates alternative metabolic
and energy generation pathways in our mutants.

Figure 12. The altered metabolic state of arcAB mutants results in impaired aerobic respiration. Cytochrome
activity was measured in exponentially growing cells of the wild-type, △arcA, △arcA+, △arcB and △arcB+ strains using
a colorimetric assay kit (Sigma-Aldrich). Activity of the cytochrome oxidase is expressed in U/mL, where U is defined
as one unit needed to oxidize 1.0 µmol of ferricytochrome in one minute at pH 7.0 at 25 °C. Data is derived from three
independent experiments, with error bars shown as +/- SEM. Student’s t-test was used to assess statistical significance,
* = p<0.05, ns = not significant relative to the wild-type.
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Figure 13. ArcAB mutants demonstrate increased susceptibility to aminoglycoside antibiotics. Determination
of bacterial growth (OD600) for the wild-type, △arcA and △arcB strains in the presence of increasing concentrations of:
(A) Gentamicin, (B) Kanamycin, and (C) Neomycin. Data is derived from three independent experiments, with error
bars shown as +/- SEM.

The accumulation of oxaloacetate in arcA mutant cells leads to aminoglycoside
hyper-susceptibility: Work by others in E. coli and Edwardsiella tarda has shown that
the addition of glutamate results in elevated levels of oxaloacetate, which favors the
formation of

pyruvate and acetyl-coA that enters the TCA cycle208. This has the

interesting side-effect of an increased susceptibility to aminoglycoside antibiotics. In the
same study, a strain with a mutation in pckG, which encodes a phosphoenolpyruvate
carboxykinase (converts oxaloacetate to phosphoenolpyruvate) had a null PMF and
increased susceptibility to aminoglycosides. This is believed to function via a
redistribution of metabolites that are directed into other metabolic pathways as a result of
a disrupted TCA cycle, leading to accumulation of TCA intermediates that can act
synergistically with aminoglycosides independent of PMF. Given that we observed
elevated levels of oxaloacetate in our mutants, we next tested our collection of strains for
sensitivity to aminoglycosides, alongside an array of control antimicrobial agents.
Intriguingly, both of our mutants showed specific increased susceptibility to
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aminoglycosides when treated with ³3.12µg/mL of gentamicin and neomycin, and ³25 µg
/mL of kanamycin (Figure 13). In contrast, the wild-type exhibited a resistant phenotype
to all concentrations of aminoglycosides tested. Importantly, no significant changes in
resistance profiles between the mutants and parental strain were observed for any of the
other antibiotics tested (Supplemental Figure S5). Thus, the increased susceptibility to
aminoglycosides of our mutant strains appears to result from an overflow of metabolites
as a result of the altered metabolism upon disruption of the ArcAB system.

DISCUSSION

In this study we follow up on our previous work exploring the regulatory networks of A.
baumannii, identifying an uncharacterized TCS with highly structural similarities to that of
ArcAB in E. coli. A key finding of our study was the response of the arcAB promoter to
the protonophore CCCP. The protonophore CCCP, has been shown to bypass the ATP
synthase-dependent active transport of protons (H+) into the cytoplasm by increasing
membrane permeability to H+. As a result, a halt in activity of ATP synthase and ATP
synthesis takes place, leading to disruption of the electron transport chain. This has the
effect of limiting the transfer of electrons to quinones and decreases the PMF; altering the
energy status of the cell.165,209 210. The effects of CCCP impacting energy generation are
similar to those observed during the transition from aerobic to anaerobic growth in E. coli.
As oxygen becomes limited, a reduction in energy generation via the respiratory chain
results in reduced quinone pools. This is sensed by two conserved cysteine residues
(aa180, aa241) within ArcB, which are oxidized when quinone pools are plentiful.
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Consequently, their depletion as a result of diminished oxygen levels leads to reduction
of the cysteine residues, activating the kinase activity of ArcB. It then undergoes
autophosphorylation, passing its phosphate group to ArcA, which in turn activates the
expression of genes involved in alternative energy generations pathways.

Importantly, during our bioinformatic study of the A. baumannii ArcB protein we observed
that one of these two cysteine residues was indeed conserved 167. When looking at other
ArcB homologs, we noted that the dual cysteine arrangement was only considered
between E. coli and the closely related S. enterica, whilst V. cholera and A. baumannii
retain only the first Cysteine residue (aa180), and H. influenzae and S. oneidensis lack
both. Notably, the ArcB of H. influenzae is incapable of fully complementing an arcB
mutant of E. coli, highlighting the importance of these residues in sensing oxygen
gradients via ubiquinone 171. Furthermore, the genes encoding for ubiquinone production
are absent in H. influenzae, perhaps eliminating the need for these cysteine residues in
its ArcB protein

211,212

. As such, one might speculate that the ArcB of A. baumannii also

senses ubiquinone pools, and is regulated by oxidation at its lone cysteine residue, which
is perhaps sufficient to control its kinase activity in a manner similar to that reported in E.
coli.

To explore our findings with CCCP a little more fully, we tested the impact of other
uncouplers with distinct mechanisms of action towards membrane energetics on the
arcAB promoter. These included DCCD, valinomycin, and 2-4 Dinitrophenol; none of
which altered the expression of this TCS. This is perhaps explained by their specific and

64

discrete effects on the cell, for example DCCD inhibits ATPase activity without
significantly reducing electron flow through the ETC

213-215

. Similarly, the disruption of

membrane potential caused by valinomycin has little impact on oxygen consumption

216

.

Finally, 2-4 DNP has been shown to accelerate respiration by stimulating complete
oxidation of intermediate metabolites such as succinate and fumarate217,218. As such,
given that none of these agents induce activity of the arcAB promoter, the specific
response of the arcAB system to CCCP could be explained by its targeted effects on
quinones pools, as it is the only uncoupler that inhibits hydrogen pumping by cytochrome
c and disrupts the electrochemical gradient192,219 This would be in line with our assertions
above proposing a role for ArcB in controlling membrane energetics through the oxidation
status of its conserved cysteine residues; akin to that seen in other organisms.

When we examined the effects of disruption of ArcAB on components of the PMF, we
observed that our mutants exhibited an absence of proton gradient in the presence of
glucose, as well as depolarization of their membranes, suggesting an inability to generate
energy from glucose. Of note, A. baumannii is unable to assimilate glucose, but instead
generates energy from the conversion of glucose to gluconate via the PQQ pathway,
which produces electrons that feeds the respiratory chain. PQQ synthesis is dependent
on the expression of six genes arranged in an operon pqqABCDEF220. Previous studies
on regulation of PQQ biosynthesis in the soil bacteria Pseudomonas putida and M.
extorquens found that expression of pqqB or ppqF drives the synthesis of PQQ, and that
levels of pqqA expression appear to have little effect on the amount of PQQ produced 221
222

. This suggests that despite the decreased expression of pqqA in our arcA mutant, the
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levels of PQQ produced may be sufficient to convert glucose to gluconate, as we
observed accumulation of pyruvate which is a product of glucose processing via
glycolysis in our mutants.

Pyruvate is further oxidized via TCA cycle feeding the ETC. However, the absence of
changes in intracellular pH in the presence of glucose in our mutants suggest that the
loss of arcA function could diminished function of any of the components of the ETC,
causing an inability to generate a proton gradient. The regulatory function of ArcA on
components of the respiratory chain has been documented previously223. Consistent with
this, we observed that our mutants have decreased expression of genes encoding
components of the respiratory chain, which would prevent generation of a proton gradient,
irrespective of glucose oxidation. In addition, in aerobically growing cells, NADH is
generated via the TCA cycle, with the electrons transferred to the respiratory chain.
Disruption of arcA in E. coli leads to overproduction of NADH that is thought to exert
allosteric control on activity of succinate dehydrogenase (complex II), likely interrupting
electron flow from the TCA cycle to the respiratory chain224. Each of these changes leads
to alteration that mirrors those caused by CCCP, disrupting the respiratory chain and
decreasing quinone pools that our mutant would be unable to sense and respond to by
regulating genes that are required for the restoration of membrane energy.
Further to this, elevated levels of NADH cause a disruption in succinate dehydrogenase
activity, resulting in replacement of the TCA cycle with the glyoxylate pathway. Indeed,
we observed accumulated succinate in our mutants and altered metabolic gene
expression that would suggest a switch to the glyoxylate cycle, an effect seen in other
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organisms bearing a disrupted ArcAB module225. A primary regulatory role for ArcAB has
been attributed to control of the TCA cycle and glyoxylate shunt pathway. Specifically, a
study exploring the effects of arcA deletion in E. coli during aerobic growth demonstrated
a high influx of metabolites through the TCA cycle, suggesting an altered metabolic
function226. Similarly, in S. enterica disruption of arcA led to the upregulation of genes that
are part of the glyoxylate shunt, glycolysis, and fermentation174. In line with these findings,
a study investigating the transcriptional changes of E. coli upon switching from anaerobic
to aerobic conditions (which ArcB senses) found upregulation of several genes involved
in the TCA cycle, terminal oxidases with high affinity to oxygen, and an abundance of
reduced equivalents for the respiratory chain. Thus, the altered expression of genes
involved in glycolysis and TCA cycle in our arcA mutant further support an altered function
in energy generation similar to that reported for other ArcAB systems223.

Among the genes altered in expression in our arcA mutant was the pta-ackA operon,
which was significantly upregulated. This module is activated in response to increased
levels of glucose, oxygen, and high metabolic activity, and converts pyruvate to acetylcoA under aerobic conditions120,225. Conversely, this pathway produces mixed-acid
products, lactate, ethanol, and acetate under anaerobic conditions201. A hallmark of
Acinetobacter species is their ability to grow on acetate as a sole carbon source; thus it
is possible that our mutant’s response to CCCP-dependent decreases in quinone pools
is translated into a hyperactive glyoxylate pathway that causes carbon overflow, diverting
into the Pta-AckA pathway. Notably, we observed higher levels of pyruvate and acetate
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in our mutants that could likely be explained by the increased expression of genes
encoding pyruvate dehydrogenases and the Pta-AckA pathway 227 201.

To date, our data supports a metabolic overflow status in our mutants that result in
saturation of the main energy generation pathways of glycolysis and the TCA cycle.
These alterations lead to accumulation of NADH, acetate, and metabolites of the TCA
cycle. Reducing equivalents generated from the above pathways are oxidized via the ETC
during aerobic respiration to generate ATP via oxidative phosphorylation. In E. coli,
decreased activity of cytochrome oxidase with high affinity to oxygen under microaerobic
conditions was found in an arcA mutant228 In line with this observation, and the regulatory
role for ArcA in controlling components of the ETC223, we observed that activity of the
terminal cytochrome oxidase was diminished in our mutants . This would tend to suggest
that ATP generation via substrate phosphorylation prevails in our mutants to compensate
for their inability to generate ATP via oxidative phosphorylation.

In summary, the data presented in this study demonstrates the importance of the ArcAB
TCS for controlling membrane energetics in A. baumannii. We reveal that loss of of ArcAB
function renders this organism unable to sense changes in ubiquinones levels resulting
from altered respiratory chain function. This consequently leads to altered metabolic
pathway utilization, affecting energy generation - highlighting the importance of ArcAB in
maintaining energy homeostasis. As such, herein we provide evidence of a novel
regulatory role of the TCS ABUW_2426/ABUW24/27 in A. baumannii, extending our
knowledge of regulatory networks in this important human pathogen.
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CHAPTER IV
CHARACTERIZATION OF A NOVEL FEC-OPERON RESPONSIVE TO HEMIN IN
ACINETOBACTER BAUMANNII

ABSTRACT.

Iron acquisition systems are essential for bacteria to overcome the

limitation of iron encounter during infection in their host. Although genes encoding for the
acinetobactin system with high affinity to ferric iron exists in A. baumannii, identification
of heme acquisition systems have yet to be described in A. baumannii. Previous work
published in our lab identified an operon with high similarity to the first Fec-operon genes
fecI, fecR and fecA found in E. coli , 4 genes with unknown function, and 1 gene encoding
a heme oxygenase. Screening of mutant strains with disruption of the fecI, fecR and
hemO showed altered growth phenotypes linked to hemin and hemoglobin utilization as
a sole source of iron. Further transcriptional studies using a reported gene showed that
the outer membrane receptor FecA is induced in the presence of hemin and appears to
be dependent on FecI-FecR activity. RNA-seq analysis revealed an altered transcription
of several genes in response to hemin limitation including downregulation of the fecoperon. Lastly, given the importance of heme degradation in iron utilization, we explored
the effects of disruption the hemO and found that it alters its ability to survive in serum,
accumulates hemin in the cell and displayed a growth defect in the presence of hemin
suggesting its important role in hemin utilization. In summary, our data supports the
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hypothesis that fecI regulates the activity of this operon in the presence of hemin and
appears to be mediated via a signaling mechanisms involving the hemin receptor FecA.

INTRODUCTION
The importance of iron for living organisms, including humans and bacteria, is defined by
its requirement for the enzymatic activity of redox proteins involved in cellular processes
such as respiration and DNA synthesis229. Because of its highly reactive nature in the
presence of oxygen, resulting in the generation of free iron and hydroxyl radicals that can
cause cellular damage, iron exists in the human body mostly bound to host proteins such
as albumin, transferrin, lactoferrin, hemoglobin, and hemopexin230. As a result of this, free
iron within our system is limited to a concentration of around 10-24 M, which is clearly lower
than the 10-7 M needed to support bacterial growth231,232. To combat this, bacteria possess
transport machineries that use the secretion of siderophores or hemophores alongside
dedicated outer membrane receptors, to capture iron from host-iron containing proteins
233,234

. The activity of these systems is subject to hierarchical regulation, to either avoid

the potential toxic effects of excess iron accumulation, or to adapt when iron becomes
scarce in niches such as those encountered during infection within a host234.

The major regulator directly linked to iron acquisition in bacteria is the ferric-uptake
regulator, Fur. In times of iron abundance, Fur acts as a negative regulator of iron uptake
in a manner that is mediated via binding of ferrous iron to the Fur protein. This event acts
as a signal that in turn leads to repression of a variety of genes, including those encoding
iron regulated proteins and iron transport systems. Conversely, iron scarcity results in
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reduced ferrous iron concentrations, leaving Fur unbound, which serves as a signal for
Fur to relieve repression of genes required for iron transport235. The next tier of iron
mediated regulation, at least in Gram-negative bacteria, is exerted by sigma (s) factors,
particularly those from the extracytoplasmic function (ECF) family, where several have
been described as controlling the process of iron acquisition236-239. This positive mode of
regulation often induces iron transport systems, and was first described for the fec-operon
of E. coli

240,241

. In this example, the proposed model of activation of this operon is

described as follows: the outermembrane receptor FecA binds ferric citrate, which in turn
induces a conformational change of FecA allowing its N-terminal to interact with the Cterminal of FecR. Upon this, FecR binds to the region 4 of the s factor FecI , resulting in
activation of genes dedicated to the active transport of iron239,240. The mechanistic
understanding of FecI inactivation still unclear. As such, the two following inactivation
mechanism for FecI have been proposed. The first one involved degradation via
proteolysis upon release of FecI from FecR. The second one argues for an inactive form
of FecR bound to FecI that prevents association of this complex to the RNA polymerase.
Homologs of the Fec system have also been described in other Gram-negative organisms
as being involved in iron acquisition. For example, in environments devoid of iron,
Pseudomonas aeruginosa secretes the siderophore pyoverdine that upon loading with
ferric iron binds the outer membrane receptor FvpA. Following this interaction, the signal
is transmitted to the PdvS s factor, which subsequently activates the pyoverdine
chromophore pvcABCD operon to synthesize pyoverdine 242. Similarly, Bordetella avium,
Bordetella pertussis and Serratia marcescens all have systems homologous to FecI. In
these first two organisms a parallel HurI-HurR-BhuR / RuhI-RhuR-BhuR axis exists that
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senses heme during iron limited conditions, resulting in activation of the bhuRSTUV
operon that encodes an ABC transporter dedicated to heme transport

238,243

. In S.

marcescens, beyond a HasI-HasS-HasR system that is homologous to FecA-FecR-FecI,
the activation and function of this system is very different to the canonical mechanism
described in E. coli244,245. Here, under heme limited conditions, the HasA hemophore, a
protein that scavenges heme from hemoglobin, binds to HasS, a TonB receptor homolog
of FecA. This interaction is required for releasing of the sigma factor HasI from HasS,
resulting in transcription of the HasADEB operon, which encodes a hemophore secretion
system that allows binding to free heme or heme bound to host proteins. 246,247 236.

In the context of infection, the complex molecule hemin is a major source of iron for
pathogenic bacteria. Upon uptake of this iron source, bacteria can either incorporate it
directly into their own hemin-requiring proteins, or further degrade it to generate free iron
and other useful byproducts such as bilirubin, which has antioxidant properties. The
presence of hemin uptake systems has been reported in several pathogenic bacteria,
where they serve to overcome host iron sequestration mechanisms. These hemin
acquisition systems are typically comprised of genes encoding a TonB-like
outermembrane receptor, and an ABC permease transporter system, all of which are
activated by cognate s factors during iron limiting conditions. In A. baumannii the
presence of iron acquisition systems that synthesize siderophores with high affinity to
ferric iron have been described. Regarding hemin uptake, a previous bioinformatic study
from our lab reported the presence of a fec-like operon containing genes for a putative
hemin acquisition system that is conserved in ~50% of clinical A. baumannii isolates.
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Interestingly, within the A. baumannii fec-like operon, there appears to be a novel hemin
oxygenase encoding gene, which further suggests the utilization of this system for hemin
assimilation.

In this study, we begin characterization of the A. baumannii fec-like operon by measuring
the effects of disruption of genes encoding homologs of FecI and FecR, as well as the
novel HemO protein, in the presence of a variety of iron sources. Our data indicates that
growth of mutants was specifically altered in the presence of both hemin or hemoglobin,
but not other iron sources, such as ferric citrate. Individual and global transcriptional
studies revealed that the fec-like operon of A. baumannii is induced in the presence of
hemin, and disruption of the fecI gene led to altered expression of genes encoding iron
regulated proteins involved in energy generation and metabolism. Finally, disruption of
hemO resulted in growth defects, the accumulation of hemin, and diminished survival in
serum. Taken together, the data presented here reveal that the this fec-like operon is
responsive to hemin and the fecI gene plays a major role in transcription control during
hemin limited conditions. Furthermore, fecI-fecR expression is required for fecA induction
by hemin, supporting a model of positive regulation for this system.

MATERIAL AND METHODS

Bioinformatic analysis. A BLASTP analysis of the FecI, FecR and FecA proteins against
their corresponding homologs in Escherichia coli, Bordetella pertussis, Bordetella avium,
and Serratia marcescens was performed using the https://blast.ncbi.nlm.nih.gov/Blast.cgi
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server. Protein sequences of TonB-like proteins within the fec-operons of A. baumannii,
E. coli, B. pertussis, B. avium, and S. marcescens were downloaded from the NCBI ftp
server (www.ncbi.nlm.nih.gov/genome) and topology maps were generated using the
protter tool (http://wlab.ethz.ch/protter/start/).

Strains and growth conditions. The strains and cloning primers used in this study are
listed in Table 4. All strains were cultured in lysogeny broth (LB), unless otherwise
indicated, with shaking at 37°C. Where appropriate, antibiotics were added for selection:
tetracycline at a final concentration of 5 µg/mL and hygromycin at a final concentration of
140 µg/mL. Mutants of ABUW_2987 (fecI), ABUW_2986 (fecR) and ABUW_2981 (hemO)
were acquired from the AB5075 transposon mutant library179. Strains were confirmed
using primers OL4383/OL4384 (fecI), OL4436/OL4437 (fecR), and OL4575/OL4576
hemO)
Construction of a fecA-lacZ transcriptional fusion strain. A PCR fragment was
generated that begins 500 nt 5’ of fecA and ends 762 nt 3’ of it, using primers
OL4380/OL4381. This fragment was cloned into the vector pAZ106, which contains a
promoter-less lacZ cassette, creating plasmid pSLG5. This plasmid was then used to
amplify the fecA-lacZ

fusion fragment using primers OL4382/OL4232, which was subsequently cloned into the
A. baumannii shuttle vector pMQ557, resulting in plasmid pSLG6. AB5075 was then
transformed with pSLG6, and colonies were selected using LB plates supplemented with
hygromycin (plasmid encoded). All strains were then confirmed by PCR.
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Construction of fecR and hemO complementation strains. A 1,362 bp fragment
including 500 bp upstream and downstream of the hemO gene, and a 2,232 bp fragment
including 500 bp upstream and downstream of the fecI gene, was amplified using primers
OL4575/OL4576 and OL4436/OL4437. These PCR products were cloned into pMQ557,
creating plasmids pSLG7 and pSLG8. Clones were confirmed by PCR and Sanger
sequencing (MWG Operon), before being transformed into the A. baumannii hemO and
fecR mutant strains, respectively. Strains were again confirmed by PCR and Sanger
sequencing (MWG Operon).
Table 1. Bacteria strains, plasmids and cloning primers
Strain
Description
E. coli
DH5α
A. baumannii
AB5075
AB5075 176::T26
AB5075 170::T26
AB5075 126::T26
LGC 2610
LGC 2611
LGC 2612
Plasmids
pMQ557

Cloning strain

Source
248

179
Parental strain
179
AB5075 with transposon insertion in ABUW_2987
179
AB5075 with transposon insertion in ABUW_2986
179
AB5075 with transposon insertion in ABUW_2981
AB5075 126::T26 complemented with
This study
pMQ557::hemO
AB5075 containing pSLG6 (PfecA–lacZ fusion)
This study
AB5075 170::T26 complemented with pMQ557::fecR This study

Cloning vector for complementation

Gift, Dr. R.
Shanks,
University of
Pittsburgh

pAZ106
pSLG5
pSLG6
pSLG7
pSLG8
Primers
OL4232

Promotorless lacZ insertion vector
pAZ106::PfecA–lacZ
pMQ557::PfecA–lacZ
pMQ557::hemO
pMQ557::fecR

249

ATGGCGGCCGCGACCCAACGCTGCCCGAGAAA

This study

OL4380

ATGGGATCCGTAGAAGCCACACAGGTTAA

This study

OL4381

ATGGAATTCACTGATTCAGTACGTTAGCA

This study

This study
This study
This study
This study
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Table 4. (Continued)
OL4382

ATGCTCGAGGTAGAAGCCACACAGGTTAA

This study

OL4383
OL4384

ATGCCCGGGGATACCTATTTGGTCGGC
ATGCCCGGGTTA GTGGTGGTGGTGGTGGTG
AATGTAAGCGTCCATGTC
ATGGCGGCCGCGATACCTATTTGGTCGGC

This study
This study

ATGCTCGAGTTAGTGGTGGTGGTGGTGGTGTTT
TAAAGAAACCATGACCA

This study

ATGGCGGCCGCCCTCAATCTACCTTACACAG
ATGCTCGAGTTAGTGGTGGTGGTGGTGGTGTTT
CAATTCATCAAGCTGATC
*Underscore indicates restriction enzyme site

This study
This study

OL4436
OL4437
OL4575
OL4576

This study

Growth assays. For iron containing experiments, cultures of the wild-type, fecI, fecR and
hemO mutants, alongside the hemO+ and fecR+ complemented strains, were grown
overnight in RPMI media supplemented with 1% casamino acid and 100µM 2-2 dipyridyl
(DIP). Overnight cultures were diluted 1:100 in fresh media and grown for an additional
3 hours. These cultures were then used to inoculate new media to an OD600 of 0.05. Test
media used in these studies was RPMI supplemented with 0.1µM/mL ferric citrate;
0.1µM/mL hemin (Sigma-Aldrich) and 0.1µg/mL apo-transferrin (Sigma-aldrich); or
0.5µg/mL hemoglobin (Sigma-Aldrich) and 0.1µg/mL apo-transferrin. Growth was
monitored over time and OD600 values were read every two hours. Data is derived from
three independent replicates.

Transcriptional profiling assays using b-galactosidase. For expression over time of
the A. baumannii PfecA-lacZ fusion strain in the WT, DfecI, and DfecR backgrounds the
overnight cultures grew in iron depleted media were used to standardized and
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synchronized cultures at an OD600 of 0.05, before the following compounds were added
to final concentration of : 1% Casamino acids, 0.1µM/mL ferric citrate, 0.1µM/mL hemin
and 0.1µg/mL apo-transferrin, and 0.5µg/mL hemoglobin and 0.1µg/mL apo-transferrin.
Cultures were incubated with shaking at 37°C, with 0.1mL samples collected every hour.
Levels of b-galactosidase were measured as described previously181. Results are
presented from three independent experiments.

RNA-seq analsyis. RNA-seq experiments were performed as described previously182 .
Briefly, the A. baumannii wild-type and fecI mutant strains were grown in RPMI with 1%
casamino acid overnight at 37°C with shaking in biological triplicate. Overnight cultures
were diluted 1:100 into 100mL of fresh RPMI with 1% casamino acids, grown to
exponential phase, and subsequently used to seed new 100mL cultures supplemented
with 0.1µM/mL hemin and 0.1µg/mL apo-transferrin at an OD600 of 0.05. Cultures were
allowed to grow for 3 hours, before 5 mL was harvested from each flask. This was added
to 5 mL of ice-cold PBS, pelleted by centrifugation at 4°C, and the supernatant removed.
Total RNA was isolated using a RNeasy Kit (Qiagen) and DNA was removed using a
TURBO DNA-free kit (Ambion). Sample quality was assessed using an Agilent 2100
Bioanalyzer system with an RNA 6000 Nano kit (Agilent). An RNA integrity value of >9.7
was used as a cutoff. Prior to mRNA enrichment, biological triplicate RNA samples were
pooled at equal concentrations followed by rRNA removal using a Ribo-Zero Kit for Gram
Negative Bacteria (Illumina) and a MICROBExpress Bacterial mRNA enrichment kit
(Agilent). Removal efficiency of rRNA was confirmed using an Agilent 2100 Bioanalyzer
system and an RNA 6000 Nano kit (Agilent). Library preparation was performed using the
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TruSeq Stranded mRNA Kit (Illumina) omitting mRNA enrichment steps. Quality,
concentration, and the average fragment size of each sample was assessed with an
Agilent TapeStation and High Sensitivity DNA ScreenTape kit. Library concentration for
the pooling of barcoded samples was assessed by qPCR using a KAPA Library
Quantification kit (KAPA Biosystems). Samples were run on an Illumina MiSeq with a
corresponding 150-cycle MiSeq Reagent kit. Upon completion, data was exported from
BaseSpace (Illumina) in fastq format and uploaded to Qiagen Bioinformatics for analysis.
Data was aligned to the AB5075 reference genome (NZ_CP008706.1), and experimental
comparisons were carried out after quantile normalization using the Qiagen
Bioinformatics experimental fold change feature.

qRT-PCR. Quantitative real time PCR (qPCR) analyses were conducted as described
previously using primers detailed in Table 5.181 Bacterial cultures were prepared and RNA
extracted as described for the RNA-seq experiments. Data is derived from three
independent replicates.
Table 2. List of qPCR primers used in this study.
Strain
OL4498

qPCR Gene
CCTAGAGATAGTGGACGTTACTCG

16S R

CCAGTATCGAATGCAATTCCCAAG

16S F

OL4405

CAAAGCTGGCTTCACCAATG

fecI F

OL4406

GTCTCGGGTTTGTAGCAGTTTA

fecI R

OL4407

GCCAAAGACAAGACCAGAC

fecR F

OL4499
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Table 5. (Continued)
OL4408

CGGTTGCCGAAGGATCATAA

fecR R

OL4409

AGAAAGAGGGTGTAGCTGGA

hemO F

OL4410

CCCGTTGGGTTGAATACCTAAA

hemO R

OL4602

TCAGACCCTTAAACTGACTTACC

fecA F

OL4603

CACCCAAGTCAGGCGTAATA

feA R

OL4700

AGTTCATACAACCGCCAATAC

citN F

OL4701

CACAGTCACCGTAGACATAGA

citN R

OL4612

GTACGCCAATGGTTGATGGA

paaI2 F

OL4613

GGGCGCTTAATTCAGGAAG

paaI2 R

OL4614

GGTGATCAGTATTGGCTGGT

citN F

OL4615

AGCTCAATCACGCCTAAACG

citN R

Letters in bold indicate F= Forward ; R= Reverse

Hemin measurements. The wild-type, hemO mutant and hemO+ complemented strains
were grown in RPMI supplemented with 1% casamino acid and 100µM DIP as described
above and used to generate synchronized cultures in fresh RPMI supplemented with
1µM/mL hemin. These were grown for 6 hours, before cells were pelleted by
centrifugation and resuspended in hemin buffer (Sigma-Aldrich), before being lysed using
a Mini BeadBeater -16 (Biospec). Hemin quantification was performed using a hemin
colorimetric assay kit MAK316 (Sigma-Aldrich) following the manufacturer’s protocol.
Data is derived from three independent replicates.
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Human serum survival assay. The wild-type, hemO mutant and its complemented strain
were separately seeded into 100µL of human serum at an OD 600 of 0.05. Samples were
incubated for 4 hours at 37 °C, before aliquots were withdrawn and CFU/mL determined
by serial dilution and plating onto LB agar. Data is derived from three independent
experiments

RESULTS

The FecI operon of A. baumannii has a distinct set of genes compared to homologs
in other organisms. In previous work by our group we identified the complete
proteinaceous regulome of A. baumannii strain AB5075

153

. As part of this, we found an

8-gene operon (Figure 14) that begins with an ORF (ABUW_2987) that encodes an ECFsigma factor bearing homology to FecI from a variety of different organisms (Table 6).
Immediately downstream of the putative fecI we found genes encoding homologs of two
other proteins typically found in other Fec systems, a FecR like transmembrane regulatory
protein (ABUW_2986), and the outer membrane receptor FecA/TonB (ABUW_2985)
(Table 6) 153.
Upon syntenic comparison with homologous systems in E. coli, B. pertussis, B. avium,
and S. marcescens we found that, despite sharing the fecI-fecR-fecA arrangement, the
fec-operon in A. baumannii appears to have a very different collection of genes
downstream of this unit (Figure 14). For example, in E. coli, the 4 genes located
downstream of fecI-fecR-fecA encode an ABC transporter dedicated for iron citrate
uptake

244

. Similarly, in B. pertussis and B. avium, downstream of the genes encoding

for HurI-HurR-BhuR / RuhI-RhuR-BhuR, the heme surface regulatory system
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homologous to FecI-FecR-FecA, 4 genes are found that encode an ABC transporter
utilized for heme transport

238,243

. In S. marcescens, the HasI-HasS-HasR system that is

homologous to FecA-FecR-FecI has 4 genes located immediately downstream of it that
encode for a hemophore secretion system comprised of the hemophore HasA, inner
membrane proteins HasD and HasE, and a TonB dependent heme transport protein
HasB 246,247 236.
Table 3. BLAST analysis of ABUW_2987, ABUW_2986 and ABUW_2985 from A.
baumannii identifies them as homologs of FecI, FecR and FecA, respectively.
Protein
Identity1
Similarity2 Reference
FecI
36%
60%
FecR
31%
48%
232
FecA
25%
40%
Bordetella pertussis
HurI
42%
64%
HurR
23%
42%
240
BhuR
26%
45%
Bordetella avium
HurI
41%
67%
HurR
22%
40%
241
BhuR
24%
41%
Serratia marcescens
HasI
30%
48%
HasS
28%
49%
228
HasR
24%
41%
1
Shown is the percent identity from a BLASTP analysis using ABUW_2987 (FecI),
ABUW_2986 (FecR) and ABUW_2985 (FecA).
2
Shown is the percent similarity from a BLASTP analysis using ABUW_2987 (FecI),
ABUW_2986 (FecR) and ABUW_2985 (FecA).
Organism
Escherichia coli

Interestingly, in A. baumannii there are five genes immediately downstream of the fecIfecR-fecA cluster in the same transcriptional orientation (and would appear to form an
operon based on our previously published RNAseq data198), but whose products share
no homology to fec-operon proteins from our comparator organisms. These are: three
hypothetical proteins with no discernable function (ABUW_2984, ABUW_2983 and
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ABUW_2980); another TonB-like protein that is predicted to have an N-terminus orienting
to the cytoplasm, 1 transmembrane domain and a C-terminus orienting to the periplasm
(ABUW_2982), which is quite different to TonB proteins present in fec-like operons from
other organisms (Figure 15); and a putative heme oxygenase (ABUW_2981). As such,
despite shared homology to the FecI sigma factor, and its controlling counterparts, the
fec-operon of A. baumannii is structured in a very different manner to that of other
organisms, perhaps reflecting a novel function.

Figure 14. Genomic organization of the fecI-like operon from A. baumannii and related Gram-negative
organisms. The genomic arrangement for Escherichia coli, Bordetella pertussis, Bordetella avium, Serratia
marcescens and Acinetobacter baumannii was generated and adapted from IMG/ MER Integrated Microbial Genomes
& Microbiomes. Organized from left to right, shown are genes encoding homologs of the FecI sigma factor (red) and
FecR anti-sigma factor (green). Also shown is the FecA outer-membrane receptor that is specific for ferric iron in E.
coli (dark blue) and its homologs that are specific for hemin in Bordetella pertussis, Bordetella avium (both named
BhuR) and Serratia marcescens (HasR) (all three in purple), alongside the uncharacterized FecA homolog from A.
baumannii (light blue). Other genes encoding known ABC transporter systems (magenta), a hemophore secretion
system (silver), tonB-like proteins (yellow); a putative heme oxygenase (orange), and hypothetical proteins of unknown
function (light green) are also shown.
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Figure 15. Predicted topology plots of outermembrane receptor proteins within the homologous fec operons.
The topology of outermembrane receptor proteins present in the fec operons of Acinetobacter baumannii, Escherichia
coli, and Serratia marcescens are shown. Predictions were generated using the Protter bioinformatic website. (A) The
TonB-dependent protein encoded by ABUW_2982 in A. baumannii. (B) The FecA homolog of A. baumannii encoded
by ABUW_2985. (C) FecA from E. coli. (D) The HasR, TonB-dependent protein of S. marcescens. (E) The HasB, TonBdependent protein of S. marcescens. Red shading indicates predicted signal peptide sequences.

The presence of hemin or hemoglobin as a sole iron source impacts growth of the
fecI and fecR mutant strains. The fec-like operon of A. baumannii is of particular interest
because it is not present in all strains of this organism, but instead appears to reside in
those clinical isolates with enhanced pathogenic potential

153

. Indeed, work by Leseleuc

et. al. also found the conservation of this operon in more virulent strains of A. baumannii,
including the clinical strain LAC-4, which displays a more robust growth in the presence
of heme iron (hemin) compared to A. baumannii strains lacking this operon 250. As such,
we hypothesized that the presence of this operon in AB5075 may be required for heme
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acquisition in this strain. To test this, the wild-type along with the fecI and fecR mutant
strains were incubated in RPMI media supplemented with ferric citrate, hemin, or human
hemoglobin as sole iron sources, alongside standard LB (rich media) as a control, with
growth monitored every two hours. As a note, Apo-transferrin was also added to media
containing hemin or human hemoglobin so as to chelate any Fe(III) as a result of hemin
oxidation, ensuring hemin or hemoglobin were the sole iron sources. Upon analysis, both
the fecI and fecR mutants displayed similar growth profiles to the wild-type in LB,
indicating no role in growth in rich media. (Figure 16A). Similarly, growth of our mutants
in the presence of ferric citrate as a sole iron source was no different to that of the wild
type (Figure 16B). Conversely, when these strains were grown in the presence of hemin

Figure 16. The presence of hemin or hemoglobin as a sole iron source affects growth of the fecI and fecR
mutant strains. Shown is growth of the WT, DfecI, and DfecR strains in: (A) LB media; (B) RPMI supplemented with
0.1µM/mL ferric citrate; (C) RPMI supplemented with 0.1µM/mL hemin and 0.1µg/mL apo-transferrin; and (D) RPMI
supplemented with 0.5µg/mL hemoglobin and 0.1µg/mL apo-transferrin. Data is derived from three biological replicates
with error bars shown +/- SEM. A 2-way ANOVA analysis was used to define statistical significance, p<0.001 = ***,
p<0.0001 = ****, ns = not significant compared to the wild-type.
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or human hemoglobin we noticed that our fecI and fecR mutant strains displayed less
robust growth (Figure 16 C and D). From the observed phenotypes, it appears that fecI
and fecR both are required for optimal growth in the presence of either hemin or
hemoglobin as the only iron source available. To explore this further, we constructed a

DfecR+ complemented strain (generating a fecI+ complemented strain proved not to be
possible), and tested its ability to restore growth of the DfecR strain in RPMI media
supplemented with different iron sources. In so doing, we observed that the DfecR+
construct restored growth to wild-type levels (Figure 17 A-C).

Figure 17.

Complementation of DfecR in trans restores growth to wild-type levels in the presence of

hemoglobin or hemin as sole iron sourcse. Growth of the WT, DfecR, and DfecR+ strains in RPMI media
supplemented with either: 0.1µM/mL ferric citrate (A); 0.1µM/mL hemin and 0.1µg/mL apo-transferrin (B); and
0.5µg/mL hemoglobin and 0.1µg/mL apo-transferrin (C). Data is derived from three biological replicates with error bars
shown +/- SEM. A 2-way ANOVA analysis was used to define statistical significance p<0.001 = ***, p<0.0001 = ****, ns
= not significant compared to the wild-type

Transcriptional analysis reveals that A. baumannii fecA is induced in response to
hemin and hemoglobin. Previously published RNA-seq data from our group
demonstrates that the expression of genes in the fec-like operon of A. baumannii is very
low during growth in rich media198. Given that in homologous systems the presence and
abundance of specific types of iron is mediated via the outermembrane protein FecA, we
sought to assess the transcriptional inducibility of the A. baumannii fecA to a variety of
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iron sources. As such, we constructed a lacZ-reporter gene fusion for the fecA promoter
in our wildtype strain, and its corresponding fecI and fecR mutants. We next measured βGalactosidase activity in RPMI media supplemented with ferric citrate, hemin,
hemoglobin, or casamino acids without iron. Upon analysis, we observed that hemin and
hemoglobin strongly induce the expression of fecA in the wildtype background, in contrast
to ferric citrate or casamino acids, which do not (Figure 18A). Importantly, when we
assessed this same series of conditions in the fecI and fecR mutants we noted that the
presence of hemin or hemoglobin was no longer able to stimulate expression fecA
(Figure 18B-C). This finding suggests that fecA is hemin and hemoglobin responsive in
A. baumannii in a FecI-FecR dependent manner.

Figure 18. The fecA promoter of A. baumannii is specifically responsive to either hemin or hemoglobin in a
FecI-FecR dependent manner. ß-galactosidase activity of the fecA-lacZ fusion in the wild-type (A), DfecI (B), and

DfecR (C) strains was measured hourly in the presence of 1% Casamino acids (black), 0.1µM/mL ferric citrate (green),
0.1µM/mL hemin and 0.1µg/mL apo-transferrin (blue), and 0.5µg/mL hemoglobin and 0.1µg/mL apo-transferrin (red).
Transcriptional activity is expressed as Miller Units. Data is derived from three independent experiments, with error
bars shown +/- SEM.

Global transcriptomic analysis reveals altered expression of iron metabolic
pathways upon disruption of fecI. Given that our fecI mutant displayed altered growth
in the presence of hemin and appears to be required for hemin-induced fecA expression,
we used RNA-seq technologies to identify the regulome of the A. baumannii FecI-sigma
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factor. The wild-type and fecI mutant strains were thus grown in RPMI in the presence of
hemin and apotransferrin (as in Figure 16C), with RNA harvested after three hours
growth. Following RNAseq analysis, we observed that 293 genes displayed a significant
alteration in expression between the two strains at a level ³ 3-fold. (Figure 19A,
Supplemental Table S1). This included 128 genes that were downregulated, and 165 that
were upregulated, in the fecI mutant. When we explored this data ontologically (Figure
19B) we observed the altered expression of genes clustered into functions such as
aromatic metabolism, energy production, ion transport, general metabolism, efflux
pumps, biofilm formation, and motility.

Figure 19. Transcriptomic Profiling of the fecI mutant. (A) Genomic map showing major transcriptional changes in

△fecI compared to the parental strain after 3h growth in RPMI containing 0.1µM/mL hemin and 0.1µg/mL apotransferrin. The outermost circle represents a heat map of changes for △fecI compared to the wild-type. The middle
circle (black) depicts RPKM values for the parent, whilst the inner circle (turquoise) depicts RPKM values for △fecI.
Arrows at specific locations within the map highlight operons with significant downregulated (red) or upregulated (blue)
changes. (B) Categorization of genes differentially expressed in △fecI compared to the wild-type based on predicted
function.
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Figure 20. qRT-PCR analysis validates RNA-seq data for genes with altered expression upon △fecI disruption.
The RNA-seq dataset was validated using qRT-PCR to analyze expression of selected genes in the WT and △fecI
strains. Each were grown in a manner identical to that of the RNAseq experiments. Error bars are shown +/- SEM.
Student’s t-test was used to assess statistical significance, p<0.05 = *, p<0.001 = **, p<0.001 = ***.
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When examining the expression of genes involved in iron acquisition, we noted that all
genes in the fec-operon were downregulated in the fecI mutant: fecR = -14.74 fold; fecA
= -45.16 fold; ABUW_2984 = -93.29 fold; ABUW_2983 = -34.12 fold; ABUW_2982 = 25.8 fold; and ABUW_2981 = -17.7 fold. This was an important finding because we
hypothesized that this operon may have a role in hemin acquisition, and our
transcriptional studies showed that fecI appears to be required for hemin -induced activity
of the fecA promoter from this cluster. Conversely, we observed upregulation of the
outermembrane ferric enterobactin (pfeA = 3 fold) and an additional putative tonB
receptor (ABUW_3403 = 3.43 fold). This could be the result of fecI disruption mediated
iron starvation inducing expression of additional iron acquisition systems in an attempt to
acquire iron from the environment.

Another operon found to be upregulated in the mutant was the csu operon (csuA = 150.9
fold, csuB = 74.5 fold, csuC = 89.17 fold, csuD = 101.48 fold, and csuE = 150.9 fold). This
operon encodes a pilus assembly machinery and is required for twitching motility and
adherence in A. baumannii. Thus, in conditions of iron starvation, one might suggest that
the upregulation of these genes is the result of a need to explore new environments to
acquire iron. Additionally, genes encoding the adeABC efflux pumps (adeA = 4.45, adeB
= 4.45, adeC = 4.75) were upregulated in our mutant strain. It has been previously shown
that this efflux pump system is upregulated in response to iron limitation in A. baumannii,
however no further studies have investigated the significance of this response or
specificity of this system to any iron source. The PAA pathway generates acetyl and
succinyl-coA from the degradation of aromatic compounds to provide intermediates to the
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TCA cycle

251

. Interestingly, the genes in this operon were downregulated (paaG = -

11.95, paaH = -11.01, paaI2 = -9.08, paaJ = -7.95, paaK = -8.98) in the fecI mutant. The
function of genes involved in this pathway, including those encoding the PA-coA
oxygenase, require iron for enzymatic activity

251

. Thus, it is possible that this operon is

downregulation as a result of a need for iron conservation in the mutant strain. From our
data, it seems that disruption of the FecI-sigma factor affects the expression of a number
of genes that respond to iron limitation or require iron for enzymatic activity, and
consequently may affect energy generation in the cell under iron limitation. To confirm
this dataset, we performed qRT-PCR on a random selection of genes, all of which
displayed similar fold changes to the RNA-seq study (Figure 20).

Disruption of the heme oxygenase hemO leads to hemin and hemoglobin
dependent growth impairment. Approximately 67% of the total iron in the body exists
in the form of heme bound to hemoglobin within red blood cells. In serum, heme is bound
to albumin or hemopexin, and is consequently transferred to host cells containing heme
oxygenases that can degrade heme to non-toxic products. As discussed above, our data
suggests that the fec-operon in A. baumannii appears to be required for heme (hemin)
acquisition. In bacteria, the role of heme oxygenases in degrading heme results in the
liberation of iron that can be further used to meet nutritional requirements or for the
enzymatic activity of certain proteins. Given their important role in iron metabolism, and
the presence of a heme oxygenase in the fec-operon of A. baumannii, we focused our
attention on the impact of hemO disruption on growth in the presence of hemin or
hemoglobin. When using rich media (LB), the hemO mutant grew to levels comparable to
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the wildtype (Figure 21A). Conversely, in the presence of hemin or human hemoglobin
our mutant showed a defect in growth compared to the wild-type, a phenotype that was
reversed upon complementation (Figure 21B-C). This thus suggests that expression of
the heme oxygenase gene appears to be needed for growth in conditions when hemin is
present either alone or bound to hemoglobin as a sole iron source.

Figure 21. Disruption of hemO leads to growth impairment in the presence of hemin or human hemoglobin.
The wild-type, △hemO and △hemO+ strains were grown the presence of: (A) LB media; or in RPMI media
supplemented with (B) 0.1µM hemin and 0.1µg/mL apo-transferrin or (C) 0.5µg/mL Human Hemoglobin. Data is derived
from three biological replicates with error bars shown +/- SEM. A 2-way ANOVA analysis was used to define statistical
significance, p<0.001 = ***, p<0.0001 = ****, ns = not significant compared to the wild-type.

Disruption of hemO results in a higher intracellular heme concentration compared
to the wild-type. Since we observed a growth defect in the hemO mutant strain when
hemin is present as a sole source of iron, we hypothesize that the hemO mutant strain
would have a higher intracellular hemin concentration as a result of its inability to degrade
hemin. Accordingly, we used a colorimetric based assay to detects hemin content within
cells for our wild-type, mutant and complemented strain. In this experiment, our limited
iron conditions (0.1µM hemin) were not detectable by the kit, thus the wild-type, hemO
mutant, and complemented strains were grown in cultures supplemented with hemin to a
final concentration of 1µM. After 6 hours of growth, cells were collected and lysed, before
being treated with the hemin detection reagent. Upon analysis, we observed an increased
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hemin content of 23% in the hemO mutant compared to the wild-type (Figure 22). The
levels of hemin in the complemented strain was restored to wild-type levels suggesting
that the lack of hemin oxygenase in the mutant strain results in less degradation of hemin
within the cell.

Figure 22. Disruption of hemO leads to increased levels of hemin within the A, baumannii cell. Intracellular levels
of hemin were measured in cultures grown for 6 hours in the presence of 1µM hemin using a heme assay kit (SigmaAldrich). Data is derived from three biological replicates with error bars are shown +/- SEM. Student’s t-test was used
to assess statistical significance, * = p<0.05, ns = not significant compared to the wild-type.

Disruption of hemO leads to decreased survival of A. baumannii in human serum. The
addition of Ga (III) protophoryn IX (GaPPIX), which blocks hemin acquisition systems in
bacteria, was reported to impair the growth of A. baumannii strain LAC-4 in mouse serum.
Interestingly LAC-4 growth levels in these conditions were found to be comparable to
strain ATCC 17978, which lacks the fec-operon, further suggesting a role for this system
in hemin acquisition. Given that our data supports a role for this operon in heme (hemin)
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acquisition, and serum provides iron sources such as ferric iron bound to transferrin or
hemin bound to albumin or hemopexin, we next set out to investigate if disruption of hemO
could have an impact on survival in serum. Accordingly, we incubated our wild-type,
hemO mutant and hemO complemented strain in Non-Heat Inactivated (NHI) and Heat
Inactivated (HI) human serum. Upon analysis we observed that the hemO mutant had
reduced survival, with a 1 log decrease in viability compared to the wild type and its
complemented strain (Figure 23A). Additionally, we observe similar results in survival
when compared to strains incubated in serum-HI (Figure 23B). Therefore, it appears that
the reduced survival in the hemO mutant could be due to a less efficient assimilation of
hemin, rather than an active complement system.

Figure 23. Disruption of hemO leads to reduce survival in human serum. Strains were inoculated into 100 µL of
heat inactivated or non-heat inactivated human serum and incubated at 37°C for 4 hours, before viability was
determined by serial dilution. Data is derived from three biological replicates, with error bars are shown +/- SEM.
Student’s t-test was used to assess statistical significance, p<0.001 = **, p<0.001 = ***, ns = not significant compared
to the wild-type
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DISCUSSION
In this study, we characterize a set of 8 genes organized within an operon, determining
that the first three genes, annotated as ABUW_2987, ABUW_2986, and ABUW_2985,
are predicted to encode homologs of FecI, FecR and FecA from E. coli, respectively. In
E. coli, this operon is dedicated to regulation of the ferric citrate transport and utilization
system. In addition, we found that FecI, FecR, and FecA from A. baumannii also shares
similarity to FecI, FecR and FecA counterparts in B. pertussis and B. avium (HurI , HurR
and BhuR), and in S. marcescens (HasI , HasS, and HasR). An interesting outcome in
this study was that, although similarities between the FecI, FecR and FecI proteins exist,
the downstream genes, which dictate specificity and function, are quite distinct from each
other. Along these lines, the A. baumannii clinical isolate Lac-4 was reported to be more
proficient at hemin utilization than other isolates due to the presence of the Fec operon in
this strain. Indeed, although several iron acquisition systems expressing siderophores
specific for ferric iron acquisition have been characterized in A. baumannii, a hemin
acquisition system have not yet been characterized in this organism.

As such, we sought to investigate the effect of several iron sources in conjunction with
mutants of the two predicted regulatory genes for this operon: fecI and fecR. When
examined, growth of our mutants in the presence of either hemin or hemoglobin resulted
in a significant growth defect compared to the wild-type. These observations, alongside
our transcriptional studies, supports a role for acquisition and utilization of hemin and
hemoglobin by this system. During infection, sequestration of iron is a defense host
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mechanism to limit bacterial growth. With heme as the major iron source in the body,
which is found to be in complex with hemoglobin or bound to host heme binding proteins,
the existence of bacterial iron acquisition systems with specificity to these iron sources
has previously been described in several pathogenic bacteria. For example, Neisseria
meningitidis has a system comprised of an outermembrane receptor HpuB and a
lipoprotein HpuA that together acquire heme from hemoglobin and the hemoglobinhaptoglobin complex. Interestingly, in several Gram-negative organisms, outermembrane
receptors found in heme acquisition systems alongside ABC transporters or hemophore
secretion proteins are under the regulatory control of FecI-FecR. Unlike the genomic
organization found in these hemin acquisition systems, the fec-operon of our strain
harbors a unique set of genes, including two predicted periplasmic proteins, a second
Ton-B dependent protein and a gene encoding a heme oxygenase. Importantly, mutation
of this latter gene also demonstrated growth defects in the presence of hemoglobin and
hemin. Therefore, it could be that interaction of FecR with FecA in A. baumannii is
required for activation of this system to acquire hemin in a similar manner to that
described for the fec-operon of E. coli. However, with the presence of a hemO gene and
the absence of an ABC transporter, the possibility exists that this operon and its genes
encodes for a system with a distinct mechanism to acquire heme or hemoglobin to that
previously described.

Under iron limited conditions in E. coli, ferric citrate is perceived by the FecA protein,
inducing a signaling cascade via FecR that activates FecI. In S. marcescens and B.
pertussis a similar mechanism has been described in iron starvation condition when
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hemin is supplemented as sole iron source. In B. avium, a study demonstrated that
disruption of rhuR (fecR homolog) renders the promoter of bhuR (fecA homolog)
unresponsive to hemin, suggesting a positive regulatory function

243,252

. Another study

using an E. coli strain with a deletion of the entire fec operon demonstrated that fecI and
fecA together failed to complement this null strain, and that the function of this operon is
only restored when complemented with fecI, fecR and fecI253. Interestingly, we observed
that our fecI and fecR mutant strains no longer respond to hemin as an inducer of
transcription suggesting that induction of the fecA promoter in the presence of hemin
depends on an active FecI- FecR system, which is necessary for inducing active transport
of hemin; mirroring findings from the homologue systems in B. avium.

RNA-seq transcriptional analysis with a fecI mutant revealed the altered expression of
genes involved in energy generation and iron-dependent metabolism in response to
hemin. From this set of genes, the fec-operon displayed a downregulation in expression,
supporting its role in transcription of this operon. As such, we investigated the effects of
hemin upon disruption of hemO, given that a previous study linked the presence of this
gene with hemin utilization in A. baumannii250. Notably, the hemO mutant displayed a
growth defect in the presence of hemin as a sole iron source, decreased survival in serum,
and increased levels of hemin within its cell. The role of bacterial hemin oxygenase in
hemin uptake systems has been described in several organisms. For example, in
Pseudomonas aeruginosa the hemin oxygenase PhuO has been shown to degrade
hemin into biliverdin, carbon monoxide, and iron. In Staphylococcus aureus the hemin
oxygenases IsdG and IsdI are required for hemin degradation. Therefore, the increased
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levels of hemin in our hemO mutant is likely explained by its inability to degrade hemin,
resulting in less robust growth when hemin is the only iron source. The decreased survival
of the hemO mutant in serum also highlights the importance of its encoded Heme
oxygenase for survival in restrictive iron environments, such as those found in a host
during infection.

In summary, our data suggests that A. baumannii appears to deploy its fec-operon to
regulate the acquisition and degradation of hemin. Although the mechanism in which this
occurs is far from decoded, our data sheds light onto the possible manner in which this
occurs. We propose that FecA senses hemin and transmits this signal, via FecR, to FecI
to further enhance transcription of the fec-operon (Figure 24). This is supported by our
transcriptional studies that demonstrate the effect of hemin on transcription of the fec
operon and activity of the fecA promoter. Furthermore, regulation of hemin assimilation
appears to be regulated by this system given the presence of HemO ,and deficiency of
fec-operon mutant strains to grow in the presence of hemin and hemoglobin. With regards
to this latter point, it is possible that the rest of the genes in this operon may be involved
in a parallel mechanism to acquire hemin from hemoglobin and further transport it for
degradation and utilization. Further work is currently being done to characterize the role
of the genes present in this operon in hemin acquisition and utilization.
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Figure 24. Model for perceiving hemin in the environment via the fec-operon of A. baumannii. Based on our
transcriptional studies and the defined regulatory mechanism for Fec-operon homologs in other Gram-negative
organisms, we propose that hemin induces activity of the FecA receptor and transmits this signal to FecI, via FecR,
resulting in activation of genes necessary for hemin uptake and utilization.
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CHAPTER V
FINAL DISCUSSION
The recognition of Acinetobacter species as pathogenic organisms in the last century
occurred as a result of its recurrent isolation from clinical samples, presenting a need to
define phenotypic characteristics that would allow for its accurate identification. As such,
the definition of inherent phenotypic traits belonging to Acinetobacter species has
revealed the opportunistic nature of the genus, with A. baumannii being the most
representative human pathogen. While epidemiological studies in the 1980’s began to
document A. baumannii outbreaks in hospitals globally, the existence of effective
antibiotic therapies to treat A. baumannii infections undermined its pathogenic nature.
The underappreciation of its pathogenic potential, however, was soon after replaced by
concerns of its rapid evolution towards multi-drug resistance. As a result, the
characterization of genes encoding virulence factors in different clinical isolates has
driven much of the Acinetobacter research over the last several decades.

Another important aspect that we have learned in the context of A. baumannii’s
pathogenic evolution is its ability to acquire genes that facilitate survival under harsh
conditions during the infectious process, for example nutrient scarcity, host immune
defensive mechanism, and antibiotic pressures. Like any other bacteria, A. baumannii
must possess regulatory systems that allow it to sense changes in the environment,
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relaying this information as a signal transmitted to an effector protein that consequently
elicits a rapid response in the form of orchestrated gene expression that ultimately is
required for adaptation. The necessity of bacterial regulatory systems is explained by the
energy required for synthesis of nucleotides and amino acids, and the assembly of a
translation machinery that together is required for protein production
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. In the absence

of regulatory control, gene expression is a costly process that translates into burden
during growth, and an altered energy status within the cell due to uncontrolled energy
investment.

Given the importance of regulatory networks, it is of fundamental importance to
understand how they enable bacteria to sense and respond to diverse stressful
conditions, striving for survival and adaptation to specific niches in the context of
pathogenicity. Although several genes encoding proteins with roles in antimicrobial
resistance and disease causation have been characterized in A. baumannii, our
knowledge regarding how these genes are regulated is limited to 6 TFs and 7 TCSs
studied in recent years. To put this in perspective, A. baumannii has a genome size of
4.0Mbp, whilst E. coli with a genome size of 4.6Mbp has 304 annotated TFs. From this
set of regulatory proteins, 185 TFs have been characterized in E. coli
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. As such, a

complete survey of the regulatory network in A. baumannii would provide a starting point
to elucidate the systems used by this organism to interact with its environment and their
relevance in the context of A. baumannii MDR infections. With this in mind, the initial work
presented in chapter II of this dissertation was developed with the goal of defining the
proteinaceous regulome of A. baumannii to provide a foundation that could serve to
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investigate individual role of regulatory proteins in assisting this organism during infection.
Given that A. baumannii AB5075 is a hypervirulent MDR strain when compared to other
clinical isolates with different degrees of MDR phenotypes and pathogenicity, it was used
as a model for our studies. The use of a combination of bioinformatic tools and available
scientific literature allowed us to uncover the presence of 243 TFs, 14TCSs, and 5 s
factors. This is the first such study of its kind, providing a comprehensive collection of
regulatory genes with most of them yet to be characterized in A. baumannii153.

After defining the proteinaceous regulome of the hypervirulent strain AB5075, we next
sought to understand how conservation or the absence of regulatory proteins could
correlate to variations in pathogenicity across representative clinical strains with different
degree of pathogenicity and antibiotic resistance. Interestingly, 202 TFs, 14 TCSs and 4
s factors were found to be conserved among clinically relevant A. baumannii strains. This
finding perhaps reflects their role in regulating essential biological process such as DNA
synthesis and repair, cell division, and metabolic adaptation. In order to establish a link
between our set of regulatory proteins and their potential role in virulence, we compared
our curated genome of AB5075 to the screening of a recent developed AB5075 Tn library
in a Galleria mellonella model of infection110. In doing so, we were able to find genes with
putative regulatory functions that were required for survival during infection, providing a
pathogenetic context to our work that can be used as tool for further investigation into
specific roles of these uncharacterized regulatory proteins.
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As an example, 4 secretion systems, including the type II secretion system (T2SS), the
type VI secretion system, the autotransporter Ata, and the outer membrane vesicle
(OMV), have been identified in A. baumannii with roles in virulence and lipid metabolism.
Although mechanism of their regulation have not yet been identified, we found a putative
TF (ABUW_2741) that was required for survival in the G. mellonella model of infection.
Interestingly, in our analysis we found that this TF is a homolog of the Crp protein from P.
aeruginosa that controls expression of genes encoding type III secretion system
components. As such, one could speculate that this TF could have a regulatory role in
governing secretion system expression in A. baumannii, particularly given its essentiality
for survival in the worm infection model.

Another regulatory protein that, although not required for pathogenicity in the Galleria
model, represents a good candidate for study is the A. baumannii homolog of the FecI s
factor from E. coli. Iron is an essential metal required for the function of a variety of
proteins involved in essential biological functions in all living organisms, including
bacteria230. Its limitation hinders these processes, resulting in growth inhibition and an
impaired infectious capacity in pathogenic bacteria. Indeed, understanding the strategies
utilized by such bacteria to acquire and assimilate essential metals such as iron has been
an active area of research in the recent years. As such, this s factor was of interest,
particularly because it is only conserved in the highly pathogenic strains of A. baumannii
used in our analysis, suggesting it may provide an advantage during disease causation.
These findings, and insights into the iron regulatory systems extant within AB5075, will
be further discussed in the last part of this chapter.
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The information provided by our work investigating regulatory circuits in A. baumannii
offers insights into potential regulatory functions of uncharacterized proteins. With this
being said, we expect that our work will provide a foundation to guide further research in
deconvoluting regulatory networks in this organism. Indeed, the work presented in
chapter II enabled us to further pursue investigations into uncharacterized regulatory
proteins in A. baumannii , and to demonstrate the usefulness of this resource. Specifically,
we utilized our fully curated annotation of TCSs in the genome of AB5075 to explore those
that have not been characterized. Interestingly, we found that the TCS ABUW_2426/2427
exhibited high homology to a TCS named ArcAB (Aerobic Respiratory Control) previously
characterized in E. coli, S. enterica, S. oneidensis, and H. influenzae168-172. Protein
alignments of the ABUW_2426 and ABUW_2427, encoding a response regulator and its
sensor kinase, respectively, with the ArcAB systems from other organisms provided
unique insights into the potential evolution of this system and its regulatory function in A.
baumannii. The ArcAB system in E. coli serves to sense transition from aerobic to
anaerobic conditions via the redox state of two conserved cysteine residues found in the
ArcB sensor; which occurs as a result of changes in quinone pools. This in turn triggers
a kinase reaction that phosphorylates ArcA and ultimately induces a remodeling of
metabolic-energy generation pathways required for survival in the absence of oxygen167.
In A. baumannii, the absence of one of the cysteine residues and a phosphotransfer
domain in its ArcB, alongside its classification as strictly aerobic organism, argues for a
divergent function and perhaps an alternative kinase mechanism for ArcAB and its
response to stimuli that perturb metabolic pathways affecting energy generation.
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Because a previously RNA seq analysis performed in our lab showed that the
ABUW_2426/2427 is lowly expressed in LB media, we performed transcriptomic profiling
on the arcAB system using different chemical stressor that would allow us to determine
how its transcription could be induced. Our data showed that this TCS responded to the
uncoupler CCCP, which perturbs the levels of electron carriers by inhibition of the ETC.
These effects mirror those conditions in which decreased oxygen levels lead bacteria to
use alternative electron transport chains via alternative electron donors/acceptors, such
as nitrogen or fumarate. Thus, this finding suggests that the ArcAB of A. baumannii could
regulate genes required to maintain sufficient energy levels to support essential cellular
functions in response to oxygen tension. Of note, bone infections are characterized by
the presence of necrotic tissue and abscesses, restricting blood flow and oxygen, and
promoting bacteria attachment and biofilm formation256. Given that AB5075 was first
isolated from an acute bone infection, one could speculate that the ArcAB system may
function to regulate metabolic pathways that would allow it to survive in such harsh
conditions encountered in infected bone tissue, including low oxygen levels and nutrients
scarcity.

An indicator of the energy state of the cell is the PMF, which is known to be influenced by
several external factors, including changes in oxygen availability and pH levels. Because
the PMF is originated from a series of oxidation and reduction reactions that involve a
functional glycolysis, TCA cycle, and ETC, creating a proton gradient to energize the
membrane, its regulation is of importance for metabolic adaptability in bacteria. In this
vein, the role of TCSs in regulating genes involved in these metabolic pathways has been
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documented by others, including for ArcAB, RegAB and PhoPQ257. Indeed, disruption of
the RR PhoP, associated with the regulation of metabolic pathways in E. coli, resulted in
an altered PMF leading to changes in membrane polarity; highlighting the importance of
these pathways to maintain energy balance in the cell 258,259.

Given that transcription of ArcAB in A. baumannii was induced upon exposure to CCCP,
which is also known to disrupt the PMF, we examined the transmembrane proton gradient
(△pH) and transmembrane potential (ΔΨ), both component of the PMF. Our findings
showed that in the absence of either ArcA or ArcB both components were affected, further
supporting a role for this TCS in the regulation of metabolic pathways to generate energy.
Because the response of ArcAB to the effects of CCCP was highly specific, we also
examined changes in gene expression upon disruption of arcA upon exposure to CCCP.
After analysis of our dataset, we observed that mainly genes with functions in metabolism
and energy generation were altered. Among these genes, significant changes in
transcription were observed for genes involved in glycolysis, the TCA cycle, and the
electron transport chain. Interestingly, some of these genes have been previously shown
to be part of the regulome of ArcAB in E. coli. Aerobic organisms can generate energy
from glucose oxidation via glycolysis, involving a number of enzymatic reactions that
convert glucose to pyruvate. Pyruvate is then further converted to acetyl-coA, and enters
the TCA cycle. Additional oxidation steps in the TCA cycle generates intermediate
metabolites and reduced equivalents that donate electrons to the ETC, and in turn the
ETC generates energy in the form of ATP. This process is relevant to findings in our work
of rapid growth of our mutants in the presence of glucose (data no shown), alongside the
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accumulation of glucose within the cell, suggesting an overwhelmed and overactive
metabolic machinery. A response to high glucose concentrations described in
Saccharomyces cerevisiae, also known as the Crabtree effect, involves inhibition of the
TCA cycle, leading to decreased oxygen consumption. As a consequence, the generation
of ATP via substrate phosphorylation is highly favorable under such conditions. These
effects have also been observed in E. coli, in which excess glucose leads to the release
of acetate as a result of active energy generation pathways replacing aerobic respiration.
With this information, we measured the abundance of several metabolites produced by
glycolysis and the TCA cycle that could provide a better understanding of metabolic
alterations as a result of the disruption of the the ArcAB system in A. baumannii. Our
results showed that our mutants have higher levels of pyruvate, suggesting an altered
glycolytic pathway. Given the observed accumulation of glucose in our mutants, one could
argue that higher levels of pyruvate could be the result of an overwhelmed glycolytic
pathway that slows conversion of pyruvate to acetyl CoA. This is a phenomenon, known
as pyruvate overflow, which was previously described in E. coli as response to increased
glucose levels in the cell. Other side effects of glucose accumulation in the cell would be
an allosteric inhibition of succinate dehydrogenase and induction of the glyoxylate shunt,
favoring acetate production. One of the roles of the glyoxylate shunt is to accommodate
the excess acetyl-coA that is generated from oxidation of carbon sources such as
glucose, and to divert metabolic overflow towards the generation of acetate and
metabolites such as oxaloacetate that feeds gluconeogenesis. Certainly, when we
measured the abundance of succinate, our mutants had higher levels, supporting an
allosteric inhibition of this complex as a result of glucose accumulation. In addition, levels
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of oxaloacetate and acetate were higher in our mutants compared to our wildtype
supporting a hyperactive glyoxylate shunt as a result of ArcAB disruption.
With a hyperactive glyoxylate shunt, we also observed increased NADH levels in our
mutants compared to its wild-type, which could again be explained by metabolic overflow,
inducing NADH production in the absence of ArcA . Indeed, a study published by Vemuri
et al investigating overflow metabolism and redox homeostasis in an arcA mutant of E.
coli showed that a hyperactive TCA cycle produces higher levels of NADH as a
consequence of ArcA mediated control of this system225. In addition to this, our RNA-seq
data showed that several genes encoding cytochrome oxidases and the ATP generation
machinery, were downregulated, suggesting decreased function of the ETC in our
mutants, which relies on oxidative phosphorylation that could contribute to the
accumulation of reduced equivalents, such as NADH, that are not oxidized via ETC.

To further gain insight into the function of the ETC in our mutants, we tested their ability
to generate ATP via oxidative phosphorylation and substrate phosphorylation. We found
that disruption of the ArcAB system favors production of ATP via substrate
phosphorylation, suggesting decreased activity of the ETC as a consequence of
metabolic imbalances in the cell. We were able to analyze the activity of the cytochrome
oxidase and found that its activity was lower in our mutants, supporting a disrupted
function of the ETC upon arcAB disruption. As such, our data collectively supports a
proposed role for ArcAB in A. baumannii in controlling metabolic pathways, while
maintaining energy balance in the cell.
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Lastly, our findings within the proteinaceous regulome of AB5075 presented in chapter II
revealed the presence of a putative ECF-FecI-like sigma factor. In E. coli, the Fec system
is comprised of FecA (a TonB outer-membrane protein) that upon sensing low external
iron concentrations transmits a signal to the FecI sigma factor via the periplasmic protein
FecR240,241,244,260. Interestingly, when we examined the genomic organization of genes
next to the putative fecI in A. baumannii, we found that the fecA, fecR, and fecI gene
arrangement of E. coli was conserved, suggesting a similar regulatory role in the context
of iron acquisition.
The putative ECF-Fec-operon in A. baumannii presents a unique collection of genes,
specifying two hypothetical periplasmic proteins and a TonB-like protein that perhaps
could be part of an auxiliary iron transport system. An iron acquisition system with a
secondary TonB-like protein (HasB) involved in heme transport has been described in S.
marcescens246. Interestingly, we also found a hemO-like oxygenase gene in the A.
baumannii fec operon, alongside an additional gene encoding a hypothetical protein.
Bacterial heme oxygenases in Gram-negative organisms are required for assimilation of
hemin within the cell. Upon the transport of hemin, heme oxygenases degrade it via three
major enzymatic reactions, involving the cleavage and reduction of the ferric atom
contained within the porphyrin ring to ferrous iron, before further oxidation to ferric iron
and biliverdin. The distinct genes contained in the A. baumannii fec operon differ from the
canonical heme – Fec dependent systems found in other pathogenic bacteria, which rely
on an ABC transport system, implying the existence of a unique mechanism for transport
and assimilation of hemin in this organism.
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When testing strains with disrupted genes for FecI, FecR, FecA and HemO, a trend
amongst the mutants became apparent: a growth defect was observed when the iron
source provided contained hemin or hemoglobin. This finding is indicative of the potential
role of these genes in the acquisition or assimilation of hemin or hemoglobin. Because
the canonical surface signaling activation mechanism described for Fec- iron regulatory
systems is initiated upon FecA sensing a specific iron source, we examined the
transcriptional response of the fecA promoter in our collection of strains. Here we showed
that this promoter was responsive to hemin, further supporting a potential regulatory
function of this operon in hemin acquisition250. Next, we evaluated transcriptional changes
upon exposure to hemin in the wild-type and fecI mutant strains. Upon analysis, we found
a significant decrease in expression of the entire Fec-operon, suggesting a role for this
system in the acquisition of hemin as an iron source.

Although disruption of the fec-operon appears to have no influence on the pathogenicity
of AB5075 when tested in a Galleria model of infection, its role in virulence should not be
dismissed. G. mellonella only contains ferric iron as an iron source, which is bound to iron
binding proteins such as ferritin, apoferritin and holoferritin.
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Thus, the absence of

hemin as an available iron source in the larval model of infection, and the ability of A.
baumannii to produce siderophores with high affinity for ferric iron, could explain why the
genes present in the fec-operon of A. baumannii are not required for survival in such
model of infection. We did, however, observe that disruption of fecI, fecR, and hemO
resulted in less survival when strains were grown in human blood or serum. As hemin is
one of the most abundant iron sources in the body, representing almost 70% of total, the
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presence of a fec-operon dedicated to the acquisition and assimilation of hemin would be
of great advantage for survival of A. baumannii within the host.

Future directions
Collectively, we expect that the work performed herein will contribute towards our
understanding of the role of regulatory proteins in A. baumannii. In collaboration with
computational biologists we were able to defined a complete set of regulatory proteins
and create a resource that can be used to guide investigation on the function of
uncharacterized regulatory proteins. Using this basis for our own projects, we were able
to provide insights into the regulatory function of the ArcAB system of A. baumannii in the
context of metabolism and energy state of the cell, and aminoglycosides resistance.
However, our structural analysis of the ArcB protein of A. baumannii revealed distinct
features such as the lack of conservation one of the cysteine residues (cys 241 in E. coli)
that is required for sensing variation in oxygen levels via quinones concentration, a signal
that determines the kinase activity of ArcB in E. coli. To determine whether the only
conserved Cys (490) in A. baumannii is required for its kinase activity, the use of site
directed mutagenesis in combination with kinase assays could be used to determine its
requirement for ArcB autokinase activity in A. baumannii. Briefly, the conserved cysteine
residue could be mutated to an alanine. ArcB from WT and ArcBC490A could be
overexpressed from a plasmid and further purified to test their kinase activity. Purified
proteins are incubated with Y32P and upon stopping the reactions samples could be
visualized by SDS/PAGE and analyzed using a phosphorimaging. In the case that the
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conserved cysteine residue is required for kinase activity of ArcB further phenotypic
assays will assess its impact of the ArcB function.

Another finding of our structural analysis of the ArcAB system of A. baumannii revealed
that this system is comprised of a TCS hybrid and the RR. This system appears to rely
on a phophorelay mechanism for its activation based on conserved domains; however,
the lack of a phosphotransferase domain in ArcB indicates the possibility of a protein with
a Hpt domain that could assist on transfer of the phosphate group from the sensor to the
receiver domain of ArcA (Figure 25). Thus, an initial computational screening using Hpt
domain as a seed to search in the genome of AB5075 could provide with protein
candidates that could be part of the ArcAB phosphorelay system. As such, the specificity
of the Hpt protein for transferring of the phosphate to ArcA could be tested in an in vitro
phosphorelay system. As such, purified phosphorylated ArcB and Hpt proteins of interest
are incubated to allow phosphorylation of Hpt. Further incubation of these reactions with
ArcA would allow transfer of the phosphate group to ArcA. Reactions could be analyzed
using SDS /phosphorimaging. Finally, interaction between ArcB and identified Hpt protein
would be evaluated using a bacterial hybrid assay. Overall these experiments would shed
light into the signaling mechanism of the ArcAB system of A. baumannii.

With respect to the fec-operon of A. baumannii, our bioinformatic findings in combination
with the generated RNA-seq data suggest the existence of four promoters induced under
hemin limitation in this operon (Figure 26). As such we will be using the 5’-3 rapid
amplification of cDNA (RACE) and Northern Blot analysis to confirm hemin-dependent

111

transcripts from each putative promoter. With this information, mapping and examination
of this operon could be performed to identify features that will provide insights into the
molecular regulation of the fec-operon. The activity of identified promoters could be
further evaluated using qPCR in the presence of a variety of iron sources to assess their
level of response to these iron forms. To further characterize the signaling mechanism of
this operon, reconstitution of the signaling cascade using lacZ constructs in the best
studied fec-system E. coli could provide further information in regard to the regulation of
this system in A. baumannii. This approach has been proven to be successful in
elucidating a similar heme surface signaling mechanism in S. marcescens236. As such, a
fecA-lacZ fusion strain could be integrated into the chromosome of an E. coli strain with
deletion of the fur gene to avoid repression of fur regulated genes and a WT E. coli. This
newly created strain could be transformed with plasmids containing either: (a) fecI, (b)
fecI and fecR, or (c) fecI, fecR and fecA to determine the transcriptional effects of each
on fecA.
Currently, we are in the process of confirming complemented strains of the fecI and fecA
genes to evaluate their ability to restore survival in serum and blood in vitro assay.
Additionally, screening of genes with Tn insertions in hypothetical genes of these operon
to evaluate their phenotypes under iron limitation are undergoing in our lab to completely
characterize the fec-operon and its regulatory function in this organism.
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Figure 25. Proposed model of activation of ArcAB in A. baumannii.

Figure 26. fec-like operon present in A. baumannii and predicted promoters based on transcripts generated from the
RNA-seq data and bioinformatic analysis.
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Appendix 2 Supplemental figures

Supplemental Figure S1. Protein alignments of ABUW_2427 from A. baumannii alongside ArcB proteins from
a variety of organisms. Protein alignments from Acinetobacter baumannii, Escherichia coli, Salmonella enterica,
Vibrio cholera, Shewanella oneidensis, and Haemophilus influenzae showing conservation and divergence of amino
acids found among ArcB homologs. Yellow shading indicates conservation of the Cys 180 and Cys 241 amino acids
that are required for ArcB kinase regulation in E. coli, whilst pink shading shows divergence of these residues. Blue
shading shows conservation of the aspartic acid residue. Green shading shows conservation of histidine residues, with
violet indicating the absence of the second of these in A. baumannii
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Supplemental Figure S2. Protein alignments of ABUW_2426 from A. baumannii alongside ArcA proteins from
a variety of organisms. Protein alignments from Acinetobacter baumannii, Escherichia coli, Salmonella enterica,
Vibrio cholera, Shewanella oneidensis, and Haemophilus influenzae showing conservation and divergence of amino
acids found among ArcA homologs. Blue shading highlights conservation of the aspartic acid residue required for
phosphorylation of ArcA. Yellow shading highlights conservation of amino acids found in the regulatory domain that are
important for dimerization, allowing an active conformational state of ArcA. Pink shading shows conservation of amino
acids found within the helix turn helix domain of the E. coli ArcA protein.
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Supplemental Figure S3. The arcAB promoter is induced upon exposure to CCCP. LB plates supplemented with
X-Gal were inoculated with the wild-type bearing an arcAB-lacZ reporter-gene fusion strain. Sterile filter disks were
placed onto plates, and inoculated with the compounds noted. The induction of expression is visualized as a blue ring
around the zone of inhibition. Shown are four representative plates
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Supplemental Figure S4. qPCR validation of RNA-seq data arcA expression in the wild-type and arcA mutant.
Changes from the RNA-seq dataset were confirmed using qRT-PCR analysis for a random selection of genes and
comparing fold changes in expression of the arcA mutant relative to the wild-type. Measurements are derived from
three independent replicates with error bars shown as +/- SEM. Student’s t-test was used to assess statistical
significance ** = p<0.001, *** = p<0.001.
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.

Supplemental Figure S5. Disruption of ArcAB does not affect susceptibility to non-aminoglycoside antibiotics.
Determination of minimal inhibitory concentration (MIC) for the wild-type, △arcA and △arcB strains was determined for:
(A) Chloramphenicol, (B) Erythromycin, (C) Levofloxacin, (D) Ampicillin, and (E) Sulfanilamide. Data is derived from
three independent experiments, with error bars shown as +/- SEM.
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APENDIX 3 Supplemental Tables
Table 1S Genes differentially expressed in the arcA mutant strain
Locus Tag

Gene

Protein / Function

ABUW_1004
ABUW_2433
ABUW_0157
ABUW_3587
ABUW_3695
ABUW_2984
ABUW_1005
ABUW_3322
ABUW_3516
ABUW_1659

-

hypothetical protein
KGG domain-containing protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
NIF3 (NGG1p interacting factor 3)
exonuclease V beta chain
hypothetical protein
hypothetical protein

ABUW_1536
ABUW_2065
ABUW_2693
ABUW_2965
ABUW_1649
ABUW_0233
ABUW_3278
ABUW_0931

-

ABUW_2448

-

ABUW_2606

-

ABUW_2297
ABUW_0710

-

hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
SnoaL-like polyketide cyclase domaincontaining protein
beta-barrel domain-containing outer
membrane protein
glycoside hydrolase/deacetylase family
protein
hypothetical protein
hypothetical protein

Fold
Change

Hypothetical protein

ABUW_0111

14.66
12.31
10.03
6.68
6.52
5.64
5.32
5.11
5.09
5.03
3.67
3.61
3.57
3.56
3.51
3.42
3.41
3.4
3.36
3.3
3.3
3.22
3.17
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Table 1S (Continued)
ABUW_3147
ABUW_2442
ABUW_1379
ABUW_2058
ABUW_0646

-

ABUW_1987
ABUW_1165
ABUW_2922

-

ABUW_2156
ABUW_1792
ABUW_1143
ABUW_3433
ABUW_2721
ABUW_1629
ABUW_0336
ABUW_3158
ABUW_1594
ABUW_1564
ABUW_0207

-

ABUW_2692
ABUW_1264
ABUW_1471
ABUW_0301
ABUW_1761
ABUW_0220
ABUW_0768
ABUW_3441
ABUW_3524
ABUW_0521
ABUW_2143
ABUW_2449
ABUW_0449
ABUW_0302

-

hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
glycosylase/bleomycin resistance/fosfomycin
resistance/dioxygenase domain-containing
protein
hypothetical protein
pirin domain protein
hypothetical protein

3.15
3.12
3.1
3.1
2.98

hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
Putative O-methyl transferase
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
pirin family protein
hypothetical protein (pseudogene:
nonfunctional due to frameshift)
hypothetical protein
hypothetical protein
LemA Family protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
rhodanese domain protein
hypothetical protein
putative SAM-dependent methyltransferase
hypothetical protein
TPM domain-containing protein

2.83
2.83
2.82
2.82
2.82
2.81
2.77
2.77
2.75
2.72
2.68

2.9
2.89
2.87

2.65
2.62
2.61
2.6
2.55
2.52
2.51
2.51
2.5
2.5
2.5
2.45
2.44
2.43
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Table 1S (Continued)
ABUW_1256
ABUW_2803
ABUW_0104
ABUW_2703
ABUW_3149
ABUW_0928
ABUW_0217
ABUW_0793

-

ABUW_1786
ABUW_2860
ABUW_3574
ABUW_0254
ABUW_3113
ABUW_0053
ABUW_1657
ABUW_3058
ABUW_1059
ABUW_2720
ABUW_2554
ABUW_2391
ABUW_0673
ABUW_3045
ABUW_3793

-

ABUW_3759
ABUW_3101
ABUW_1283
ABUW_2621
ABUW_0181
ABUW_3458
ABUW_0206
ABUW_1603
ABUW_1988
ABUW_0593
ABUW_3375
ABUW_3827

-

hypothetical protein
hypothetical protein
secretory lipase
hypothetical protein
hypothetical protein
lytic transglycosylase, catalytic
hypothetical protein
hypothetical protein
tetratricopeptide-like helical domaincontaining protein
hypothetical protein
hypothetical protein
acetyltransferase
Sua5/YciO/YrdC/YwlC family protein
UPF0391 membrane protein
hypothetical protein
putative metal-dependent hydrolase
hypothetical protein
hypothetical protein
HYpothetical protein
hypothetical protein
hypothetical protein
OmpA/MotB domain protein
SnoaL-like polyketide cyclase domaincontaining protein
hypothetical protein
GDYXXLXY domain-containing protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
isochorismate hydrolase
putative acetyltransferase
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein

2.42
2.41
2.41
2.38
2.37
2.37
2.36
2.36
2.36
2.3
2.29
2.29
2.28
2.27
2.26
2.26
2.23
2.22
2.15
2.15
2.14
2.11
2.07
2.06
2.05
2.05
2.05
2
2
2
2
-2
-2.01
-2.04
-2.06
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Table 1S (Continued)
ABUW_2610
ABUW_2886
ABUW_0703
ABUW_0058
ABUW_0117
ABUW_3702
ABUW_3282
ABUW_0382
ABUW_2612
ABUW_2962
ABUW_2677
ABUW_1451
ABUW_1971
ABUW_0902
ABUW_1051
ABUW_3001
ABUW_3582
ABUW_1752
ABUW_2660
ABUW_3882
ABUW_0813
ABUW_3698
ABUW_3825
ABUW_2599
ABUW_0524
ABUW_3337
ABUW_1443
ABUW_1045
ABUW_3687
ABUW_1237
ABUW_0088
ABUW_1455
ABUW_3866
ABUW_1331
ABUW_2181
ABUW_3555
ABUW_2626

-

hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
YaeQ domain-containing protein
hypothetical protein
GatB/Yqey domain protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
putative lysozyme
hypothetical protein
hypothetical protein
YCII-related protein
Hypothetical protein
Hypothetical protein
GGDEF family protein
hypothetical protein
hypothetical protein
hypothetical protein
AAA ATPase superfamily protein
hypothetical protein
exodeoxyribonuclease X, putative
Hypothetical protein
hypothetical protein
Hypothetical protein

-2.07
-2.07
-2.07
-2.09
-2.09
-2.09
-2.1
-2.1
-2.13
-2.13
-2.15
-2.17
-2.18
-2.18
-2.18
-2.2
-2.21
-2.22
-2.23
-2.24
-2.25
-2.25
-2.27
-2.28
-2.28
-2.29
-2.3
-2.3
-2.32
-2.32
-2.33
-2.33
-2.34
-2.34
-2.35
-2.37
-2.38
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Table 1S (Continued)
ABUW_2665
ABUW_1534
ABUW_1644
ABUW_2317
ABUW_1797
ABUW_1746
ABUW_1083
ABUW_1245
ABUW_0506
ABUW_1990
ABUW_0865
ABUW_0346
ABUW_1719
ABUW_2868
ABUW_1554
ABUW_2862
ABUW_1587
ABUW_2932
ABUW_0864
ABUW_0554
ABUW_1241
ABUW_0636

-

ABUW_0087
ABUW_0365
ABUW_0514
ABUW_0937
ABUW_1727
ABUW_1995
ABUW_0435
ABUW_3112
ABUW_2932
ABUW_0864
ABUW_0554
ABUW_1241
ABUW_0636

-

Hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
Hypothetical protein
Hypothetical protein
GGDEF domain protein
Hypothetical protein
rhodanese domain protein
hypothetical protein
Hypothetical protein
Hypothetical protein
RDD family protein
Hypothetical protein
Hypothetical protein
Hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
histidine kinase domain-containing ATPaselike protein
hypothetical protein
Hypothetical protein
Hypothetical protein
Hypothetical protein
Hypothetical protein
Hypothetical protein
hypothetical protein
Hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein

-2.38
-2.4
-2.41
-2.42
-2.43
-2.43
-2.46
-2.46
-2.46
-2.48
-2.49
-2.53
-2.57
-2.58
-2.58
-2.59
-2.59
-2.61
-2.62
-2.63
-2.63
-2.64
-2.65
-2.71
-2.72
-2.73
-2.74
-2.76
-2.76
-2.8
-2.61
-2.62
-2.63
-2.63
-2.64
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Table 1S (Continued)
ABUW_0087
ABUW_0365
ABUW_0514
ABUW_0937
ABUW_1727
ABUW_1995
ABUW_0435
ABUW_3112
ABUW_2932
ABUW_0864
ABUW_0554
ABUW_1241
ABUW_0636

-

ABUW_0087
ABUW_0365
ABUW_0514
ABUW_0937
ABUW_1727
ABUW_1995
ABUW_0435
ABUW_3112
ABUW_1126
ABUW_3453
ABUW_2061
ABUW_3271
ABUW_3452
ABUW_0697
ABUW_1918
ABUW_0596
ABUW_2655
ABUW_2200
ABUW_1317
ABUW_0683
ABUW_2672

-

histidine kinase domain-containing ATPaselike protein
hypothetical protein
Hypothetical protein
Hypothetical protein
Hypothetical protein
Hypothetical protein
Hypothetical protein
hypothetical protein
Hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
histidine kinase domain-containing ATPaselike protein
hypothetical protein
Hypothetical protein
Hypothetical protein
Hypothetical protein
Hypothetical protein
Hypothetical protein
hypothetical protein
putative transferase
Hypothetical protein
Hypothetical protein
Hypothetical protein
Hypothetical protein
Hypothetical protein
Hypothetical protein
Hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein

-2.65
-2.71
-2.72
-2.73
-2.74
-2.76
-2.76
-2.8
-2.61
-2.62
-2.63
-2.63
-2.64
-2.65
-2.71
-2.72
-2.73
-2.74
-2.76
-2.76
-2.8
-2.82
-2.84
-2.85
-2.91
-2.92
-2.92
-2.93
-2.96
-3.02
-3.03
-3.05
-3.06
-3.13
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Table 1S (Continued)
ABUW_2445
ABUW_1541
ABUW_1920
ABUW_0225
ABUW_3016
ABUW_2439
ABUW_2833
ABUW_1769
ABUW_2103
ABUW_2346
ABUW_0187
ABUW_2145
ABUW_2374
ABUW_1919
ABUW_1318
ABUW_1641
ABUW_2673
ABUW_0886
ABUW_2595
ABUW_2672
ABUW_2445
ABUW_1541
ABUW_1920
ABUW_0225
ABUW_3016
ABUW_2439
ABUW_2833
ABUW_1769
ABUW_2103
ABUW_2346
ABUW_0187
ABUW_2145
ABUW_2374
ABUW_1919
ABUW_1318
ABUW_1641
ABUW_2673

-

hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
isochorismatase hydrolase
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
isochorismatase hydrolase
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein

-3.14
-3.15
-3.15
-3.16
-3.16
-3.18
-3.18
-3.19
-3.2
-3.3
-3.31
-3.31
-3.34
-3.38
-3.43
-3.45
-3.48
-3.55
-3.58
-3.13
-3.14
-3.15
-3.15
-3.16
-3.16
-3.18
-3.18
-3.19
-3.2
-3.3
-3.31
-3.31
-3.34
-3.38
-3.43
-3.45
-3.48
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Table 1S (Continued)
ABUW_0886
ABUW_2595
ABUW_0786
ABUW_2811
ABUW_2616
ABUW_2103
ABUW_2346
ABUW_0187
ABUW_2145
ABUW_2374
ABUW_1919
ABUW_1318
ABUW_1641
ABUW_2673
ABUW_0886
ABUW_2595
ABUW_0786
ABUW_2811
ABUW_2616
ABUW_3710
ABUW_1162
ABUW_3025
ABUW_0236
ABUW_3656
ABUW_1376
ABUW_1598
ABUW_2598
ABUW_2756
ABUW_3526
ABUW_3718
ABUW_0364
ABUW_3805
ABUW_0507
ABUW_0688
ABUW_3006
ABUW_3283
ABUW_1780

-

hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
isochorismatase hydrolase
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
putative acetyltransferase
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein

-3.55
-3.58
-3.69
-3.7
-3.72
-3.2
-3.3
-3.31
-3.31
-3.34
-3.38
-3.43
-3.45
-3.48
-3.55
-3.58
-3.69
-3.7
-3.72
-3.78
-3.93
-3.97
-3.98
-4.02
-4.2
-4.21
-4.43
-4.47
-4.47
-4.52
-4.54
-4.69
-4.77
-4.98
-5.02
-5.15
-5.18
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Table 1S (Continued)
ABUW_0462
ABUW_2211
ABUW_0901
ABUW_0812
ABUW_0796
ABUW_3232
ABUW_0520
ABUW_1052
ABUW_1725
ABUW_1961
ABUW_2191
ABUW_1592
ABUW_0835
ABUW_2600
ABUW_3156
ABUW_3184
ABUW_2832
ABUW_2700
ABUW_2666
Small RNA
ABUWs050
ABUWs008
ABUWs056
ABUWs011
ABUWs001
ABUWs047
ABUWs043
ABUWs033
ABUWs044
ABUWs046
ABUWs052
ABUWs009
ABUWs069
ABUWs017
ABUWs030
ABUWs048
ABUWs042

-

hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
Hypothetical protein

-

small RNA
small RNA
small RNA
small RNA
small RNA
small RNA
small RNA
small RNA
small RNA
small RNA
small RNA
small RNA
small RNA
small RNA
small RNA
small RNA
small RNA

-5.26
-5.26
-5.27
-5.35
-5.49
-5.6
-5.61
-5.65
-5.9
-6.22
-6.41
-8.11
-12.29
-13.82
-25.92
-32.06
-33
-45.63
-68.58
6.56
6.28
5.84
5.74
4.74
4.52
4.46
4.34
4.05
3.98
3.8
3.56
3.55
3.41
3.4
3.15
3.09
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ABUWs071
ABUWs035
ABUWs010
ABUWs019
ABUWs073
ABUWs068
ABUWs003
ABUWs062
ABUWs064
ABUWs018
ABUWs024
ABUWs026
ABUWs029
ABUWs036
ABUWs049
ABUWs014
ABUWs080
ABUWs004
ABUWs054
Amino acid metabolism
ABUW_3214
ABUW_3217
ABUW_1464
ABUW_3018
ABUW_1726
ABUW_2452

ABUW_0077
ABUW_3463
ABUW_1638
ABUW_1200
ABUW_2823
ABUW_0894
ABUW_0704
ABUW_3150
ABUW_2976
ABUW_1777
Regulators

gcdH
add2

small RNA
small RNA
small RNA
small RNA
small RNA
small RNA
small RNA
small RNA
small RNA
small RNA
small RNA
small RNA
small RNA
small RNA
small RNA
small RNA
small RNA
small RNA
Small RNA

glutaryl-CoA dehydrogenase
adenosine deaminase
methylmalonate-semialdehyde
mmsA2 dehydrogenase
ggt
gamma-glutamyltransferase
D-amino acid dehydrogenase 3 small subunit
isovaleryl-CoA dehydrogenase
hutU
urocanate hydratase
leuC
3-isopropylmalate dehydratase, large subunit
chorismate mutase
trpC
indole-3-glycerol phosphate synthase
argG
argininosuccinate synthase
carA
carbamoyl-phosphate synthase, small subunit
agcS
amino acid transport protein
lysine exporter protein
arcD
arginine/ornithine antiporter
branched-chain amino acid transport system
brnQ
II carrier protein

2.93
2.89
2.81
2.8
2.77
2.53
2.47
2.46
2.44
2.43
2.41
2.38
2.25
2.22
2.09
2.07
-2.96
-5.51
-14.32
6.88
5.89
5.09
4.27
4.25
3.19
3.08
2.46
2.56
-2.01
-2.04
-2.49
-2.6
-2.8
-2.85
-2.86
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Table 1S (Continued)
ABUW_1266
ABUW_3665

cadR

ABUW_2284
ABUW_3741
ABUW_3653
ABUW_2775
ABUW_0190
ABUW_2354
ABUW_0219
ABUW_3209
ABUW_3639

npdA
zur
nrdR
vanR
gacA

ABUW_1732
ABUW_0942

ntrC
-

ABUW_0257
ABUW_0855
ABUW_1338
ABUW_3615
ABUW_1533
ABUW_0169
ABUW_1856

ompR
algR
fis
-

ABUW_3595
ABUW_1145
ABUW_2472
ABUW_3627
ABUW_2376
ABUW_1016

nusG
dcaR
dksA
cbl

ABUW_1585
ABUW_3203
ABUW_3206
ABUW_2074
ABUW_2236
ABUW_0892
ABUW_1715

kdpE
greA
-

regulator protein, putative
Transcriptional regulator
NAD-dependent deacetylase regulatory
protein
transcriptional regulator, Fur family
transcriptional regulator NrdR
transcriptional regulator, GntR family
transcriptional regulator, TetR family
transcriptional regulator, AraC family
transcriptional regulator, AraC family
LysR-family transcriptional regulator
response regulator
nitrogen metabolism transcriptional
regulator, NtrC, Fis Family
transcriptional regulator, TetR family
two-component system response regulator
protein
transcriptional regulator, HxlR family
transcriptional regulator, LysR family
alginate biosynthesis regulatory protein
transcriptional regulator, Fis-type
transcriptional regulator, ArsR family
transcriptional regulator, MarR-family
transcription termination/antitermination
factor NusG
transcriptional regulator, LysR family
transcriptional regulator, IclR family
DnaK suppressor protein
transcriptional regulator, GntR family
transcriptional regulator, LysR family
two-component system regulatory protein
KdpE
transcriptional regulator, AraC family
transcriptional regulator, LysR family
transcriptional regulator, fur family
transcriptional regulator, AraC family
transcription elongation factor GreA
transcriptional regulator, GntR family

4.99
3.33
2.92
2.73
2.59
2.53
2.44
2.44
2.43
2.4
2.32
2.31
2.27
2.24
2.2
2.05
2.01
-2.01
-2.04
-2.05
-2.07
-2.09
-2.1
-2.1
-2.11
-2.13
-2.14
-2.17
-2.18
-2.2
-2.22
-2.23
-2.24
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Table 1S (Continued)
ABUW_0431
ABUW_2276
ABUW_2101
ABUW_2852
ABUW_1103
ABUW_1896
ABUW_0832
ABUW_2446
ABUW_3033
ABUW_2801
ABUW_3877
ABUW_3640
ABUW_3261
ABUW_2328
ABUW_3845
ABUW_2084
ABUW_1692
ABUW_0678
ABUW_1731
ABUW_3264

ABUW_0400
ABUW_2275
ABUW_1848
ABUW_3352
ABUW_2344

ABUW_1103
ABUW_1896
ABUW_0832
ABUW_2446
ABUW_3033
ABUW_2801
ABUW_3877
ABUW_3640
ABUW_3261
ABUW_2328
ABUW_3845

rpoA
fur
pilS
pilG
pcaU
fur
pilS
-

RNA polymerase alpha subunit
Transcription Factor
Transcription Factor
Transcription Factor
Transcription Factor
Transcription Factor
Transcription Factor
Transcription Factor
Transcription Factor
Transcription Factor
transcriptional regulator, LysRfamily
sensor protein histidine kinase
Anti-Anti sigma factor
transcriptional regulator, TetR family
transcriptional regulator, TetR family
transcriptional regulator, AraC family
transcriptional regulator, TetR family
type IV pilus response regulator receiver
protein PilG
transcriptional regulator, TetR family
transcriptional regulator OhrR
transcriptional regulator, BadM/Rrf2 family
transcriptional regulator, TetR family
pca operon regulatory protein
putative transcriptional regulator
transcriptional regulator, Crp/Fnr family
Transcription Factor
Transcription Factor
Transcription Factor
Transcription Factor
Transcription Factor
Transcription Factor
transcriptional regulator, LysRfamily
sensor protein histidine kinase
Anti-Anti sigma factor
transcriptional regulator, TetR family
transcriptional regulator, TetR family

-2.25
-2.33
-2.33
-2.4
-2.4
-2.46
-2.48
-2.53
-2.53
-2.59
-2.65
-2.68
-2.72
-3.26
-3.28
-3.98
-4.14
-4.38
-4.56
-4.63
-4.87
-4.87
-4.97
-7.62
-8.41
-2.4
-2.46
-2.48
-2.53
-2.53
-2.59
-2.65
-2.68
-2.72
-3.26
-3.28
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Table 1S (Continued)
ABUW_2084
ABUW_1692

-

pilG
ABUW_0400
ABUW_2275
pcaU
ABUW_1848
ABUW_3352
ABUW_2344
Energy production and conversion
ABUW_2458
ABUW_2411
ABUW_1227
ABUW_2099
ABUW_3849
cioB
ABUW_2390
ABUW_1467
ABUW_2503
cioA
ABUW_2389
ABUW_2122
ABUW_0678
ABUW_1731
ABUW_3264

ABUW_0944

-

ABUW_3806
ABUW_0175
ABUW_0662
ABUW_2770
ABUW_1887
ABUW_0218
ABUW_2435
ABUW_1196
ABUW_1588
ABUW_1888
ABUW_1573
ABUW_2594

acnD
acsA
xdhA
-

transcriptional regulator, AraC family
transcriptional regulator, TetR family
type IV pilus response regulator receiver
protein PilG
transcriptional regulator, TetR family
transcriptional regulator OhrR
transcriptional regulator, BadM/Rrf2 family
transcriptional regulator, TetR family
pca operon regulatory protein
putative transcriptional regulator
transcriptional regulator, Crp/Fnr family

-3.98
-4.14

oxidoreductase
glutathione S-transferase family protein
acyl-CoA dehydrogenase
acetyl-CoA acetyltransferase
short chain dehydrogenase
cytochrome D ubiquinol oxidase, subunit II
acyl-CoA dehydrogenase
cytochrome B561
cytochrome bd ubiquinol oxidase, subunit I
oxidoreductase
oxidoreductase alpha (molybdopterin)
subunit
2-methylisocitrate dehydratase, Fe/Sdependent
acetate--CoA ligase
NADPH dehydrogenase
GMC oxidoreductase
oxidoreductase FMN-binding
aldo-keto reductase
oxidoreductase
xanthine dehydrogenase, small subunit
ubiquinone biosynthesis protein COQ7
saccharopine dehydrogenase
acyl-CoA dehydrogenase
glutathione-dependent formaldehyde
dehydrogenase

8.16
5.63
5.43
5.24
4.77
4.72
4.54
4.3
4.27
3.85

-4.38
-4.56
-4.63
-4.87
-4.87
-4.97
-7.62
-8.41

3.84
3.82
3.69
3.52
3.51
3.49
3.22
3.17
2.88
2.77
2.74
2.67
2.52
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Table 1S (Continued)
ABUW_1572
ABUW_1794
ABUW_1843
ABUW_2835
ABUW_0912
ABUW_2410
ABUW_2779
ABUW_3443
ABUW_3865
ABUW_2437
ABUW_0011
ABUW_3429
ABUW_1978
ABUW_0433
hppD
ABUW_3390
ABUW_0702
ABUW_2902
ABUW_1980
ABUW_2076

cydB
quiA
glpD
hcaB
calB
hppD
gapN
rubA
-

ABUW_0350
ABUW_1449
ABUW_3798
ABUW_2913
ABUW_3830
ABUW_0376
ABUW_0874
ABUW_1549

gdh
tkrA
aroE
lpdA1
cyoE

ABUW_0160
ABUW_3135
ABUW_2753
ABUW_1344
ABUW_2071
TCA Cycle
ABUW_3346

pqqA

short-chain dehydrogenase/reductase
cytochrome D ubiquinol oxidase, subunit II
quinate/shikimate dehydrogenase
oxidoreductase, FAD/FMN-binding
glycerol-3-phosphate dehydrogenase
glutathione S-transferase family protein
aldehyde dehydrogenase
alcohol dehydrogenase, zinc-binding
putative flavoprotein
Iron-containing redox enzyme family protein
iron-sulfur cluster assembly accessory protein
aldehyde dehydrogenase
flavin binding monooxygenase
flavin-containing monooxygenase FMO
4-hydroxyphenylpyruvate dioxygenase
aldehyde dehydrogenase
nitroreductase
rubredoxin
oxidoreductase
2,3-dihydro-2,3-dihydroxybenzoate
dehydrogenase
glutamate dehydrogenase
2-ketogluconate reductase
short-chain dehydrogenase/reductase SDR
carbonate dehydratase
UDP-glucose/GDP-mannose dehydrogenase
shikimate 5-dehydrogenase
dihydrolipoamide dehydrogenase
protoheme IX farnesyltransferase
(transferase)
metallo-beta-lactamase family protein
cytochrome c assembly protein
cytochrome B561
iron-sulfur cluster-binding protein
Energy metabolism

acnA

aconitate hydratase 1

2.42
2.42
2.41
2.38
2.32
2.29
2.27
2.26
2.17
2.16
2.15
2.15
2.11
2.09
2.08
2.03
2.01
2
2
-2.04
-2.08
-2.1
-2.21
-2.21
-2.22
-2.26
-2.47
-2.64
-2.65
-2.81
-4.14
-4.73
-30.47
5.42
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Table 1S (Continued)

ABUW_3396
ABUW_3395
ABUW_3807
ABUW_2888
ABUW_0871
ABUW_2113

atoA
pta
ackA
prpC
aceA
sdhB
sucC

ABUW_0869

sdhD

ABUW_0868
General metabolism

sdhC

ABUW_2454

mgh
otsA
mdcE
-

ABUW_2097

ABUW_1020
ABUW_1468
ABUW_2453

ABUW_3123
ABUW_2425

ABUW_0055
ABUW_1470

ABUW_2398
ABUW_1064
ABUW_1111
ABUW_2455

ABUW_2129
ABUW_2881
ABUW_2456

ABUW_2092
ABUW_1113
ABUW_1521
ABUW_2603
ABUW_2126
ABUW_1621
ABUW_0191
ABUW_1469

ABUW_2128
ABUW_2506

acoC
ureE
bdhA
sndH1
bccA
ald1
lpdA2
-

3-oxoacid CoA-transferase, subunit B
phosphate acetyltransferase
acetate kinase
2-methylcitrate synthase
isocitrate lyase
succinate dehydrogenase iron-sulfur subunit
succinate dehydrogenase
succinate dehydrogenase, hydrophobic
membrane anchor protein
succinate dehydrogenase, cytochrome b556
subunit

5.18
3.54
3.37
2.18
2.05
-2.04
-2.05

3-methylglutaconyl-CoA hydratase
alpha/beta hydrolase fold protein
LmbE-like protein
methylcrotonoyl-CoA carboxylase beta chain
trehalose-6-phosphate synthase
acetyltransferase, gnat family
glucose sorbosone dehydrogenase
glycosyl transferase, family 2
malonate decarboxylase, gamma subunit
glycosyltransferase
aldehyde dehydrogenase
methylcrotonoyl-CoA carboxylase subunit
alpha
dihydrolipoamide acetyltransferase
urease accessory protein E
hydroxymethylglutaryl-CoA lyase
3-hydroxybutyrate dehydrogenase
indole-3-pyruvate decarboxylase
L-sorbosone dehydrogenase
carbamoyl-phosphate synthase
zinc-binding alcohol dehydrogenase
aldehyde dehydrogenase
alcohol dehydrogenase, zinc-binding
methyltransferase type 12
dihydrolipoamide dehydrogenase
3-hydroxy-3-methylglutaryl-CoA lyase

8.05
7.96
7.78
7.22
6.43
6.34
6.32
6.17
6.12
5.8
5.74

-2.43
-3.72

5.65
5.04
4.4
4.29
4.2
3.97
3.92
3.9
3.79
3.47
3.23
3.22
3.2
3.02
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Table 1S (Continued)
ABUW_2933
ABUW_2373
ABUW_3204
ABUW_1712
ABUW_2780
ABUW_1671

moaCB
hcaC
tal

ABUW_2787
ABUW_1905

-

ABUW_0156
ABUW_3309
ABUW_1871
actP2
ABUW_0184

aceF
hyi
pcaD2
actP2
-

ABUW_2332
ABUW_3321
ABUW_1015
ABUW_3019
ABUW_1003
ABUW_2093

gltJ
copA
carO
emrB
-

ABUW_2330
ABUW_3446
ABUW_0328

gltL
-

ABUW_0182
ABUW_3320
ABUW_2747
ABUW_3246
ABUW_3231
ABUW_2296
ABUW_1097
ABUW_2218
ABUW_0685
ABUW_1050
ABUW_3133

copB
epd
pabB
rpe
metK
thiE
cysQ
gap
coaX

aldose 1-epimerase
amidohydrolase
amidohydrolase
molybdenum cofactor biosynthesis protein C
feruloyl-CoA synthetase
transaldolase
NADP-dependent fatty aldehyde
dehydrogenase
isochorismatase hydrolase
pyruvate dehydrogenase complex
dihydrolipoamide acetyltransferase
hydroxypyruvate isomerase
3-oxoadipate enol-lactonase
copper-translocating P-type ATPase
Na+/solute symporter
glutamate/aspartate transport system
permease protein GltJ
copper resistance protein A
outer membrane protein CarO
multidrug resistance protein B
MFS family drug transporter
GntP family transporter
glutamate/aspartate transport ATP-binding
protein GltL
RhtB family transporter
hemerythrin
Solute carrier 5 family, sodium/glucose
transporters a
copper resistance protein B
glyceraldehyde 3-phosphate dehydrogenase
P-aminobenzoate synthetase PabB
ribulose-phosphate 3-epimerase
methionine adenosyltransferase
thiamine-phosphate pyrophosphorylase
3'(2'),5'-bisphosphate nucleotidase
alpha/beta hydrolase fold protein
glyceraldehyde-3-phosphate dehydrogenase
pantothenate kinase, type III

2.67
2.62
2.55
2.53
2.51
2.44
2.41
2.41
2.21
2.2
2.04
2.65
2.65
2.63
2.57
2.38
2.34
2.33
2.24
2.21
2.2
2.15
2.11
2.07
-2.03
-2.03
-2.06
-2.06
-2.07
-2.12
-2.19
-2.34
-2.35
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Table 1S (Continued)
ABUW_0591
ABUW_0615
ABUW_0913
ABUW_3686

pckG
ppa

glycosyltransferase
vitamin B12 receptor
phosphoenolpyruvate carboxykinase
inorganic diphosphatase
4-(cytidine 5'-diphospho)-2-C-methyl-Derythritol kinase
phosphopyruvate hydratase (enolase)
5-formyltetrahydrofolate cyclo-ligase
family 1 glycosyl transferase
alpha/beta hydrolase fold protein
HAD-superfamily hydrolase

-2.4
-2.4
-2.4
-2.44

ABUW_3092
ABUW_1827
ABUW_2863
ABUW_3826
ABUW_1364
ABUW_1750
Fatty acid metabolism

ispE
eno
-

ABUW_2098

lpxL
ABUW_2096
ABUW_3573
ABUW_3808
ABUW_3065

atoE
atoD
fadA
prpB
fabB

3.4
2.83
2.83
2.4
2.09
-2.02

ybgC
fabG
acpP

short-chain fatty acid transporter
lipid A biosynthesis lauroyl acyltransferase
3-oxoacid CoA-transferase, subunit A
acetyl-CoA C-acyltransferase FadA
methylisocitrate lyase
3-oxoacyl-[acyl-carrier-protein] synthase 1
acyl-(acyl-carrier-protein)--UDP-Nacetylglucosamine O-acyltransferase
beta-hydroxyacyl-(acyl-carrier-protein)
dehydratase
acetyl-CoA carboxylase, biotin carboxylase
biotin synthase
tol-pal system-associated acyl-CoA
thioesterase
3-oxoacyl-(acyl-carrier-protein) reductase
acyl carrier protein

ABUW_1745

lpxA

ABUW_1744
ABUW_1696
ABUW_2307

fabZ
accC
bioB

ABUW_0997
ABUW_3108
ABUW_3107
DNA repair/metabolism
ABUW_2210
ABUW_2431
ABUW_0189
ABUW_0660
ABUW_2736
ABUW_2198
ABUW_3723
ABUW_2247
ABUW_0319

mfd
umuD
uvrA
cinA2
hup
dprA
ung
comF

transcription-repair coupling factor
DNA polymerase V component
excinuclease ABC, A subunit
DNA-3-methyladenine glycosylase
competence/damage-inducible protein CinA
DNA-binding protein HU
DNA protecting protein DprA
uracil-DNA glycosylase
pilin like competence factor

2.48
2.45
2.12
2.05
-2.11
-2.18
-2.19
-2.38
-2.82

-2.54
-2.55
-2.75
-3.09
-3.44
-3.59

-2.12
-2.17
-2.18
-2.29
-2.45
-2.49
-3.47
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Table 1S (Continued)
ABUW_3647
ABUW_3299
ABUW_0538

holC
-

ABUW_2279
Transporters

-

ABUW_2381

ABUW_0057
ABUW_2430
ABUW_3124
ABUW_1021
ABUW_2708

tauB
cpo
tauC
cysP
-

ABUW_2333
ABUW_1583
actP2
ABUW_0184

gltI
kdpC
actP2
-

ABUW_2332
ABUW_3321
ABUW_1015
ABUW_3019
ABUW_1003
ABUW_2093

gltJ
copA
carO
emrB
-

ABUW_2330
ABUW_3446
ABUW_0328

gltL
-

ABUW_0182
ABUW_3320
ABUW_1805
ABUW_2925
ABUW_3632
ABUW_0159

copB
pit
feoB
-

ABUW_1886
ABUW_2380

DNA polymerase III, chi subunit
putative DNA uptake protein ComEA
putative integrase/recombinase
nucleoprotein/polynucleotide-associated
enzyme

-3.39
-3.42
-3.73

taurine import ATP-binding protein
alpha/beta hydrolase
taurine transport system permease protein
formate/nitrite transporter family
transporter, LysE family
major facilitator superfamily MFS_1
thiosulfate-binding protein
Heavy metal Transport detoxification
glutamate/aspartate ABC transporter,
periplasmic glutamate/aspartate-binding
protein
K+-transporting ATPase, C subunit
copper-translocating P-type ATPase
Na+/solute symporter
glutamate/aspartate transport system
permease protein GltJ
copper resistance protein A
outer membrane protein CarO
multidrug resistance protein B
MFS family drug transporter
GntP family transporter
glutamate/aspartate transport ATP-binding
protein GltL
RhtB family transporter
hemerythrin
Solute carrier 5 family, sodium/glucose
transporters a
copper resistance protein B
K+ uptake system component
phosphate transporter
ferrous iron transport protein B
TonB-dependent receptor protein

6.88
6.35
5.01
4.22
3.95
3.92
3.58
3.35

-4.21

3.24
3.03
2.65
2.65
2.63
2.57
2.38
2.34
2.33
2.24
2.21
2.2
2.15
2.11
2.07
-2.01
-2.02
-2.02
-2.04
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Table 1S (Continued)
ABUW_2792
ABUW_3424
ABUW_3831
ABUW_3425
ABUW_2182
ABUW_1800

wza
-

ABUW_1798
ABUW_0426
ABUW_2277
ABUW_0707
ABUW_1509

secY
sstT
-

ABUW_2916
ABUW_3596
ABUW_3403
ABUW_2316
ABUW_3426
ABUW_3449
ABUW_2154
ABUW_2403
ABUW_1845
ABUW_0857
ABUW_1520

pfeA
secE
dctA
-

ABUW_3037

-

ABUW_2737
ABUW_3252
ABUW_3515
ABUW_3473
ABUW_0687

clpB
raiA
cbpA
ecnB

ABUW_0133
ABUW_1661
ABUW_2639
ABUW_0372
ABUW_1749

hslR

EamA-like transporter family protein
biopolymer transport protein ExbD/TolR
polysaccharide export protein
MotA/TolQ/ExbB proton channel
TonB-dependent receptor
ferrichrome-iron receptor
iron-sulfur cluster-binding protein, Rieske
family
preprotein translocase, SecY subunit
inner membrane symporter YgjU
microcin B17 transport protein
ABC transporter, ATP-binding protein
TonB dependent outer membrane
siderophore receptor protein
Protein translocase subunit SecE
TonB-dependent receptor
EamA-like transporter family protein
TonB protein
C4-dicarboxylate transport protein
tolA_full family protein

-2.07
-2.13
-2.18
-2.2
-2.22
-2.25
-2.26
-2.32
-2.36
-2.4
-2.56
-2.59
-2.62
-2.65
-2.66
-2.96
-3.16
-3.17
-3.33
-3.37
-3.58
-5.96

MFS permease
sulfur transport domain-containing protein
putrescine importer
EamA-like transporter family protein
hemerythrin/HHE cation-binding motifcontaining protein
-42.1
Stress response
ATP-dependent chaperone ClpB
4.55
ribosomal subunit interface protein
3.39
curved DNA-binding protein
3.34
glutathione S-transferase
3.18
entericidin EcnAB
3.13
ribosomal protein S30EA/sigma 54
modulation protein
3.1
universal stress protein family
2.87
universal stress protein family
2.64
phage shock protein C
2.32
heat shock protein 15
2.04
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Table 1S (Continued)
ABUW_2513
ABUW_2197
ABUW_0492
ABUW_2690
ABUW_2901

csp2
ppiD
sspA
csp1
-

ABUW_0906
ABUW_3219
ABUW_3546
ABUW_0537
ABUW_3467
ABUW_0231
ABUW_0326
ABUW_2146
ABUW_3905
ABUW_2289
Oxidative stress
ABUW_2436

nudH
truB
rnd
rnpA
trmA

cold-shock DNA-binding domain protein
-2.01
peptidyl-prolyl cis-trans isomerase
-2.02
stringent starvation protein A
-2.23
cold-shock DNA-binding domain protein
-5.77
activator of HSP90 ATPase
-19.87
tRNA / tRNA processing
tRNA
7.76
tRNA
5.49
tRNA
5.43
tRNA
4.65
(di)nucleoside polyphosphate hydrolase
2.8
tRNA
2.31
tRNA pseudouridine synthase B
-2.54
ribonuclease D
-2.69
ribonuclease P protein componen
-2.99
tRNA (uracil-5-)-methyltransferase
-4.41

katE
msrB
pqiA2
katG
ychF
-

catalase
catalase
methionine-R-sulfoxide reductase
paraquat-inducible protein A
catalase/peroxidase HPI
GTP-binding protein YchF
protein YaaA
OsmC-like peroxiredoxin

4.63
3.18
2.1
2.09
2.03
-2.1
-2.44
-4

bfr2
basJ

3.05
-2.41

9.94
4.31

ABUW_2504

ABUW_2356
ABUW_1501
ABUW_3469
ABUW_2342
ABUW_1371
ABUW_3027
Iron acqusition
ABUW_3125
ABUW_1188
ABUW_2189

-

ABUW_0307
ABUW_0143
ABUW_2184
Virulence
ABUW_1631
ABUW_0885

-

bacterioferritin
putative acinetobactin biosynthesis protein
IucA/IucC-family aerobactin siderophore
biosynthesis component
BFD-like [2Fe-2S]-binding domain-containing
protein
TonB-dependent receptor protein
ferric iron reductase FhuF

-

spore coat protein U
biofilm-associated protein

-3.22
-4.49
-4.52
-5.37
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Table 1S (Continued)
ABUW_2440
ABUW_1634
ABUW_2578
ABUW_1904

-

ABUW_1633

-

ABUW_2566
ABUW_2887
ABUW_2576
ABUW_0563
ABUW_0632
ABUW_0305
ABUW_2572
ABUW_0680
ABUW_1992
ABUW_1604
ABUW_1355
Translation

pilI
-

ABUW_0172
ABUW_3284
ABUW_2937
ABUW_1546
ABUW_2216
ABUW_0494
ABUW_0322
ABUW_0418
ABUW_0430
ABUW_0427

rplT
def2
rplI
rpsT
rplM
trmD
rplE
rpsD
rpmJ

ABUW_0714
ABUW_2264
ABUW_1141
ABUW_0424
ABUW_1609
ABUW_0989
ABUW_0420

gatC
gidB
efp
rpmD
hfq
rpsH

surface antigen
spore coat protein U
type VI secretion system effector, Hcp1 family
antibiotic biosynthesis monooxygenase
fimbrial biogenesis outer membrane usher
protein
type IV / VI secretion system protein, DotU
family
lipoprotein
type VI secretion protein, family
beta-lactamase OXA-23
hemolysin-3
O-antigen polymerase family
type IV secretion-associated protein, family
type IV pilus signal transduction protein PilI
zonular occludens toxin (ZOT) protein
RelB/DinJ antitoxin
complement control module protein
ribosomal RNA small subunit
methyltransferase E
ribosomal protein L20
peptide deformylase
ribosomal protein L9
ribosomal protein S20
ribosomal protein L13
tRNA (guanine-N1)-methyltransferase
ribosomal protein L5
ribosomal protein S4
ribosomal protein L36
glutamyl-tRNA(Gln) amidotransferase, C
subunit
methyltransferase GidB
translation elongation factor P
ribosomal protein L30
Host Factor
tRNA/rRNA methyltransferase
ribosomal protein S8

3.88
2.53
2.27
2.19
2.04
-2.1
-2.18
-2.26
-2.28
-2.47
-2.64
-3.03
-3.12
-3.19
-5.45
-5.48

2.91
2.62
2.19
2.08
-2
-2
-2.01
-2.04
-2.13
-2.25
-2.27
-2.35
-2.49
-2.49
-2.56
-2.71
-2.73
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Table 1S (Continued)
ABUW_3431
rpmG
ABUW_0408
rplW
ABUW_2847
Post translational modification

ribosomal protein L33
ribosomal protein L23
rRNA small subunit methyltransferase 1

-2.81
-2.87
-3.12

ABUW_0860
ABUW_1535
ABUW_0745
ABUW_0086
ABUW_2961
ABUW_0020
Lipoprotein
ABUW_3874
ABUW_3875
ABUW_3588
ABUW_1048

lipB
prmA1
-

lipoate-protein ligase B
ribosomal protein L11 methyltransferase
N6 adenine-specific DNA methyltransferase
DNA cytosine methyltransferase
peptidyl-prolyl cis-trans isomerase
glutathione S-transferase

-2.14
-2.36
-2.41
-2.47
-2.85
-2.88

-

6.39
3.62
3.42
2.13

ABUW_0850
Protease
ABUW_0072
ABUW_1146
ABUW_3575
ABUW_0711
ABUW_1630
ABUW_2738
ABUW_1345
ABUW_3863
ABUW_3880
Detoxification

lolA

lipoprotein, putative
lipoprotein, putative
lipoprotein, putative
outer membrane lipoprotein Blc
outer membrane lipoprotein carrier protein
LolA

pepN
lspA2
-

peptidase M15 family
proline dipeptidase
serine hydrolase domain-containing protein
intracellular protease, PfpI family
peptidase M1, alanyl aminopeptidase
peptidase M23/M37 family
peptidase U32
Signal peptidase II
matrixin superfamily

2.72
2.47
2.16
2.08
2.02
-3.03
-2.08
-2.81
-5.88

heavy metal detoxification protein
glyoxalase
glyoxalase I

8.11
6.13
2

cadA
ABUW_3026
ABUW_1135
gloA
Lipid transport / metabolism
ABUW_3383
ABUW_1939
ABUW_1683
Nucleotide biosynthesis
ABUW_1944
ABUW_3664

putative phosphatidylglycerophosphatase B
2-hydroxy-3-oxopropionate reductase
thioesterase family protein
ADP-ribose pyrophosphatase

2.08

10.43
2.71
2.14
2.22
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Table 1S (Continued)
ABUW_1943
ABUW_2754

add1

ABUW_3300
ABUW_2239
ABUW_3381
ABUW_3142
Purine metabolism

pyrF
ndk
dcd

nicotinamide phosphoribosyltransferase
adenosine deaminase
nucleoside triphosphate
pyrophosphohydrolase
orotidine 5'-phosphate decarboxylase
nucleoside diphosphate kinase
deoxycytidine triphosphate deaminase

xanthine dehydrogenase, molybdopterin
ABUW_1197
xdhB
binding subunit
phosphoribosylaminoimidazoleABUW_0059
purC
succinocarboxamide synthase
ABUW_3427
purU
formyltetrahydrofolate deformylase
ABUW_0980
purN
phosphoribosylglycinamide formyltransferase
ABUW_1122
purB
adenylosuccinate lyase
ABUW_3897
hpt
hypoxanthine phosphoribosyltransferase
Proton ion translocation / ATP synthesis
ABUW_3737
atpE
ATP synthase F0, C subunit
ABUW_0388
corA
magnesium and cobalt transport protein
ABUW_3738
atpB
ATP synthase F0, A subunit
ABUW_3735
atpH
ATP synthase F1, delta subunit
pH adaptation potassium efflux system
ABUW_3538
phaF
protein F
ABUW_3737
atpE
ATP synthase F0, C subunit
Cell division
ABUW_3402
tig
trigger factor
ABUW_2235
cell division protein ZapE
ABUW_0525
ispZ
intracellular septation protein A
Cell wall synthesis
UDP-N-acetylenolpyruvoylglucosamine
ABUW_1687
murB
reductase
D-ala-D-ala-carboxypeptidase penicillinABUW_1070
binding protein
penicillin-binding protein 6 (D-alanyl-DABUW_1127
dacC
alanine carboxypeptidase)
ABUW_1737
uppS
undecaprenyl diphosphate synthase
ABUW_1544
alr
alanine racemase
ABUW_0404
glutamine amidotransferase, class I

2.77
-2.01
-2.06
-2.1
-2.17
-2.79

3.87
-2.07
-2.09
-2.09
-2.15
-3.32
-2.02
-2.25
-2.28
-2.65
-2.92
-2.02
-2.06
-2.33
-2.96

-2.09
-2.11
-2.14
-2.14
-2.16
-5.46
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Table 1S (Continued)

ABUW_0074
Cell adhesion / motility
ABUW_0294
ABUW_2313
ABUW_2310

-

acyltransferase 3

-5.33

comQ
-

-2.09
-2.17
-2.46

ABUW_2312
ABUW_2311
ABUW_0648
ABUW_1489
ABUW_0304
Protein synthesis
ABUW_0014
ABUW_0432
ABUW_3099
ABUW_0411
ABUW_3490
Phage
ABUW_2322
ABUW_1312

fimD

-

fimbrial assembly protein PilQ
fimbrial protein
fimbrial protein
fimbrial biogenesis outer membrane usher
protein
pili assembly chaperone
type 4 fimbrial biogenesis protein FimT
CsuB
type IV pilin structural subunit

tyrS
rplQ
pth
rplV
rpmE2

tyrosyl-tRNA synthetase
ribosomal protein L17
peptidyl-tRNA hydrolase
ribosomal protein L22
ribosomal protein L31

-

-5.99
-5.26

ABUW_3569
Outer membrane protiens
ABUW_0021
ABUW_3833
ABUW_3583
Membrane proteins
ABUW_3829
ABUW_3890
ABUW_0505
ABUW_2473
ABUW_1610

-

phage integrase
phage protein
bacteriophage SFi21 - peptidoglycan
hydrolase

ptk
-

outer membrane protein
tyrosine-protein kinase ptk
putative phosphatidylglycerophosphatase B

-2.8
-2.11
-7.55

-

UDP-N-acetylglucosamine 2-epimerase
undecaprenyl-diphosphatase
tRNA/rRNA methyltransferase
major facilitator superfamily MFS_1
integral membrane protein

-2.25
-2.52
-2.67
-3.97
-8.52

-2.89
-3.32
-3.37
-8.84
-11
-2.06
-2.14
-2.21
-3.34
-10.27

-3.37
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Table 2S. Genes differentially expressed in the fecI mutant strain
Locus Tag
Gene
Hypothetical proteins

Protein / Function

ABUW_1914
ABUW_2607
ABUW_2605
ABUW_2445
ABUW_1792
ABUW_2626
ABUW_1158
ABUW_3186
ABUW_2812
ABUW_1416
ABUW_2060
ABUW_2655
ABUW_0044
ABUW_2796
ABUW_0748
ABUW_2550
ABUW_2309
ABUW_0187
ABUW_1988
ABUW_2179
ABUW_1282
ABUW_2797
ABUW_1268
ABUW_0746
ABUW_2611
ABUW_2433

-

ABUW_0933
ABUW_1796
ABUW_3193
ABUW_2676
ABUW_3702
ABUW_2290

-

hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
KGG domain-containing
protein
hypothetical Protein
hypothetical Protein
hypothetical Protein
Hypothetical Protein
Hypothetical Protein
Hypothetical Protein

Fold Change

41.94
36.48
25.89
14.4
10.7
9.91
9.12
7.9
7.04
6.66
6.46
5.92
5.46
5.38
5.35
5.2
5.05
4.76
4.63
4.54
4.44
4.3
4.12
3.5
3.48
3.43
3.12
3.09
3.09
3.07
-3.06
-3.18
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Table 2S (Continued)
ABUW_0720
ABUW_2686
ABUW_0220
ABUW_0814
ABUW_3198

-

ABUW_2671
ABUW_1485
ABUW_3851
ABUW_1860
ABUW_2980
ABUW_2983
Small RNA
ABUWs081
ABUWs083
ABUWs002
ABUWs072
ABUWs005
Amino Acid Transport and Metabolism
ABUW_2548
ABUW_2543
ABUW_2541
ABUW_1114
aroP3
ABUW_2548
Aromatic Metabolism
bdhA
ABUW_2092
ABUW_2359
ABUW_1862

aspQ

ABUW_2535

paaG

ABUW_2534

paaH

ABUW_2533

paaI2

-

Hypothetical Protein
Hypothetical Protein
Hypothetical Protein
Hypothetical Protein
Hypothetical Protein

-3.53
-3.84
-3.86
-4.4
-4.55

Hypothetical Protein
Hypothetical Protein
Hypothetical Protein
Hypothetical Protein
Hypothetical Protein
Hypothetical Protein

-5.42
-5.53
-8.12
-11.23
-17.48
-34.12
-10.83
-3.83
-3.3
-3.15
-3.14

proline racemase
shikimate transporter
amino acid transporter
proline racemase
3-hydroxybutyrate
dehydrogenase
L-asparaginase 2
aromatic-ringhydroxylating
dioxygenase beta subunit
phenylacetate-CoA
oxygenase, PaaG subunit
phenylacetate-CoA
oxygenase, PaaH subunit
phenylacetate-CoA
oxygenase, PaaI subunit

29.52
8.63
8.04
-4.36
29.52
3.26
5.04
-21.81
-11.95
-11.01
-9.08

174

Table 2S (Continued)
ABUW_2531

paaK

ABUW_2536

paaN

ABUW_2527

paaE

ABUW_2529
ABUW_1863

paaB
-

ABUW_2532

paaJ

ABUW_2528

paaC

ABUW_2526
ABUW_2525

paaF
paaX

ABUW_2524

paaY

ABUW_1834

pcaB

phenylacetate-CoA
oxygenase/reductase,
PaaK subunit
phenylacetic acid
degradation protein PaaN
beta-ketoadipyl CoA
thiolase
enoyl-CoA hydratase
short-chain
dehydrogenase/reductase
phenylacetate-CoA
oxygenase, PaaJ subunit
3-hydroxyacyl-CoA
dehydrogenase
phenylacetate-CoA ligase
phenylacetic acid
degradation operon
negative regulatory
protein PaaX
phenylacetic acide
degradation protein PaaY
3-carboxy-cis,cismuconate cycloisomerase

-8.98
-8.51
-8.39
-8.33
-8.22
-7.95
-7.8
-7.69
-3.93

-3.35
-3.09

Metabolism
ABUW_3782

mmsB

ABUW_1861
Fatty Acid Metabolism
ABUW_2530
caiD
ABUW_3780
ABUW_3779

-

ABUW_2630
Biofilm
ABUW_1487
ABUW_1488
ABUW_1491
ABUW_1490

CsuA/B
CsuA
CsuD
CsuC

3-hydroxyisobutyrate
dehydrogenase
ring hydroxylating
dioxygenase, Rieske
enoyl-coA hydratase
acyl-CoA dehydrogenase
short-chain enoyl-CoA
hydratase
lipid A biosynthesis
lauroyl acyltransferase

-7.78
-6.51
-6.38
-5.72
-4.88
-3.56
255.69
150.91
101.48
89.17
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Table 2S (Continued)
ABUW_1492
CsuE
ABUW_1489
CsuB
Carbohydrate Metabolism
ABUW_2606
Efllux Pumps

-

ABUW_1976

adeC

ABUW_1974

adeA

ABUW_1975
Energy Conversion

adeB

ABUW_2546

-

ABUW_2547
ABUW_2542

-

ABUW_2545

-

ABUW_1795

cydA

ABUW_2385

-

ABUW_1794

cydB

ABUW_1864
ABUW_3403

ABUW_3403

ABUW_1115
Metabolism

ABUW_1115

aldH

ABUW_2551

ABUW_2551

ABUW_3781

-

76.91
74.5
glycoside
hydrolase/deacetylase
family protein
multidrug efflux protein
AdeC
multidrug efflux protein
AdeA
multidrug efflux protein
AdeB
2Fe-2S ferredoxin-type
domain-containing
protein
FAD dependent
oxidoreductase
aldehyde dehydrogenase
pyridine nucleotidedisulfide oxidoreductase
cytochrome D ubiquinol
oxidase subunit I
monooxygenase,
NtaA/SnaA/SoxA family
cytochrome D ubiquinol
oxidase, subunit II
2Fe-2S iron-sulfur cluster
binding domain protein
TonB-dependent receptor
phosphate ABC
transporter, substratebinding protein
dihydrodipicolinate
synthetase
acetyl-coenzyme A
synthetase

22.63

4.75
4.45
4.45

79
54.22
42.61
26.91
7.05
4.9
4.85
-4.86
3.43
3.33

4.35
-4.77
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Table 2S (Continued)

ABUW_3783

mmsA1

ABUW_1113
Motility
ABUW_2310
ABUW_2053
ABUW_2052
Nucleotide metabolism

methylmalonatesemialdehyde
dehydrogenase
indole-3-pyruvate
decarboxylase

-4.58

fimbrial protein
pili assembly chaperone
fimbrial subunit

12.84
4.74
4.33

ABUW_3042
Outermebrane

dut

deoxyuridine 5'triphosphate
nucleotidohydrolase

ABUW_3583
Replication

-

putative outer membrane
protein W

ABUW_3007
Ribosomal Protein
ABUW_0408
rplW
ABUW_0406
rplC
Transcriptional Regulators
ABUW_1159
ABUW_2986

-

ABUW_0224
Transport
ABUW_3201
ABUW_2892

-

ABUW_2602
Urea Metabolism
ABUW_2604

-

citN

-

ABUW_2603
bccA
Inorganic Ion Transport and Metabolism

-3.93

3.22
35.02

single-strand binding
protein

3.61

ribosomal protein L23
ribosomal protein L3

5.68
3.24

transcriptional regulator,
TetR family
Anti-sigma factor fecR
transcriptional regulator,
HxlR family

15.7
-14.74
-3.13

transporter
citrate transporter
voltage-gated chloride
channel

6.7
3.72

allophanate hydrolase
carbamoyl-phosphate
synthase

28.98

3.19

17.54
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Table 2S (Continued)
ABUW_2985

-

ABUW_2982
ABUW_2981

-

ABUW_2707

actP2

ABUW_2708

TonB Outermembrane
receptor
TonB C binds Fe+3
siderophore complex
Hemeoxygenase
copper-translocating Ptype ATPase
heavy metal transport /
detoxification protein
thiosulfate-binding
protein

ABUW_0280
sbp
Lipid Metabolism
ABUW_1858
acyl-CoA dehydrogenase
Posttranslational modification, protein turnover, chaperones
activator of HSP90
ABUW_2901
ATPase
Protein synthesis
Glu-tRNA
ABUW_1857
amidotransferase
Putative Lipoprotein
ABUW_3874
lipoprotein, putative
Putative Outermebrane protein
ABUW_1656
OmpW family protein
transporter, LysE family
ABUW_2430
-

-45.16
-25.8
-17.7
-5.36
-4.37
-3.13
-16.96

-3.59

-11.73
-3.35
-5.73
-5.95
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